0001193125-23-205535.txt : 20230808 0001193125-23-205535.hdr.sgml : 20230808 20230808065049 ACCESSION NUMBER: 0001193125-23-205535 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 60 CONFORMED PERIOD OF REPORT: 20230630 FILED AS OF DATE: 20230808 DATE AS OF CHANGE: 20230808 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MADRIGAL PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001157601 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-33277 FILM NUMBER: 231149218 BUSINESS ADDRESS: STREET 1: 200 BARR HARBOR DRIVE, SUITE 400 CITY: WEST CONSHOHOCKEN STATE: PA ZIP: 19428 BUSINESS PHONE: 404-380-9263 MAIL ADDRESS: STREET 1: 200 BARR HARBOR DRIVE, SUITE 400 CITY: WEST CONSHOHOCKEN STATE: PA ZIP: 19428 FORMER COMPANY: FORMER CONFORMED NAME: SYNTA PHARMACEUTICALS CORP DATE OF NAME CHANGE: 20010815 10-Q 1 d530762d10q.htm 10-Q 10-Q
falseQ20001157601--12-31 0001157601 2023-06-30 0001157601 2022-12-31 0001157601 2023-01-01 2023-06-30 0001157601 2022-01-01 2022-06-30 0001157601 2023-04-01 2023-06-30 0001157601 2022-04-01 2022-06-30 0001157601 2023-01-01 2023-03-31 0001157601 2022-01-01 2022-03-31 0001157601 2023-08-03 0001157601 2022-05-01 2022-05-31 0001157601 2022-05-01 2022-05-01 0001157601 2022-05-09 2022-05-09 0001157601 2021-12-31 0001157601 2022-06-30 0001157601 2023-03-31 0001157601 2022-03-31 0001157601 us-gaap:CashMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueInputsLevel1Member 2023-06-30 0001157601 us-gaap:CashMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueInputsLevel1Member 2023-06-30 0001157601 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2023-06-30 0001157601 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2023-06-30 0001157601 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-06-30 0001157601 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-06-30 0001157601 us-gaap:EmployeeStockOptionMember 2023-06-30 0001157601 mdgl:HoffmanLaRocheMember mdgl:ResearchDevelopmentAndCommercializationAgreementMember 2023-06-30 0001157601 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2023-06-30 0001157601 us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:AgencySecuritiesMember 2023-06-30 0001157601 us-gaap:FairValueInputsLevel2Member us-gaap:AgencySecuritiesMember 2023-06-30 0001157601 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2023-06-30 0001157601 mdgl:AtTheMarketIssuanceSalesAgreementMember mdgl:TwoThousandAndTwentyThreeSalesAgreementMember 2023-06-30 0001157601 mdgl:TwoThousandAndTwentyOneSalesAgreementMember mdgl:AtTheMarketIssuanceSalesAgreementMember 2023-06-30 0001157601 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-06-30 0001157601 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:AgencySecuritiesMember us-gaap:FairValueInputsLevel2Member 2023-06-30 0001157601 mdgl:LoanFacilityAndAmendedLoanFacilityMember mdgl:TrancheTwoMember 2023-06-30 0001157601 us-gaap:RestrictedStockUnitsRSUMember 2023-06-30 0001157601 us-gaap:CashMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueInputsLevel1Member 2022-12-31 0001157601 us-gaap:CashMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueInputsLevel1Member 2022-12-31 0001157601 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2022-12-31 0001157601 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2022-12-31 0001157601 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2022-12-31 0001157601 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-12-31 0001157601 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001157601 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001157601 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001157601 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001157601 us-gaap:EmployeeStockOptionMember 2023-04-01 2023-06-30 0001157601 us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0001157601 us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-01 2023-06-30 0001157601 us-gaap:RestrictedStockUnitsRSUMember 2023-04-01 2023-06-30 0001157601 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001157601 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001157601 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001157601 us-gaap:EmployeeStockOptionMember 2022-04-01 2022-06-30 0001157601 us-gaap:ResearchAndDevelopmentExpenseMember 2022-04-01 2022-06-30 0001157601 us-gaap:GeneralAndAdministrativeExpenseMember 2022-04-01 2022-06-30 0001157601 us-gaap:RestrictedStockUnitsRSUMember 2022-04-01 2022-06-30 0001157601 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001157601 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001157601 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001157601 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-06-30 0001157601 us-gaap:PreferredStockMember 2022-01-01 2022-06-30 0001157601 us-gaap:WarrantMember 2022-01-01 2022-06-30 0001157601 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-06-30 0001157601 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-06-30 0001157601 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-06-30 0001157601 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-06-30 0001157601 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-06-30 0001157601 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001157601 us-gaap:PreferredStockMember 2023-01-01 2023-06-30 0001157601 us-gaap:WarrantMember 2023-01-01 2023-06-30 0001157601 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-06-30 0001157601 mdgl:AtTheMarketIssuanceSalesAgreementMember mdgl:TwoThousandAndTwentyThreeSalesAgreementMember 2023-01-01 2023-06-30 0001157601 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001157601 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30 0001157601 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-06-30 0001157601 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-06-30 0001157601 srt:MaximumMember 2023-01-01 2023-06-30 0001157601 us-gaap:CorporateDebtSecuritiesMember 2023-01-01 2023-06-30 0001157601 us-gaap:AgencySecuritiesMember 2023-01-01 2023-06-30 0001157601 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001157601 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001157601 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001157601 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001157601 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001157601 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001157601 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001157601 mdgl:TermLoanMember 2022-05-01 2022-05-31 0001157601 mdgl:TermLoanMember 2022-05-31 0001157601 mdgl:TermLoanMember mdgl:DrawnInTwoSeparateTranchesUponAchievementOfResmetiromClinicalAndRegulatoryMilestoneMember 2022-05-31 0001157601 mdgl:DrawnInTwoSeparateTranchesUponAchievementOfResmetiromClinicalAndRegulatoryMilestoneMember 2022-05-31 0001157601 mdgl:LoanFacilityAndAmendedLoanFacilityMember mdgl:TermLoanMember 2023-02-03 2023-02-03 0001157601 mdgl:TrancheTwoMember mdgl:LoanFacilityAndAmendedLoanFacilityMember 2023-02-03 2023-02-03 0001157601 mdgl:LoanFacilityAndAmendedLoanFacilityMember us-gaap:PrimeRateMember 2023-02-03 0001157601 mdgl:LoanFacilityAndAmendedLoanFacilityMember 2023-02-03 0001157601 mdgl:LoanFacilityAndAmendedLoanFacilityMember mdgl:TrancheTwoMember 2023-02-03 0001157601 mdgl:LoanFacilityAndAmendedLoanFacilityMember mdgl:TrancheThreeMember 2023-02-03 0001157601 mdgl:LoanFacilityAndAmendedLoanFacilityMember mdgl:TrancheFouthMember 2023-02-03 0001157601 mdgl:LoanFacilityAndAmendedLoanFacilityOneMember mdgl:TrancheFouthMember 2023-02-03 0001157601 mdgl:LoanFacilityAndAmendedLoanFacilityMember mdgl:TrancheTwoMember 2023-06-19 0001157601 mdgl:TrancheTwoMember mdgl:LoanFacilityAndAmendedLoanFacilityMember us-gaap:SubsequentEventMember 2023-09-30 0001157601 mdgl:LoanFacilityMember 2023-01-01 0001157601 mdgl:ConvertibleSeriesAAndBPreferredStockMember 2017-06-30 0001157601 us-gaap:SeriesBPreferredStockMember mdgl:PurchaseAgreementMember mdgl:TwoThousandAndTwentyTwoRegisteredDirectOfferingMember 2022-12-01 2022-12-23 0001157601 us-gaap:CommonStockMember mdgl:PurchaseAgreementMember mdgl:TwoThousandAndTwentyTwoRegisteredDirectOfferingMember 2022-12-01 2022-12-23 0001157601 mdgl:PurchaseAgreementMember mdgl:TwoThousandAndTwentyTwoRegisteredDirectOfferingMember 2022-12-01 2022-12-23 0001157601 us-gaap:SeriesBPreferredStockMember mdgl:PurchaseAgreementMember mdgl:TwoThousandAndTwentyTwoRegisteredDirectOfferingMember 2022-12-23 0001157601 us-gaap:CommonStockMember mdgl:PurchaseAgreementMember mdgl:TwoThousandAndTwentyTwoRegisteredDirectOfferingMember 2022-12-23 0001157601 mdgl:TwoThousandAndTwentyOneSalesAgreementMember mdgl:AtTheMarketIssuanceSalesAgreementMember 2021-01-01 2021-12-31 0001157601 srt:MaximumMember mdgl:CowenCo.LlcMember mdgl:AtTheMarketIssuanceSalesAgreementMember 2021-06-01 2021-06-30 0001157601 mdgl:TwoThousandAndTwentyOneSalesAgreementMember mdgl:AtTheMarketIssuanceSalesAgreementMember 2022-01-01 2022-12-31 0001157601 us-gaap:CorporateDebtSecuritiesMember 2022-01-01 2022-12-31 0001157601 srt:MaximumMember mdgl:CowenCo.LlcMember mdgl:AtTheMarketIssuanceSalesAgreementMember 2023-05-01 2023-05-31 0001157601 mdgl:ConvertibleSeriesAAndBPreferredStockMember 2017-06-01 2017-06-30 0001157601 mdgl:LoanFacilityMember 2023-01-01 2023-01-02 0001157601 mdgl:AtTheMarketIssuanceSalesAgreementMember mdgl:TwoThousandAndTwentyOneSalesAgreementMember 2021-01-01 2022-12-31 0001157601 us-gaap:CommonStockMember 2023-06-30 0001157601 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001157601 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001157601 us-gaap:RetainedEarningsMember 2023-06-30 0001157601 us-gaap:PreferredStockMember 2023-06-30 0001157601 us-gaap:CommonStockMember 2022-06-30 0001157601 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001157601 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001157601 us-gaap:RetainedEarningsMember 2022-06-30 0001157601 us-gaap:PreferredStockMember 2022-06-30 0001157601 us-gaap:EmployeeStockOptionMember 2022-12-31 0001157601 us-gaap:RetainedEarningsMember 2021-12-31 0001157601 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001157601 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001157601 us-gaap:CommonStockMember 2021-12-31 0001157601 us-gaap:PreferredStockMember 2021-12-31 0001157601 us-gaap:CommonStockMember 2022-03-31 0001157601 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001157601 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001157601 us-gaap:RetainedEarningsMember 2022-03-31 0001157601 us-gaap:PreferredStockMember 2022-03-31 0001157601 us-gaap:RetainedEarningsMember 2022-12-31 0001157601 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001157601 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001157601 us-gaap:CommonStockMember 2022-12-31 0001157601 us-gaap:PreferredStockMember 2022-12-31 0001157601 us-gaap:CommonStockMember 2023-03-31 0001157601 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001157601 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001157601 us-gaap:RetainedEarningsMember 2023-03-31 0001157601 us-gaap:PreferredStockMember 2023-03-31 iso4217:USD xbrli:shares xbrli:pure utr:Year iso4217:USD xbrli:shares mdgl:Vote
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM
10-Q
 
 
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2023
OR
 
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from
        
    
    
    
to
    
    
        
    
Commission file number:
001-33277
 
 
MADRIGAL PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
 
 
 
Delaware
 
04-3508648
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer
Identification No.)
   
Four Tower Bridge
200 Barr Harbor Drive, Suite 200
West Conshohocken, Pennsylvania
 
19428
(Address of principal executive offices)
 
(Zip Code)
Registrant’s telephone number, including area code: (267)
824-2827
 
    
Former name, former address and former fiscal year, if changed since last report:
 
 
 
Title of each class
 
Trading
Symbol(s)
 
Name of each exchange
on which registered
Common Stock, $0.0001 Par Value Per Share
 
MDGL
 
The NASDAQ Stock Market LLC
Securities registered pursuant to Section 12(g) of the Exchange Act: None.
 
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    ☒  Yes    ☐  No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation
S-T
(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    ☒  Yes    ☐  No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated
filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule
12b-2
of the Exchange Act.
 
Large accelerated filer      Accelerated filer  
       
Non-accelerated
filer
     Smaller reporting company  
       
         Emerging growth company  
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule
12b-2
of the Exchange Act).    Yes  ☐    No  
As of
August 3
, 2023, the registrant had 18,471,233 shares of common stock outstanding.
 
 
 


TABLE OF CONTENTS

 

Item

  Description    Page  
 

Part I. Financial Information

     3  

Item 1.

 

Financial Statements (Unaudited):

     3  
 

Condensed Consolidated Balance Sheets at June 30, 2023 and December 31, 2022

     3  
 

Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2023 and 2022

     4  
 

Condensed Consolidated Statements of Comprehensive Loss for the Three and Six Months Ended June 30, 2023 and 2022

     5  
 

Condensed Consolidated Statements of Stockholders’ Equity for the Three and Six Months Ended June 30, 2023 and 2022

     6  
 

Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2023 and 2022

     7  
 

Notes to Condensed Consolidated Financial Statements

     8  

Item 2.

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations

     19  

Item 3.

 

Quantitative and Qualitative Disclosures About Market Risk

     26  

Item 4.

 

Controls and Procedures

     26  
 

Part II. Other Information

     27  

Item 1.

 

Legal Proceedings

     27  

Item 1A.

 

Risk Factors

     27  

Item 2.

 

Unregistered Sales of Equity Securities and Use of Proceeds

     27  

Item 3.

 

Defaults Upon Senior Securities

     27  

Item 4.

 

Mine Safety Disclosures

     27  

Item 5.

 

Other Information

     27  

Item 6.

 

Exhibits

     27  
 

Signatures

     29  

 

2


PART I—FINANCIAL INFORMATION
 
Item 1.
Financial Statements.
MADRIGAL PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited; in thousands, except share and per share amounts)

 
 
  
June 30,

2023
 
 
December 31,
2022
 
Assets
                
Current assets:
                
Cash and cash equivalents
   $ 77,196     $ 331,549  
Marketable securities
     221,222       27,225  
Prepaid expenses and other current assets
     3,177       2,595  
    
 
 
   
 
 
 
Total current assets
     301,595       361,369  
Property and equipment, net
     455       601  
Right-of-use
asset
     411       602  
    
 
 
   
 
 
 
Total assets
   $ 302,461     $ 362,572  
    
 
 
   
 
 
 
Liabilities and Stockholders’ Equity
                
Current liabilities:
                
Accounts payable
   $ 17,534     $ 23,831  
Accrued expenses
     81,761       91,461  
Lease liability
     411       602  
    
 
 
   
 
 
 
Total current liabilities
     99,706       115,894  
Long term liabilities:
                
Loan payable, net of discount
     99,249       49,289  
    
 
 
   
 
 
 
Total long term liabilities
     99,249       49,289  
    
 
 
   
 
 
 
Total liabilities
     198,955       165,183  
    
 
 
   
 
 
 
Stockholders’ equity:
                
Preferred stock, par value $0.0001 per share authorized: 5,000,000 shares at June 30, 2023 and December 31,
2022; 2,369,797 and 2,369,797
 shares issued and outstanding at June 30, 2023 and December 31, 2022,
respectively
       —         —  
Common stock, par value $0.0001 per share authorized: 200,000,000 at June 30, 2023 and December 31, 2022; 18,459,033 and 18,102,523 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively
     2       2  
Additional
paid-in-capital
     1,228,949       1,160,079  
Accumulated other comprehensive loss
     (89     (32
Accumulated deficit
     (1,125,356
 
    (962,660
    
 
 
   
 
 
 
Total stockholders’ equity
     103,506  
  197,389  
    
 
 
   
 
 
 
Total liabilities and stockholders’ equity
   $ 302,461     $ 362,572  
    
 
 
   
 
 
 
See accompanying notes to condensed consolidated financial statements.
 
3

MADRIGAL PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited; in thousands, except share and per share amounts)
 
    
Three Months Ended June 30,
   
Six Months Ended June 30,
 
    
2023
   
2022
   
2023
   
2022
 
Revenues:
        
Total revenues
   $ —       $ —       $ —       $ —    
Operating expenses:
        
Research and development
     68,605       58,499       130,759       106,428  
General and administrative
     17,845       11,774       34,027       21,432  
  
 
 
   
 
 
   
 
 
   
 
 
 
Total operating expenses
     86,450       70,273       164,786       127,860  
  
 
 
   
 
 
   
 
 
   
 
 
 
Loss from operations
     (86,450     (70,273     (164,786     (127,860
Interest income
     3,551       323       7,327       392  
Interest expense
     (2,901     (780     (5,237     (780
  
 
 
   
 
 
   
 
 
   
 
 
 
Net loss
   $ (85,800   $ (70,730   $ (162,696   $ (128,248
  
 
 
   
 
 
   
 
 
   
 
 
 
Net loss per common share:
        
Basic and diluted net loss per common share
   $ (4.69   $ (4.14   $ (8.91   $ (7.50
Basic and diluted weighted average number of common shares outstanding
     18,310,952       17,103,395       18,249,778       17,103,395  
See accompanying notes to condensed consolidated financial statements.
 
4

MADRIGAL PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(Unaudited; in thousands)
 
    
Three Months Ended June 30,
   
Six Months Ended June 30,
 
    
2023
   
2022
   
2023
   
2022
 
Net Loss
   $ (85,800   $ (70,730   $ (162,696   $ (128,248
Other comprehensive income (loss):
        
Unrealized loss on
available-for-sale
securities
     (3     (45     (57     (367
  
 
 
   
 
 
   
 
 
   
 
 
 
Comprehensive loss
   $ (85,803   $ (70,775   $ (162,753   $ (128,615
  
 
 
   
 
 
   
 
 
   
 
 
 
See accompanying notes to condensed consolidated financial statements.
 
5

MADRIGAL PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(Unaudited; in thousands, except share and per share amounts)
 
                                
Additional
paid-in

Capital
    
Accumulated
other
comprehensive
income (loss)
   
Accumulated
deficit
   
Total
stockholders’
equity
 
    
Preferred stock
    
Common stock
 
    
Shares
    
Amount
    
Shares
    
Amount
 
Balance at December 31, 2022
     2,369,797      $ —          18,102,523      $ 2      $ 1,160,079      $ (32   $ (962,660   $ 197,389  
Sale of common shares to related parties and exercise of common stock options, net of transaction costs
     —          —          180,551        —          17,903        —         —         17,903  
Compensation expense related to stock options for services
     —          —          —          —          11,250        —         —         11,250  
Unrealized loss on marketable securities
     —          —          —          —          —          (54     —         (54
Hercules warrant
     —          —          —          —          544        —         —         544  
Net loss
     —          —          —          —          —          —         (76,896     (76,896
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
   
 
 
   
 
 
 
Balance at March 31, 2023
     2,369,797      $ —          18,283,074      $ 2      $ 1,189,776      $ (86   $ (1,039,556   $ 150,136  
Issuance of common shares in equity offering, excluding to related parties, net of transaction costs
     —          —          85,901        —          21,754        —         —         21,754  
Sale of common shares to related parties and exercise of common stock options, net of transaction costs
     —          —          90,058        —          6,251        —         —         6,251  
Compensation expense related to stock options for services
     —          —          —          —          10,973        —         —         10,973  
Unrealized loss on marketable securities
     —          —          —          —          —          (3     —         (3
Hercules warrant
     —          —          —          —          195        —         —         195  
Net loss
     —          —          —          —          —          —         (85,800     (85,800
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
   
 
 
   
 
 
 
Balance at June 30, 2023
     2,369,797      $ —          18,459,033      $ 2      $ 1,228,949      $ (89   $ (1,125,356   $ 103,506  
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
   
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Balance at December 31, 2021
     1,969,797      $ —          17,103,395      $ 2      $ 863,495      $ (80   $ (667,310   $ 196,107  
Compensation expense related to stock options for services
     —          —          —          —          7,477        —         —         7,477  
Unrealized loss on marketable securities
     —          —          —          —          —          (322     —         (322
Net loss
     —          —          —          —          —          —         (57,518     (57,518
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
   
 
 
   
 
 
 
Balance at March 31, 2022
     1,969,797      $ —          17,103,395      $ 2      $ 870,972      $ (402   $ (724,828   $  145,744  
Compensation expense related to stock options for services
     —          —          —          —          7,944        —         —         7,944  
Unrealized loss on marketable securities
     —          —          —          —          —          (45     —         (45
Hercules warrant
     —          —          —          —          622        —         —         622  
Net loss
     —          —          —          —          —          —         (70,730     (70,730
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
   
 
 
   
 
 
 
Balance at June 30, 2022
     1,969,797      $  —          17,103,395      $ 2      $ 879,538      $ (447   $ (795,558   $ 83,535  
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
   
 
 
   
 
 
 
See accompanying notes to condensed consolidated financial statements.
 
6
MADRIGAL PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited; in thousands)
 
    
Six Months Ended June 30,
 
    
2023
   
2022
 
Cash flows from operating activities:
    
Net loss
   $ (162,696   $ (128,248
Adjustments to reconcile net loss to net cash used in operating activities:
    
Stock-based compensation expense
     22,223       15,421  
Depreciation and amortization expense
     250       217  
Amortization of debt issuance costs and discount
     987       178  
Changes in operating assets and liabilities:
    
Prepaid expenses and other current assets
     (582     (1,442
Accounts payable
     (6,297     (10,086
Accrued expense
     (9,700     16,788  
Accrued interest, net of interest received on maturity of investments
     (3,562     (101
  
 
 
   
 
 
 
Net cash used in operating activities
     (159,377     (107,273
  
 
 
   
 
 
 
Cash flows from investing activities:
    
Purchases of marketable securities
     (290,696     (116,496
Sales and maturities of marketable securities
     100,204       191,813  
Purchases of property and equipment, net of disposals
     (104     (155
  
 
 
   
 
 
 
Net cash provided by (used in) investing activities
     (190,596     75,162  
  
 
 
   
 
 
 
Cash flows from financing activities:
    
Proceeds from issuances of stock, excluding related parties, net of transaction costs
     21,754           
Proceeds from the sale of related party stock and exercise of common stock options, net of transaction costs
     24,154           
Proceeds from issuance of loan payable
     50,000       50,000  
Payment of debt issuance costs
     (288     (886
  
 
 
   
 
 
 
Net cash provided by financing activities
     95,620       49,114  
  
 
 
   
 
 
 
Net increase (decrease) in cash and cash equivalents
     (254,353     17,003  
Cash and cash equivalents at beginning of period
     331,549       36,269  
  
 
 
   
 
 
 
Cash and cash equivalents at end of period
   $ 77,196     $ 53,272  
  
 
 
   
 
 
 
Supplemental disclosure of cash flow information:
    
Obtaining a
right-of-use
asset in exchange for a lease liability
   $        $ 583  
See accompanying notes to condensed consolidated financial statements.
 
7

MADRIGAL PHARMACEUTICALS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
1. Organization, Business, and Basis of Presentation
Organization and Business
Madrigal Pharmaceuticals, Inc. (the “Company” or “Madrigal”) is a clinical-stage pharmaceutical company developing novel, high-quality, small-molecule drugs addressing major unmet needs in cardiovascular, metabolic, and liver diseases. The Company’s lead compound, resmetirom, is being advanced for
non-alcoholic
steatohepatitis (“NASH”), a liver disease that commonly affects people with metabolic diseases such as obesity and diabetes, and
non-alcoholic
fatty liver disease (“NAFLD”). The Company initiated two Phase 3 studies of resmetirom in NASH in 2019 that are ongoing. The Company announced certain topline results from the
MAESTRO-NAFLD-1
safety study of resmetirom in January 2022 and the MAESTRO-NASH study in December 2022. In August 2022, Madrigal initiated a third study, MAESTRO-NASH-OUTCOMES.
Basis of Presentation
Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) have been condensed or omitted. Accordingly, the unaudited condensed consolidated financial statements do not include all information and footnotes required by GAAP for complete annual financial statements. However, we believe that the disclosures included in these financial statements are adequate to make the information presented not misleading. The unaudited condensed consolidated financial statements, in the opinion of management, reflect all adjustments, which include normal recurring adjustments, necessary for a fair statement of such interim results. The interim results are not necessarily indicative of the results that we will have for the full year ending December 31, 2023 or any subsequent period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes to those statements for the year ended December 31, 2022.
2. Summary of Significant Accounting Policies
Principle of Consolidation
The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries. All significant intercompany balances have been eliminated in consolidation.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities, and the reported amounts of revenues and expenses during the reporting periods. The Company bases its estimates on historical experience and various other assumptions that management believes to be reasonable under the circumstances. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.
Cash and Cash Equivalents
The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. The Company maintains its cash in bank accounts, the balance of which, at times, exceeds Federal Deposit Insurance Corporation insured limits.
The primary objective of the Company’s investment activities is to preserve its capital for the purpose of funding operations and the Company does not enter into investments for trading or speculative purposes. The Company’s cash is deposited in highly rated financial institutions in the United States. The Company invests in money market funds and high-grade, commercial paper and corporate bonds, which management believes are subject to minimal credit and market risk.
Marketable Securities
Marketable securities consist of investments in high-grade corporate obligations and government and government agency obligations that are classified as
available-for-sale.
Since these securities are available to fund current operations, they are classified as current assets on the consolidated balance sheets.
 
8

The Company adjusts the cost of
available-for-sale
debt securities for amortization of premiums and accretion of discounts to maturity. The Company includes such amortization and accretion as a component of interest income, net. Realized gains and losses and declines in value, if any, that the Company judges to be the result of impairment or as a result of recognizing an allowance for credit losses on
available-for-sale
securities are reported as a component of interest income. To determine whether an impairment exists, the Company considers whether it intends to sell the debt security and, if the Company does not intend to sell the debt security, it considers available evidence to assess whether it is more likely than not that it will be required to sell the security before the recovery of its amortized cost basis. During the six months ended June 30, 2023 and 2022, the Company determined it did not have any securities that were other-than-temporarily impaired.
Marketable securities are stated at fair value, including accrued interest, with their unrealized gains and losses included as a component of accumulated other comprehensive income or loss, which is a separate component of stockholders’ equity. The fair value of these securities is based on quoted prices and observable inputs on a recurring basis. Realized gains and losses are determined on the specific identification method. During the six months ended June 30, 2023 and 2022, the Company did not have any realized gains or losses on marketable
securitie
s.
Fair Value of Financial Instruments
The carrying amounts of the Company’s financial instruments, which include cash equivalents and marketable securities, approximate their fair values. The fair value of the Company’s financial instruments reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels:
Level 1—quoted prices in active markets for identical assets and liabilities.
Level 2—observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.
Level 3—unobservable inputs that reflect the Company’s own assumptions about the assumptions market participants would use in pricing the asset or liability.
Financial assets and liabilities are classified in their entirety within the fair value hierarchy based on the lowest level of input that is significant to the fair value measurement. The Company measures the fair value of its marketable securities by taking into consideration valuations obtained from third- party pricing sources. The pricing services utilize industry standard valuation models, including both income and market based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker-dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities and other observable inputs.
As of June 30, 2023, the Company’s financial assets valued based on Level 1 inputs consisted of cash and cash equivalents in a money market fund, its financial assets valued based on Level 2 inputs consisted of high-grade corporate and government agency bonds and commercial paper, and it had no financial assets valued based on Level 3 inputs. During the six months ended June 30, 2023 and 2022, the Company did not have any transfers of financial assets between Levels 1 and 2. As of June 30, 2023 and December 31, 2022, the Company did not have any financial liabilities that were recorded at fair value on a recurring basis on the balance sheet.
Research and Development Costs
Research and development costs are expensed as incurred. Research and development costs are comprised of costs incurred in performing research and development activities, including internal costs (including stock-based compensation), costs for consultants, milestone payments under licensing agreements, and other costs associated with the Company’s preclinical and clinical programs. In particular, the Company has conducted safety studies in animals, optimized and implemented the manufacturing of our drug, and conducted clinical trials, all of which are considered research and development expenditures. Management uses significant judgment in estimating the amount of research and development costs recognized in each reporting period. Management analyzes and estimates the progress of its clinical trials, completion of milestone events per underlying agreements, invoices received and contracted costs when estimating the research and development costs to accrue in each reporting period. Actual results could differ from the Company’s estimates.
Patents
Costs to secure and defend patents are expensed as incurred and are classified as general and administrative expense in the Company’s consolidated statements of operations.
 
9

Stock-Based Compensation
The Company recognizes stock-based compensation expense based on the grant date fair value of stock options and restricted stock units granted to employees, officers, and directors. Awards that vest as the recipient provides service are expensed on a straight-line basis over the requisite service period. The Company uses the Black-Scholes option pricing model to determine the grant date fair value of stock options as management believes it is the most appropriate valuation method for its option grants. The Black-Scholes model requires inputs for risk-free interest rate, dividend yield, volatility and expected lives of the options. The expected lives for options granted represent the period of time that options granted are expected to be outstanding. The Company uses the simplified method for determining the expected lives of options. Expected volatility is based upon an industry estimate or blended rate including the Company’s historical trading activity. The risk-free rate for periods within the expected life of the option is based on the U.S. Treasury yield curve in effect at the time of the grant. The Company estimates the forfeiture rate based on historical data. This analysis is
re-evaluated
at least annually and the forfeiture rate is adjusted as necessary.
Income Taxes
The Company uses the asset and liability method to account for income taxes. Deferred tax assets and liabilities are determined based on the expected future tax consequences of temporary differences between the Company’s financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates expected to be in effect in the years in which the differences are expected to reverse. The Company currently maintains a 100% valuation allowance on its deferred tax assets.
Comprehensive Loss
Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from
non-owner
sources. Changes in unrealized gains and losses on marketable securities represent the only difference between the Company’s net loss and comprehensive loss.
Basic and Diluted Loss Per Common Share
Basic net loss per share is computed using the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed using the weighted average number of common shares outstanding and the weighted average dilutive potential common shares outstanding using the treasury stock method. However, for the six months ended June 30, 2023 and 2022, diluted net loss per share is the same as basic net loss per share because the inclusion of weighted average shares of common stock issuable upon the exercise of stock options and warrants or vesting of restricted stock units, and common stock issuable upon the conversion of preferred stock would be anti-dilutive. The following table summarizes outstanding securities not included in the computation of diluted net loss per common share, as their inclusion would be anti-dilutive:
 
    
Six Months Ended June 30,
 
    
2023
    
2022
 
Common stock options
     2,583,540        2,976,545  
Restricted stock units
     222,300            
Preferred stock
     2,369,797        1,969,797  
Warrants
     18,403        14,899  
Recent Accounting Pronouncements
None
3. Liquidity and Uncertainties
The Company is subject to risks common to development stage companies in the biopharmaceutical industry including, but not limited to, uncertainty of product development and commercialization, dependence on key personnel, uncertainty of market acceptance of products and product reimbursement, product liability, uncertain protection of proprietary technology, potential inability to raise additional financing necessary for development and commercialization, and compliance with the U.S. Food and Drug Administration (FDA) and other government regulations.
 
10

The Company has incurred losses since inception, including approximately $162.7 million for the six months ended June 30, 2023, resulting in an accumulated deficit of approximately $1,125 million as of June 30, 2023. Management expects to incur losses for the foreseeable future. To date, the Company has funded its operations primarily through proceeds from sales of the Company’s capital stock and debt financings. The Company believes that its cash, cash equivalents and marketable securities at June 30, 2023 will be sufficient to fund operations past one year from the issuance of these financial statements. To meet its future capital needs, the Company intends to raise additional capital through debt or equity financings, collaborations, partnerships or other strategic transactions. However, there can be no assurance that the Company will be able to complete any such transactions on acceptable terms or otherwise. The inability of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations and financial condition. The Company has the ability to delay certain research activities and related clinical expenses if necessary due to liquidity concerns until a date when those concerns are
relieved
.
4. Cash, Cash Equivalents and Marketable Securities
A summary of cash, cash equivalents and
available-for-sale
marketable securities held by the Company as of June 30, 2023 and December 31, 2022 is as follows (in thousands):
 
    
June 30, 2023
 
    
Cost
    
Unrealized

gains
    
Unrealized

losses
    
Fair

value
 
Cash and cash equivalents:
           
Cash (Level 1)
   $ 8,185      $  —        $ —        $ 8,185  
Money market funds (Level 1)
     69,011        —          —          69,011  
  
 
 
    
 
 
    
 
 
    
 
 
 
Total cash and cash equivalents
     77,196        —          —          77,196  
Marketable securities:
           
Corporate debt securities due within
1
 
year of date of purchase (Level 2)
     144,036        13        (105      143,944  
U.S. government and government sponsored entities due within 1 year of date of purchase (Level 2)
     77,275        6        (3      77,278  
  
 
 
    
 
 
    
 
 
    
 
 
 
Total cash, cash equivalents and marketable securities
   $ 298,507      $ 19      $ (108    $  298,418  
  
 
 
    
 
 
    
 
 
    
 
 
 
 
    
December 31, 2022
 
    
Cost
    
Unrealized

gains
    
Unrealized

losses
    
Fair

value
 
Cash and cash equivalents:
           
Cash (Level 1)
   $ 15,100      $  —        $  —        $ 15,100  
Money market funds (Level 1)
     316,449        —          —          316,449  
  
 
 
    
 
 
    
 
 
    
 
 
 
Total cash and cash equivalents
     331,549        —          —          331,549  
Marketable securities:
           
Corporate debt securities due within 1 year of date of purchase (Level 2)
     27,257        7        (39      27,225  
  
 
 
    
 
 
    
 
 
    
 
 
 
Total cash, cash equivalents and marketable securities
   $  358,806      $ 7      $ (39    $  358,774  
  
 
 
    
 
 
    
 
 
    
 
 
 
 
11

5. Accrued Liabilities
Accrued liabilities as of June 30, 2023 and December 31, 2022 consisted of the following (in thousands):
 
    
June 30,
2023
    
December 31,
2022
 
Contract research organization costs
   $  58,050      $  53,119  
Other clinical study related costs
     3,605        6,582  
Manufacturing and drug supply
     3,556        11,262  
Compensation and benefits
     5,453        14,864  
Professional fees
     9,494        4,867  
Other
     1,603        767  
    
 
 
    
 
 
 
Total accrued liabilities
   $ 81,761      $ 91,461  
    
 
 
    
 
 
 
6. Long Term Debt
In May 2022 the Company and its wholly-owned subsidiary, Canticle Pharmaceuticals, Inc., entered into the $250.0 million Loan Facility with the several banks and other financial institutions or entities party thereto (each, a “Lender” and collectively referred to as the “Lenders”), and Hercules Capital, Inc. (“Hercules”), in its capacity as administrative agent and collateral agent for itself and the Lenders. Under the terms of the Loan Facility, the first $50.0 million tranche was drawn at closing. The Company also could draw up to an additional $125.0 million in two separate tranches upon achievement of certain resmetirom clinical and regulatory milestones. A fourth tranche of $75.0 million could be drawn by the Company, subject to the approval of Hercules. The Loan Facility had a minimum interest rate of 7.45% and adjusts with changes in the prime rate. The Company will pay interest-only monthly payments of accrued interest under the Loan Facility for a period of 30 months, which period may be extended to 36, 48, and 60 months upon the successive achievement of certain clinical and regulatory milestones and if the Company maintains compliance with applicable covenants. The Loan Facility matures in May 2026 and may be extended an additional year upon the achievement of certain clinical and regulatory milestones. The Loan Facility is secured by a security interest in substantially all of the Company’s assets, other than intellectual property. It includes an end of term charge of 5.35% of the aggregate principal amount, which is accounted for in the loan discount. In connection with the first tranche drawn at closing, the Company issued Hercules a warrant to purchase 14,899 shares of Company common stock, which had a Black-Scholes value of $0.6 million.
On February 3, 2023, the Company entered into the First Amendment (the “Amendment”) to the Loan Facility (as amended, the “Amended Loan Facility”). Under the Amended Loan Facility, an additional $35.0 million was drawn under a second, expanded, $65.0 million tranche (“Tranche 2”) in February of 2023 following the Company’s achievement of the Phase 3 clinical development milestone. An additional $15.0 million was drawn under Tranche 2 in June of 2023. The Company has the ability to draw the remaining $15.0 million available under Tranche 2 by September 30, 2023
 
in accordance with the Amended Loan Facility.
The third tranche (“Tranche 3”) of $75.0 million remains unchanged by the Amendment, and such borrowings are available subject to the Company obtaining a certain FDA approval for resmetirom. Coincident with the expansion of Tranche 2 borrowing capacity by $15 million, the Amendment reduced the fourth tranche under the Loan Facility (“Tranche 4”) by $15.0 million to $60.0 million , which amount is available subject to Hercules’ sole discretion. In connection with the $35.0 million drawn under
Tranche 2
at the closing of the Amendment and $15.0 million drawn in June of 2023, the Company issued to Hercules and affiliates Tranche 2 Warrants to purchase 3,504 shares of common stock, which had a Black-Scholes value of $0.7 million. The Amendment reduced the interest rate under the Amended Loan Facility to the greater of (i) the prime rate as reported in The Wall Street Journal plus 2.45% and (ii) 8.25%. The Amendment and the Amended Loan Facility summary terms were disclosed in the Company’s Current Report on Form
8-K
filed with the Securities and Exchange Commission on February 9, 2023.
The Loan Facility includes affirmative and restrictive financial covenants commencing on January 1, 2023, including maintenance of a minimum cash, cash equivalents and liquid funds covenant of $35.0 million, which may decrease in certain circumstances if the Company achieves certain clinical milestones and a revenue milestone, and a revenue-based covenant that could apply commencing at or after the time that financial reporting is due for the quarter ending September 30, 2024. The Loan Facility contains event of default provisions for: the Company’s failure to make required payments or maintain compliance with covenants under the Loan Facility; the Company’s breach of certain representations or default under certain obligations outside the Loan Facility; insolvency, attachment or judgment events affecting the Company; and any circumstance which has occurred or could reasonably be expected to have a material adverse effect on the Company, provided that, any failure to achieve a clinical milestone or approval milestone under the Loan Facility shall not in and of itself constitute a material adverse effect. The Loan Facility also includes customary covenants associated with a secured loan facility, including covenants concerning financial reporting obligations, and certain limitations on indebtedness, liens (including a negative pledge on intellectual property and other assets), investments, distributions (including dividends), collateral, investments, distributions, transfers, mergers or acquisitions, taxes, corporate changes, and deposit accounts.
 
12

As of June 30, 2023, the outstanding principal under the Loan Facility was $100.0 million. The interest rate as of June 30, 2023 was 10.70%. As of June 30, 2023, the Company was in compliance with all loan covenants and provisions.
Future minimum payments, including interest and principal, under the loans payable outstanding as of June 30, 2023 are as follows (in thousands):
 
Period Ending June 30, 2023:
  
Amount
 
2023 (remaining six months)
   $ 5,372  
2024
     10,878  
2025
     69,044  
Thereafter
     46,363  
    
 
 
 
     $ 131,657  
Less amount representing interest
     (26,307
Less unamortized discount
     (6,101
    
 
 
 
Loans payable, net of discount
   $ 99,249  
    
 
 
 
7. Stockholders’ Equity
Common Stock
Each common stockholder is entitled to one vote for each share of common stock held. The common stock will vote together with all other classes and series of stock of the Company as a single class on all actions to be taken by the Company’s stockholders. Each share of common stock is entitled to receive dividends, as and when declared by the Company’s board of directors. The Company has never declared cash dividends on its common stock and does not expect to do so in the foreseeable future.
Preferred Stock
The Series A and B Preferred Stock have a par value of $0.0001 per share and are convertible into shares of the common stock at a
one-to-one
ratio, subject to adjustment as provided in the Certificates of Designation of Preferences, Rights and Limitations of Series A Preferred Stock and Series B Preferred Stock that the Company filed with the Secretary of State of the State of Delaware on June 21, 2017 and December 22, 2022, respectively. The terms of the Series A and B Preferred Stock are set forth in such Certificates of Designation. Each share of the Series A and B Preferred Stock is convertible into shares of Common Stock following notice that may be given at the holder’s option. Upon any liquidation, dissolution or
winding-up
of the Company, whether voluntary or involuntary, after the satisfaction in full of the debts of the Company and the payment of any liquidation preference owed to the holders of shares of capital stock of the Company ranking prior to the Series A and B Preferred Stock upon liquidation, the holders of the Series A and B Preferred Stock shall participate pari passu with the holders of the Common Stock (on an
as-if-converted-to-Common-Stock
basis) in the net assets of the Company. Shares of the Series A and B Preferred Stock will generally have no voting rights, except as required by law. Shares of the Series A and B Preferred Stock will be entitled to receive dividends before shares of any other class or series of capital stock of the Company (other than dividends in the form of the Common Stock) equal to the dividend payable on each share of the Common Stock, on an
as-converted
basis.
December 2022 Registered Direct Offering
In December 2022, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with a group of institutional accredited investors, who were existing,
non-controlling
stockholders of the Company, pursuant to which the Company sold securities to the Investors in an offering that was registered under the Company’s existing shelf registration statement (the “2022 Registered Direct Offering”). Under the terms of the Purchase Agreement, the Company sold 44,444 shares of its common stock at a price of $225 per share, and 400,000 shares of its Series B Convertible Preferred Stock at a price of $225 per share. The 2022 Registered Direct Offering resulted in gross proceeds to the Company of approximately $100.0 million, and net proceeds to the Company of approximately $99.5 million. The 2022 Registered Direct Offering closed on December 23, 2022.
 
13
At-The-Market
Issuance Sales Agreement
In June 2021, the Company entered into an
at-the-market
sales agreement (the “2021 Sales Agreement”) with Cowen and Company, LLC (“Cowen”), pursuant to which the Company could, from time to time, issue and sell shares of its common stock. The 2021 Sales Agreement
 initially
authorized an aggregate offering of up to $200 million in shares of our common stock, at the Company’s option, through Cowen as its sales agent. Sales of common stock through Cowen could be made by any method that is deemed an
“at-the-market”
offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, including by means of ordinary brokers’ transactions at market prices, in block transactions or as otherwise agreed by the Company and Cowen. Subject to the terms and conditions of the 2021 Sales Agreement, Cowen would use commercially reasonable efforts consistent with its normal trading and sales practices to sell the common stock based upon the Company’s instructions (including any price, time or size limits or other customary parameters or conditions the Company imposed).
In December 2022, the Company sold 738,900 shares
 of common stock
under the 2021 Sales Agreement for an aggregate of $159.1 million in gross proceeds, with net proceeds to the Company of $155.9 million after deducting commissions and other transaction costs. In total, under the 2021 Sales Agreement the Company sold 1,235,943 shares for an aggregate of $199.9 million in gross proceeds, with net proceeds to the Company of approximately $195.8 million after deducting commissions and other transaction costs
 through December 31, 2022.
Of those shares sold, 738,900 were sold in 2022, and 497,043 were sold in 2021. All shares were sold pursuant to the Company’s effective shelf registration statement
on Form S-3 (the “Registration Statement”) and
 the prospectus supplement relating thereto. As of June 30, 2023, no amounts remained reserved and available for sale under the 2021 Sales Agreement and the related prospectus supplement.
In May 2023, the Company amended the 2021 Agreement (the “Sales Agreement
 Amendment
”), with Cowen, pursuant to which the Company may, from time to time, issue and sell
 in additional $200 million in
shares of its common stock. The Company is not obligated to make any sales of its common stock under this arrangement. Any shares sold will be sold pursuant to the Company’s effective
Registration Statement
on Form
S-3
(the “Registration Statement”) and prospectus supplement filed pursuant to the Registration Statement. The Sales Agreement Amendment authorizes
sales of
shares of our common stock, from time to time, at the Company’s option, through Cowen as its sales agent. Sales of common stock through Cowen may be made by any method that is deemed an
“at-the-market”
offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, and as described in the prospectus supplement. In total, under the Sales Agreement
 Amendment,
the Company sold 85,901 shares for an aggregate of $22.4 million in gross proceeds, with net proceeds to the Company of approximately $21.8 million after deducting commissions and other transaction costs. All shares were sold pursuant to the Company’s effective
Registration Statement
and the prospectus supplement relating thereto. As of June 30, 2023, $177.6 million remained reserved and available for sale under the 2023 Sales Agreement
 
Amendment 
and the Company’s related prospectus supplement.
8. Stock-based Compensation
The Company’s 2015 Stock Plan, as amended, is our primary equity incentive compensation plan through which equity based grants are awarded. The 2015 Stock Plan provides for the grant of incentive stock options,
non-statutory
stock options, restricted stock, restricted stock units and other stock-based compensation awards to employees, officers, directors, and consultants of the Company. The administration of the 2015 Stock Plan is under the general supervision of the Compensation Committee of the Board of Directors. The terms of stock options awarded under the 2015 Stock Plan, in general, are determined by the Compensation Committee, provided the exercise price per share generally shall not be set at less than the fair market value of a share of the common stock on the date of grant and the term shall not be greater than ten years from the date the option is granted. As of June 30, 2023, the Company had restricted stock units and options outstanding to purchase
 an aggregate of
2,805,840 shares of its common stock, which includes options outstanding under its prior incentive compensation plan, the 2006 Stock Plan. As of June 30, 2023, 670,634 shares were available for future issuance under the 2015 Stock Plan.
Stock Options
The following table summarizes stock option activity during the six months ended June 30, 2023:
 
    
Shares
    
Weighted
average exercise
price
 
Outstanding at January 1, 2023
     2,857,054      $ 81.78  
Options granted
     5,205        283.08  
Options exercised
     (270,609      89.26  
Options cancelled
     (8,110      84.12  
    
 
 
    
 
 
 
Outstanding at June 30, 2023
     2,583,540      $ 81.40  
    
 
 
    
 
 
 
Exercisable at June 30, 2023
     1,719,944      $ 76.62  
 
14

The total cash received by the Company as a result of stock option exercises was $21.8 million and $0 million, respectively, for the six months ended June 30, 2023 and 2022. The total intrinsic value of options exercised was $48.9 million and $0 million, respectively, for the six months ended June 30, 2023 and 2022. The weighted-average grant date fair values, based on the Black-Scholes option model, of options granted during the six months ended June 30, 2023 and 2022 were $219.02 and $55.84, respectively.
Restricted Stock Units
The Company’s share-based compensation plan provides for awards of restricted stock units to employees, officers, directors and consultants to the Company. Restricted stock units vest over the service period, and are subject to forfeiture if employment or service terminates before vesting. As of June 30, 2023, the Company had 222,300 restricted stock units outstanding, with a weighted average grant date fair value of $294.19 per unit.
Stock-Based Compensation Expense
Stock-based compensation expense during the six months ended June 30, 2023 and 2022 was as follows (in thousands):
 
    
Three Months Ended June 30,
    
Six Months Ended June 30,
 
    
2023
    
2022
    
2023
    
2022
 
Stock-based compensation expense by type of award:
                                   
Stock options
   $ 7,431      $ 7,944      $ 16,029      $ 15,421  
Restricted stock units
     3,542                  6,194            
    
 
 
    
 
 
    
 
 
    
 
 
 
Total stock-based compensation expense
   $ 10,973      $ 7,944      $ 22,223      $ 15,421  
    
 
 
    
 
 
    
 
 
    
 
 
 
Effect of stock-based compensation expense by line item:
                                   
Research and development
   $ 5,184      $ 3,301      $ 10,570      $ 6,488  
General and administrative
     5,789        4,643        11,653        8,933  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total stock-based compensation expense included in net loss
   $ 10,973      $ 7,944      $ 22,223      $ 15,421  
    
 
 
    
 
 
    
 
 
    
 
 
 
Unrecognized stock-based compensation expense as of June 30, 2023 was $98.2 million with a weighted average remaining period of 2.90 years.
9. Commitments and Contingencies
The Company has a Research, Development and Commercialization Agreement with
Hoffmann-La
Roche (“Roche”) which grants the Company a sole and exclusive license to develop, use, sell, offer for sale and import any Licensed Product as defined by the agreement.
The agreement requires future milestone payments to Roche. Remaining milestones under the agreement total $8 million and are payable upon Madrigal achieving specified objectives related to future regulatory approval in the United States and Europe of resmetirom or a product developed from resmetirom. Furthermore, a tiered single-digit royalty is payable on net sales of resmetirom or a product developed from resmetirom, subject to certain reductions. The Company has not achieved any additional product development or regulatory milestones and had no Licensed Product sales for the six months ended June 30, 2023 and 2022.
The Company has entered into customary contractual arrangements and letters of intent in preparation for and in support of the clinical trials.
********** END OF FINANCIAL STATEMENTS **********
 
15


CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q includes “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, that are based on our beliefs and assumptions and on information currently available to us, but are subject to factors beyond our control Forward-looking statements: reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events; include all statements that are not historical facts; and can be identified by terms such as “accelerate,” “achieve,” “allow,” “anticipates,” “appear,” “be,” “believes,” “can,” “continue,” “confidence,” “could,” “demonstrates,” “design,” “estimates,” “expectation,” “expects,” “forecasts,” “future,” “goal,” “help,” “hopeful,” “inform,” “informed,” “intends,” “may,” “might,” “on track,” “planned,” “planning,” “plans,” “positions,” “potential,” “powers,” “predicts,” ”predictive,” “projects,” “seeks,” “should,” “will,” “will achieve,” “will be,” “would” or similar expressions and the negatives of those terms. In particular, forward-looking statements contained in or incorporated by reference to this Quarterly Report relate to, among other things,

 

   

Anticipated or estimated future results, including the risks and uncertainties associated with our future operating performance and financial position;

 

   

Our possible or assumed future results of operations and expenses, business strategies and plans (including ex-U.S. launch/partnering plans), capital needs and financing plans, including incurrence of indebtedness and compliance with debt covenants under the Loan and Security Agreement with Hercules Capital, Inc., as agent and lender, market trends, market sizing, competitive position, industry environment and potential growth opportunities, among other things;

 

   

Our ability to delay certain research activities and related clinical expenses as necessary;

 

   

Our projected resources and sufficiency of capital to fund our operating expenses through the projected commercial launch of resmetirom, assuming Food and Drug Administration (“FDA”) approval is obtained;

 

   

Our clinical trials, including the anticipated timing of disclosure, presentations of data from, or outcomes from our trials,

 

   

Research and development activities, and the timing and results associated with the future development of our lead product candidate, resmetirom (formerly known as MGL-3196), including projected market size, sector leadership, and patient treatment estimates for non-alcoholic steatohepatitis (“NASH”) and nonalcoholic fatty liver disease (“NAFLD”) patients,

 

   

The timing and completion of projected future clinical milestone events, including enrollment, additional studies, top-line data and open label projections,

 

   

Resmetirom’s potential to be a cost-effective specialty therapy for NASH patients with significant liver fibrosis,

 

   

Plans, objectives and timing for making a Subpart H (Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses) submission to the FDA,

 

   

Projections or objectives for obtaining accelerated or full approval for resmetirom for NASH patients with significant fibrosis (or non-cirrhotic NASH patients) and NASH patients with compensated cirrhosis,

 

   

Our primary and key secondary study endpoints for resmetirom, and the potential for achieving such endpoints and projections, including NASH resolution, safety, fibrosis treatment, cardiovascular effects and lipid treatment with resmetirom,

 

   

Optimal dosing levels for resmetirom and projections regarding potential NASH or NAFLD and potential patient benefits with resmetirom, including future NASH resolution, safety, fibrosis treatment, cardiovascular effects, lipid treatment and/or biomarker effects with resmetirom,

 

   

Our ability to address the unmet needs of patients suffering from NASH with significant fibrosis,

 

   

The potential efficacy and safety of resmetirom for non-cirrhotic NASH patients and cirrhotic NASH patients,

 

   

The potential for resmetirom to become the best-in-class and/or first-to-market treatment option for patients with NASH and liver fibrosis;

 

   

Anticipated or estimated future results of operations and expenses as we expand our resmetirom clinical development program and our commercial development program;

 

   

Ex-U.S. launch/partnering plans,

 

   

The ability to develop clinical evidence demonstrating the utility of non-invasive tools and techniques to screen and diagnose NASH and/or NAFLD patients,

 

16


   

The predictive power of liver fat reduction with resmetirom, as measured by non-invasive tests, on NASH resolution and/or fibrosis reduction or improvement, and potential NASH or NAFLD patient risk profile benefits with resmetirom,

 

   

The predictive power of liver fat, liver volume changes or MAST scores for NASH and/or NAFLD patients,

 

   

The predictive power of NASH resolution and/or liver fibrosis reduction with resmetirom or improvement using non-invasive tests, including the use of ELF, FibroScan, MRE and/or MRI-PDFF,

 

   

The predictive power of non-invasive tests generally, including for purposes of diagnosing NASH, monitoring patient response to resmetirom, or recruiting and conducting a NASH clinical trial,

 

   

Market demand for and acceptance of our products,

 

   

Research, development and commercialization of new products,

 

   

The potential for resmetirom to be an effective treatment for other disease indications,

 

   

Obtaining and maintaining regulatory approvals, including, but not limited to, potential regulatory delays or rejections,

 

   

Risks associated with meeting the objectives of our clinical studies, including, but not limited to our ability to achieve enrollment objectives concerning patient numbers (including an adequate safety database), outcomes objectives and/or timing objectives for our studies, any delays or failures in enrollment, the occurrence of adverse safety events, and the risks of successfully conducting trials that are substantially larger, and have patients with different disease states, than our past trials,

 

   

our continued reliance on third-party contract manufacturers for the manufacture of our product candidates, including resmetirom,

 

   

Risks related to the effects of resmetirom’s mechanism of action and our ability to accomplish our business and business development objectives and realize the anticipated benefit of any such transactions, and

 

   

Assumptions underlying any of the foregoing.

We caution you that the foregoing list may not include all of the forward-looking statements made in this Quarterly Report. Although management presently believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements.

Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to: our clinical and commercial development of resmetirom; enrollment and trial outlook uncertainties, generally, based on blinded, locked or limited trial data and in relation to COVID-19-related measures and individual precautionary measures that may be implemented or continued for an uncertain period of time; our potential inability to raise sufficient capital to fund our ongoing operations as currently planned or to obtain financings on terms similar to those we have arranged in the past; our ability to service our indebtedness and otherwise comply with our debt covenants; outcomes or trends from competitive studies; future topline data timing or results; the risks of achieving potential benefits in studies that includes substantially more patients, and patients with different disease states, than our prior studies; limitations associated with early stage or non-placebo controlled study data; the timing and outcomes of clinical studies of resmetirom; and the uncertainties inherent in clinical testing. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Madrigal undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. Please refer to Madrigal’s submissions filed or furnished with the U.S. Securities and Exchange Commission for more detailed information regarding these risks and uncertainties and other factors that may cause actual results to differ materially from those expressed or implied. We specifically discuss these risks and uncertainties in greater detail in the section appearing in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on February 23, 2023 (the “2022 Form 10-K”), as well as in our other filings with the SEC. You should read the 2022 Form 10-K, this Quarterly Report, and the other documents that we file or have filed with the SEC, with the understanding that our actual future results may be materially different from the results expressed or implied by these forward-looking statements.

Moreover, we operate in an evolving environment. New risks and uncertainties emerge from time to time and it is not possible for our management to predict all risks and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual future results to be materially different from those expressed or implied by any forward-looking statements.

 

17


Except as required by applicable law or the rules of the NASDAQ Stock Market, or NASDAQ, we assume no obligation to update any forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. We qualify all of our forward-looking statements by these cautionary statements.

 

18


Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The consolidated financial statements, included elsewhere in this Quarterly Report on Form 10-Q, and this Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read together with our audited financial statements and accompanying notes for year ended December 31, 2022 and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, both of which are included in our Annual Report on Form 10-K. In addition to historical information, this discussion and analysis contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions. As disclosed in this report under “Cautionary Note Regarding Forward-Looking Statements,” our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the “Cautionary Note Regarding Forward-Looking Statements” and “Risk Factors” sections contained in our Annual Report on Form 10-K for the year ended December 31, 2022. Our operating results are not necessarily indicative of results that may occur for the full fiscal year or any other future period.

About Madrigal Pharmaceuticals, Inc.

Our Focus. We are a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis, or NASH. Our lead product candidate, resmetirom, is a proprietary, liver-directed, selective thyroid hormone receptor-ß, or THR-ß, agonist being developed as a once-daily oral pill for the treatment of NASH.

Our Patient Market Opportunity. NASH is a serious inflammatory form of nonalcoholic fatty liver disease, or NAFLD. NAFLD has become the most common liver disease in the United States and other developed countries and is characterized by an accumulation of fat in the liver with no other apparent causes. NASH can progress to cirrhosis or liver failure, require liver transplantation and can also result in liver cancer. Progression of NASH to end stage liver disease will soon surpass all other causes of liver failure requiring liver transplantation. Importantly, beyond these critical conditions, NASH and NAFLD patients additionally suffer heightened cardiovascular risk and, in fact, die more frequently from cardiovascular events than from liver disease. NASH and NAFLD have grown as a consequence of rising worldwide obesity-related disorders. In the United States, NAFLD is estimated to affect approximately 25% of the population, and approximately 25% of those will progress from NAFLD to NASH. Current estimates place NASH prevalence at approximately 22 million people in the United States by 2024, with similar prevalence in Europe and Asia. The prevalence of NASH is also increasing in developing regions due to the adoption of a more sedentary lifestyle and a diet consisting of processed foods with high fat and fructose content.

Our Completed Studies. For NASH, we enrolled 125 patients in a Phase 2 clinical trial with resmetirom. We achieved the 12-week primary endpoint for this Phase 2 clinical trial and reported the results in December 2017, and we reported positive topline 36-week results at the conclusion of the Phase 2 clinical trial in May 2018. We also completed a 36-week, open-label extension study in 31 participating NASH patients from our Phase 2 clinical trial, which included 14 patients who received placebo in the main study.

On December 18, 2019 the Company announced it had opened for enrollment MAESTRO-NAFLD-1, a 52-week, non-invasive, multi-center, double-blind, placebo-controlled Phase 3 clinical study of patients with biopsy-confirmed or presumed NASH recruited from sites in the U.S. Key endpoints are safety, including safety biomarkers. Secondary endpoints include LDL cholesterol, lipid biomarkers, MRI-PDFF, NASH and fibrosis biomarkers. Except for serial liver biopsies, the study protocol is similar to the MAESTRO-NASH study (discussed below under “—Our Ongoing and Planned Studies”), with resmetirom doses of 80 mg or 100 mg or placebo. Enrollment objectives for this study were exceeded, with approximately 1,300 patients enrolled overall. Using noninvasive measures, MAESTRO-NAFLD-1 was designed to provide incremental safety information to support the NASH indication as well as provide additional data regarding clinically relevant key secondary efficacy endpoints to better characterize the potential clinical benefits of resmetirom on cardiovascular- and liver-related endpoints. In November of 2021, we reported data from the open label non-cirrhotic arm of MAESTRO-NAFLD-1, and in January 2022 we announced that we achieved primary and secondary endpoints for the double-blind portion of MAESTRO-NAFLD-1.

An additional open-label active treatment arm in 180 patients with early (well-compensated) NASH cirrhosis was conducted. Resmetirom was safe and well tolerated in the MAESTRO-NAFLD-1 open-label cohort of patients with well-compensated NASH cirrhosis. As observed in patients with noncirrhotic NASH, mild GI adverse events were seen at the beginning of therapy. Resmetirom reduced LDL-C, other atherogenic lipids and lipoproteins, and MRI-PDFF in patients with NASH cirrhosis and also reduced liver and spleen volume.

Our Ongoing and Planned Studies. On March 28, 2019, the Company announced that it had initiated MAESTRO-NASH, a Phase 3 trial in NASH with its once daily, oral thyroid hormone receptor beta selective agonist, resmetirom. This double-blind, placebo-controlled study is being conducted at more than 220 sites in the United States and the rest of the world. MAESTRO-NASH is a

 

19


multicenter, randomized, double-blind, placebo-controlled Phase 3 study of resmetirom in patients with liver biopsy-confirmed NASH and was initiated in March 2019. The subpart H portion of the study enrolled more than 1,000 patients with biopsy-proven NASH (at least half with F3 (advanced) fibrosis, the remainder F2 or F1B (moderate fibrosis) with a few earlier F1 patients), randomized 1:1:1 to receive once-daily resmetirom 80 mg, resmetirom 100 mg, or placebo. After 52 weeks of treatment, a second liver biopsy is performed. The dual primary surrogate endpoints on biopsy are NASH resolution with ≥2-point reduction in NAS (NAFLD Activity Score), and with no worsening of fibrosis OR a 1-point decrease in fibrosis with no worsening of NAS. Achievement of either primary endpoint is considered a successful trial outcome. A key secondary endpoint is lowering of LDL-C. All patients enrolled in the

 

20


MAESTRO-NASH study (approximately 1,750) continue on therapy after the initial 52-week treatment period for up to 54 months to accrue and measure hepatic clinical outcome events including progression to cirrhosis on biopsy (52 weeks and 54 months) and hepatic decompensation events, as well as all-cause mortality. In December 2022, we reported topline results from the subpart H portion of the study: resmetirom achieved both primary endpoints with both daily oral doses, 80 mg and 100 mg, relative to placebo, as summarized in “- Key Developments” in our Annual Report on Form 10-K for the year ended December 31, 2022.

On July 13, 2021 we announced first patient dosed in a planned 52-week open label active treatment extension study of MAESTRO-NAFLD-1, named MAESTRO-NAFLD-Open Label Extension (OLE). The OLE study allows patients who complete MAESTRO-NAFLD-1 to consent to 52 weeks of active treatment with resmetirom, making this treatment available to both patients who were assigned to placebo in MAESTRO-NAFLD-1 and patients who were on resmetirom in MAESTRO-NAFLD-1.

In August 2022, Madrigal initiated MAESTRO-NASH-OUTCOMES, a randomized double-blind placebo-controlled study in approximately 700 patients with early NASH cirrhosis to allow for noninvasive monitoring of progression to liver decompensation events. A positive outcome is expected to support the full approval of resmetirom for noncirrhotic NASH, potentially accelerating the timeline to full approval. In addition, this study has the potential to support an additional indication for resmetirom in patients with well-compensated NASH cirrhosis.

Key Developments

In July 2023, Madrigal announced the completion of the rolling submission of its New Drug Application (NDA) to the FDA for resmetirom for the treatment of adults with NASH with liver fibrosis, a disease with no approved therapy. Madrigal has requested a priority review of the resmetirom NDA.

In April 2023, Madrigal announced that resmetirom has received Breakthrough Therapy designation from the FDA for the treatment of patients with NASH with liver fibrosis. Breakthrough Therapy designation is a process intended to expedite the development and review of drugs for serious or life-threatening conditions. The criteria for breakthrough therapy designation require preliminary clinical evidence that demonstrates the drug may have substantial improvement on at least one clinically significant endpoint over available therapy, or over placebo if there is no available therapy. A drug that receives Breakthrough Therapy designation is eligible for more intensive guidance on an efficient drug development program and organizational commitment involving senior managers from FDA.

Also in April 2023, Madrigal announced that the outcomes portion of the Phase 3 MAESTRO-NASH biopsy trial has completed enrollment. Enrollment of the MAESTRO-NASH study was closed at approximately 1,750 patients based on the enrollment target of the 54-month long-term clinical outcome portion of the study.

Basis of Presentation

Research and Development Expenses

Research and development expenses primarily consist of costs associated with our research activities, including the preclinical and clinical development of our product candidates. We expense our research and development expenses as incurred. We contract with clinical research organizations to manage our clinical trials under agreed upon budgets for each study, with oversight by our clinical program managers. We account for nonrefundable advance payments for goods and services that will be used in future research and development activities as expenses when the service has been performed or when the goods have been received. Manufacturing expense includes costs associated with drug formulation development and clinical drug production. We do not track employee and facility related research and development costs by project, as we typically use our employee and infrastructure resources across multiple research and development programs. We believe that the allocation of such costs would be arbitrary and not be meaningful.

Our research and development expenses consist primarily of:

 

   

salaries and related expense, including stock-based compensation;

 

   

external expenses paid to clinical trial sites, contract research organizations, laboratories, database software and consultants that conduct clinical trials;

 

   

expenses related to development and the production of nonclinical and clinical trial supplies, including fees paid to contract manufacturers;

 

   

expenses related to preclinical studies;

 

   

expenses related to compliance with drug development regulatory requirements; and

 

   

other allocated expenses, which include direct and allocated expenses for depreciation of equipment and other supplies.

 

21


We expect to continue to incur substantial expenses related to our development activities for the foreseeable future as we conduct our clinical studies programs, manufacturing and toxicology studies. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later stage clinical trials, additional drug manufacturing requirements, and later stage toxicology studies such as carcinogenicity studies. Our research and development expenses have increased period over period in each of 2023 and 2022 and we expect that our research and development expenses may increase in the future. The process of conducting preclinical studies and clinical trials necessary to obtain regulatory approval is costly and time consuming. The probability of success for each product candidate is affected by numerous factors, including preclinical data, clinical data, competition, manufacturing capability and commercial viability. Accordingly, we may never succeed in achieving marketing approval for any of our product candidates.

Completion dates and costs for our clinical development programs as well as our research program can vary significantly for each current and future product candidate and are difficult to predict. As a result, we cannot estimate with any degree of certainty the costs we will incur in connection with the development of our product candidates at this point in time. We expect that we will make determinations as to which programs and product candidates to pursue and how much funding to direct to each program and product candidate on an ongoing basis in response to the scientific success of research, results of ongoing and future clinical trials, potential collaborative agreements with respect to programs or potential product candidates, as well as ongoing assessments as to each current or future product candidate’s commercial potential.

General and Administrative Expenses

General and administrative expenses consist primarily of salaries, benefits and stock-based compensation expenses for employees, management costs, costs associated with obtaining and maintaining our patent portfolio, professional fees for accounting, auditing, consulting and legal services, and allocated overhead expenses.

We expect that our general and administrative expenses will increase in the future as we expand our operating activities, prepare for commercialization, maintain and expand our patent portfolio and incur additional costs associated with being a public company and maintaining compliance with exchange listing and SEC requirements. We expect these potential increases will likely include management costs, legal fees, accounting fees, directors’ and officers’ liability insurance premiums and expenses associated with investor relations.

Critical Accounting Policies and Estimates

Our management’s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amount of assets, liabilities, and expenses and the disclosure of contingent assets and liabilities as of the date of the financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to accrued research and development expenses and stock-based compensation expense. We base our estimates on historical experience, known trends and events, and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates under different assumptions or conditions. There have been no material changes in our critical accounting policies and significant judgments and estimates during the six months ended June 30, 2023, as compared to those disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed with the SEC on February 23, 2023.

 

22


Results of Operations

Three Months Ended June 30, 2023 and 2022

The following table provides comparative unaudited results of operations for the three months ended June 30, 2023 and 2022 (in thousands):

 

     Three Months Ended June 30,      Increase / (Decrease)  
     2023      2022      $      %  

Research and Development Expenses

   $ 68,605      $ 58,499        10,106        17

General and Administrative Expenses

     17,845        11,774        6,071        52

Interest (Income)

     (3,551      (323      3,228        999

Interest Expense

     2,901        780        2,121        272
  

 

 

    

 

 

       
   $ 85,800      $ 70,730        15,070        21

Revenue

We had no revenue for the three months ended June 30, 2023 and 2022.

Research and Development Expenses

Our research and development expenses were $68.6 million for the three months ended June 30, 2023, compared to $58.5 million in the corresponding period in 2022. Research and development expenses increased by $10.1 million in the 2023 period due primarily to the additional activities related to our Phase 3 clinical trials, including MAESTRO-NASH Outcomes, an increase in headcount, and an increase in stock compensation expense. We expect our research and development expenses to increase as we advance our clinical and preclinical development programs for resmetirom.

General and Administrative Expenses

Our general and administrative expenses were $17.8 million for the three months ended June 30, 2023, compared to $11.8 million in the corresponding period in 2022. General and administrative expenses increased by $6.1 million in the 2023 period due primarily to increases in commercial preparation activities, including a corresponding increase in headcount, and an increase in stock compensation expense. We believe our general and administrative expenses may increase over time as we advance our clinical and preclinical development programs for resmetirom, prepare for commercialization, and expand our operating activities, which will likely result in an increase in our headcount, consulting services, and related overhead needed to support those efforts.

Interest Income

Our net interest income was $3.6 million for the three months ended June 30, 2023, compared to $0.3 million in the corresponding period in 2022. The increase in interest income was due primarily to higher principal balances and interest rates in 2023.

Interest Expense

Our interest expense was $2.9 million for the three months ended June 30, 2023, compared to $0.8 million in the corresponding period in 2022. The increase in interest expense was primarily as a result of higher outstanding principal balances during the period under the Loan Facility with Hercules.

Six Months Ended June 30, 2023 and 2022

The following table provides comparative unaudited results of operations for the six months ended June 30, 2023 and 2022 (in thousands):

 

     Six Months Ended June 30,      Increase / (Decrease)  
     2023      2022      $      %  

Research and Development Expenses

   $ 130,759      $ 106,428        24,331        23

General and Administrative Expenses

     34,027        21,432        12,595        59

Interest (Income)

     (7,327      (392      6,935        1769

Interest Expense

     5,237        780        4,457        571
  

 

 

    

 

 

       
   $ 162,696      $ 128,248        34,448        27

 

23


Revenue

We had no revenue for the six months ended June 30, 2023 and 2022.

Research and Development Expenses

Our research and development expenses were $130.8 million for the six months ended June 30, 2023, compared to $106.4 million in the corresponding period in 2022. Research and development expenses increased by $24.3 million in the 2023 period due primarily to the additional activities related to our Phase 3 clinical trials, including MAESTRO-NASH Outcomes, an increase in headcount, and an increase in stock compensation expense. We expect our research and development expenses to increase as we advance our clinical and preclinical development programs for resmetirom.

General and Administrative Expenses

Our general and administrative expenses were $34.0 million for the six months ended June 30, 2023, compared to $21.4 million in the corresponding period in 2022. General and administrative expenses increased by $12.6 million in the 2023 period due primarily to increases in commercial preparation activities, including a corresponding increase in headcount, and an increase in stock compensation expense. We believe our general and administrative expenses may increase over time as we advance our clinical and preclinical development programs for resmetirom, prepare for commercialization, and expand our operating activities, which will likely result in an increase in our headcount, consulting services, and related overhead needed to support those efforts.

Interest Income

Our net interest income was $7.3 million for the six months ended June 30, 2023, compared to $0.4 million in the corresponding period in 2022. The increase in interest income was due primarily to higher principal balances and interest rates in 2023.

Interest Expense

Our interest expense was $5.2 million for the six months ended June 30, 2023, compared to $0.8 million in the corresponding period in 2022. The increase in interest expense was primarily as a result of higher outstanding principal balances during the period under the Loan Facility with Hercules.

Liquidity and Capital Resources

Since inception, we have incurred significant net losses and we have funded our operations primarily through the issuance of shares of our common stock and shares of our preferred stock, borrowings under the Loan Facility with Hercules, the issuance of convertible debt and the proceeds from the merger with Synta Pharmaceuticals Corp. Our most significant use of capital pertains to salaries and benefits for our employees, including clinical, scientific, operational, financial and management personnel, and external research and development expenses, such as clinical trials and preclinical activity related to our product candidates.

As of June 30, 2023, we had cash, cash equivalents and marketable securities totaling $298.4 million compared to $358.8 million as of December 31, 2022, with this decrease attributable to funding of operations, partially offset by $50.0 million drawn from the Loan Facility with Hercules, proceeds from the exercise of stock options, and proceeds from the at-the-market sales agreement with Cowen and Company, LLC (“Cowen”). Our cash and investment balances are held in a variety of interest-bearing instruments, including obligations of U.S. government agencies, U.S. Treasury debt securities, corporate debt securities and money market funds. Cash in excess of immediate requirements is invested in accordance with our investment policy with a view toward capital preservation and liquidity.

We anticipate continuing to incur operating losses for the foreseeable future. While our rate of cash usage will likely increase in the future, in particular to support our product development and clinical trial efforts, as well as preparation for commercialization, we believe our available cash resources as of June 30, 2023 will be sufficient to fund our operations past one year from the issuance of the financial statements contained herein. Our future long-term liquidity requirements will be substantial and will depend on many factors. To meet future long-term liquidity requirements, as well as maintain compliance with certain of our Loan Facility covenants, we will need to raise additional capital to fund our operations through equity or debt financings, collaborations, partnerships or other strategic transactions. We regularly consider fundraising opportunities and may decide, from time to time, to raise capital based on various factors, including market conditions and our plans of operation. Additional capital may not be available on terms acceptable to us, or at all. We also have the ability to delay certain research activities and related clinical expenses, as well as commercial preparation investments, if necessary due to liquidity concerns until a date when those concerns are relieved. If adequate funds are not available, or if the terms of potential funding sources are unfavorable, our business and our ability to develop our product candidates would be harmed. Furthermore, any sales of additional equity securities may result in dilution to our stockholders, and any debt financing may include covenants that restrict our business.

 

24


At-the-Market Sales Agreement

On May 9, 2023, the Company entered into Amendment No. 1 (the “Amendment”) to the Sales Agreement, dated June 1, 2021 (as amended, the “Sales Agreement”) with Cowen, which Amendment increased by up to an additional $200,000,000 the amount of common stock that can be issued and sold by the Company from time to time through or to Cowen under the Sales Agreement, acting as agent or principal.

Sales of our common stock, if any, under the Sales Agreement will be made by any method that is deemed to be an “at the market” offering as defined in Rule 415(a)(4) of the Securities Act of 1933, as amended. The Company has no obligation to sell any common stock and may at any time suspend offers under the Sales Agreement or terminate the Sales Agreement pursuant to its terms.

Loan Facility

Please see “Note 6 – Long Term Debt” to the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for information on our Loan Facility with Hercules.

Cash Flows

The following table provides a summary of our net cash flow activity (in thousands):

 

     Six Months Ended June 30,  
     2023      2022  

Net cash used in operating activities

   $ (159,377    $ (107,273

Net cash provided by (used in) investing activities

     (190,596      75,162  

Net cash provided by financing activities

     95,620        49,114  
  

 

 

    

 

 

 

Net increase (decrease) in cash and cash equivalents

   $ (254,353    $ 17,003  

Net cash used in operating activities was $159.4 million for the six months ended June 30, 2023, compared to $107.3 million for the corresponding period in 2022. The use of cash in these periods resulted primarily from our losses from operations, as adjusted for non-cash charges for stock-based compensation, and changes in our working capital accounts.

Net cash used in investing activities was $190.6 million for the six months ended June 30, 2023, compared to $75.2 million provided by for the corresponding period in 2022. Net cash used in investing activities for the six months ended June 30, 2023 primarily consisted of $290.7 million of purchases of marketable securities for our investment portfolio, partially offset by $100.2 million from sales and maturities of marketable securities. Net cash provided by investing activities for the corresponding period in 2022 primarily consisted of $191.8 million from sales and maturities of marketable securities, partially offset by $116.5 million of purchases of marketable securities for our investment portfolio.

Net cash provided by financing activities was $95.6 million for the six months ended June 30, 2023, compared to $49.1 million for the corresponding period in 2022. Financing activities for the six months ended June 30, 2023 consisted of $50.0 million from borrowings under the Loan Facility, $24.2 million of proceeds from the exercise of common stock options, and $21.8 million from sales of our common stock under the 2023 Sales Agreement, partially offset by $0.3 million of loan issuance costs.

Contractual Obligations and Commitments

Except for the future minimum payments due on the Loan Facility with Hercules set forth in “Note 6 – Long Term Debt” to the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q, no significant changes to contractual obligations and commitments occurred during the six months ended June 30, 2023, as compared to those disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed with the SEC on February 23, 2023.

 

25


Item 3.

Quantitative and Qualitative Disclosures About Market Risk.

Interest Rate Risk

Our exposure to market risk is confined to our cash, cash equivalents and marketable securities and Loan Facility. We regularly review our investments and monitor the financial markets. We invest in high-quality financial instruments, primarily money market funds, U.S. government and agency securities, government- sponsored bond obligations and certain other corporate debt securities, with the effective duration of the portfolio less than twelve months and no security with a duration in excess of twenty-four months, which we believe are subject to limited credit risk. We currently do not hedge interest rate exposure. Due to the short-term duration of our investment portfolio and the current risk profile of our investments, we believe that an immediate 10% change in interest rates would not have a material effect on the fair market value of our portfolio. We do not believe that we have any material exposure to interest rate risk or changes in credit ratings arising from our investments.

In May 2022 we entered into the Loan Facility, which has an interest rate that is linked to the prime rate. We do not believe that we have any material exposure to interest rate risk given the current principal amount of the loan.

Capital Market Risk

We currently have no product revenues and depend on funds raised through other sources. One source of funding is through future debt or equity offerings. Our ability to raise funds in this manner depends upon, among other things, capital market forces affecting our stock price and the factors described in our “Cautionary Note Regarding Forward-Looking “Statements.” “Liquidity and Capital Resources” and “Risk Factors” disclosures included or referred to in this filing.

Effects of Inflation

Inflation generally affects us with increased cost of labor and clinical trial costs. We do not believe that inflation and changing prices had a significant impact on our results of operations for any periods presented herein.

 

Item 4.

Controls and Procedures.

Definition and Limitations of Disclosure Controls

Our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) are designed to provide reasonable assurance that information required to be disclosed by us in the reports that we file under the Exchange Act, such as this Quarterly Report, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Our management evaluates these controls and procedures on an ongoing basis.

We carried out an evaluation, under the supervision of and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level.

Limitations on the Effectiveness of Controls and Procedures

In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute, assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

Changes in Internal Control over Financial Reporting

There has been no change in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

26


PART II – OTHER INFORMATION

 

Item 1.

Legal Proceedings.

We are not party to any material pending legal proceedings. From time to time, we may be involved in legal proceedings arising in the ordinary course of business.

 

Item 1A.

Risk Factors.

Except as set forth below, there have been no material changes to the risk factors included in detail in the “Risk Factors” sections appearing in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on February 23, 2023.

Funds affiliated with Baker Bros. Advisors LP hold a significant portion of our total outstanding shares of common stock (including shares of our common stock issuable upon conversion of shares of our Series A Convertible Preferred Stock and Series B Convertible Preferred Stock), and any sale of such shares into the market, or perception that sales could occur, in the future could cause the market price of our common stock to drop significantly.

Pursuant to a Registration Rights Agreement, dated August 7, 2023, among the Company, 667, L.P. and Baker Brothers Life Sciences, L.P., the Company filed with the SEC on August 8, 2023 a prospectus supplement to the prospectus that forms a part of its effective registration statement on Form S-3 registering for resale up to 3,914,910 shares of our common stock (which includes 1,969,797 shares of common stock issuable upon the conversion of our Series A Convertible Preferred Stock and 400,000 shares of common stock issuable upon the conversion of our Series B Convertible Preferred Stock, each of which are common stock equivalents with no voting rights, that are convertible into shares of common stock on a 1-for-1 basis only to the extent that after giving effect to such conversion the holders thereof and their affiliates and any persons who are members of a Section 13(d) group with the holders or their affiliates would beneficially own (in the aggregate, for purposes of Rule 13d-3 under the Exchange Act) no more than 4.99% of the outstanding common stock, which may be increased or decreased up to 19.99% at the holder’s election on 61 days’ notice and certain limitations) owned by funds affiliated with Baker Bros. Advisors LP (“Baker Bros.”). This represents approximately 18.8% of our total outstanding shares of common stock as of July 31, 2023 on a fully as-converted to common stock basis. Sales of a substantial number of shares of our common stock in the public market by Baker Bros., or the perception that these sales might occur, could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect that sales by Baker Bros., or any perception that sales may occur, may have on the prevailing market price of our common stock.

 

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds.

In June of 2023, in accordance with the terms of its Loan and Security Agreement, as amended, (the “Loan Facility”) with Hercules Capital, Inc. (“Hercules”) the Company issued Hercules and affiliates warrants to purchase 1,051 shares of its common stock at an exercise price of $285.31 per share. The warrant had a Black-Scholes value of $0.2 million, and was issued as consideration in connection with the Company’s borrowing of $15 million under the second tranche of the Loan Facility (as described in “Note 6 – Long Term Debt” to the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q).

All warrants issued to Hercules under the Loan Facility have been issued in reliance upon the exemption provided in Section 4(a)(2) of the Securities Act of 1933, as amended and/or Regulation D promulgated thereunder.

 

Item 3.

Defaults Upon Senior Securities.

None.

 

Item 4.

Mine Safety Disclosures.

Not applicable.

 

Item 5.

Other Information.

On June 15, 2023, Julian Baker and Raymond Cheong, Ph.D./MD were appointed to the Board as Class III directors and will serve terms lasting until the Company’s Annual Meeting of Stockholders to be held in 2025, and until their respective successors have been elected and qualified. The same day the Board determined that it was appropriate for the Company to institute changes to its Board governance structure and implement a separation of the Chairman and Chief Executive Officer functions. Effective June 15, 2023, Julian Baker was appointed to serve as the independent Chairman of the Board of Directors and Paul A. Friedman, M.D. continued service as the Company’s Chief Executive Officer and as a Class I director on the Board until the Company’s Annual Meeting of Stockholders to be held in 2026, and until his successor has been elected and qualified.

Mr. Baker and Dr. Cheong are affiliated with Baker Bros. Advisors LP and its related funds (collectively, “Baker Bros.”), which are significant owners of the Company’s capital stock, as disclosed in SEC filings. Mr. Baker is a managing member of the general partner of Baker Bros. Advisors LP., and Dr. Cheong is a Managing Director at Baker Brothers Investments. In connection with the appointment of Mr. Baker and Dr. Cheong to the Board, Baker Bros. waived rights under that certain Securities Purchase Agreement, dated June 20, 2017 (the “2017 SPA”), as amended by Amendments No. 1 and 2 (collectively, the “SPA”), to designate a director to the Board while Mr. Baker or Dr. Cheong are on the Board or to appoint a Board observer subject the SPA, while Mr. Baker or Dr. Cheong are on the Board or serving as a Board observer.

Registration Rights Agreement Signing; Resale Prospectus Filing

Pursuant to the terms of the 2017 SPA, the Company agreed with certain fund affiliates of Baker Bros. (the “Baker Bros. Funds” or “BBA Investors”) that if the BBA Investors determined, based on the totality of the circumstances, that they may be deemed to be “affiliates” of the Company within the meaning of Rule 144 of the Securities Act of 1933, as amended (the “Securities Act”), whether through the exercise of their board designation rights under the SPA or otherwise, the Company would enter into the registration rights agreement with the BBA Investors in the form attached to the 2017 SPA (the “Registration Rights Agreement”). The BBA Investors informed the Company prior to the filing of this Form 10-Q they may be deemed to be “affiliates” of the Company and thereafter entered into the Registration Rights Agreement with the Company on August 7, 2023 covering certain resale registration rights with respect to shares of the Company’s common stock (including shares of common stock issuable upon the conversion of any securities of the Company) that are now held or are hereafter acquired by the BBA Investors (the “Registrable Securities”).

Under the Registration Rights Agreement, and following request by the BBA Investors, the Company filed, in connection with the filing of this Form 10-Q, a resale prospectus supplement to the prospectus that forms a part of the Company’s effective Registration Statement on Form S-3ASR (the “Resale Prospectus”) registering the Registrable Securities for resale in satisfaction of the Company’s obligations under the Registration Rights Agreement. The Resale Prospectus registers or covers for resale up to 3,914,910 shares of our common stock currently owned or that may be acquired upon the conversion of securities beneficially owned by the Baker Bros. Funds (the “Resale Shares”). The Company is obligated under the Registration Rights Agreement to register additional Registrable Securities acquired by the BBA Investors, so the Company may be required to file additional supplements to the Resale Prospectus in the future to increase the number of shares that are covered thereby. The Company is obligated to use its reasonable best efforts to maintain the effectiveness of the Resale Prospectus (or any other appropriate subsequent form registering the Registrable Securities) until the earlier of such time that (i) all Registrable Securities covered by the Resale Prospectus have been sold or may be sold freely without limitations or restrictions as to volume or manner of sale pursuant to Rule 144 of the Securities Act, or (ii) all Registrable Securities covered by the Resale Prospectus otherwise cease to be considered Registrable Securities pursuant to the terms of the Registration Rights Agreement. Under the Registration Rights Agreement, the Baker Bros. Funds have the right to one underwritten public offering per calendar year, but no more than three underwritten public offerings in total, to effect the sale or distribution of their Registrable Securities, subject to specified exceptions, conditions and limitations. The rights of the Baker Bros. Funds concerning Registrable Securities under the Registration Rights Agreement will continue in effect for up to ten years following the date of the Registration Rights Agreement.

The foregoing description of the Registration Rights Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Registration Rights Agreement, which is incorporated by reference as an exhibit to this Form 10-Q and is incorporated herein by reference. The Company is filing herewith a copy of the opinion of Hogan Lovells US LLP regarding the legality of the Resale Shares, attached hereto as an exhibit to this Form 10-Q.

The Company is not offering for sale any shares of common stock under the Resale Prospectus, and the Company will not receive any proceeds from the sale of any Resale Shares by the selling stockholder from time to time pursuant to the resale prospectus.

 

Item 6.

Exhibits.

The exhibits filed or furnished as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index, which Exhibit Index is incorporated herein by reference.

 

27


EXHIBIT INDEX

 

Exhibit

Number

   Exhibit Description    Incorporated by Reference   

Filed

Herewith

 
   Form   File No.    Exhibit   Filing Date
    3.1    Certificate of Amendment to Restated Certificate of Incorporation of Madrigal Pharmaceuticals, Inc., as filed on June 16, 2023 with the Secretary of State of the State of Delaware    8-K   001-33277    3.1   June 20, 2023   
    5.1    Legal Opinion of Hogan Lovells US LLP                X  
  10.1    Amendment No. 1 to Sales Agreement, dated May 9, 2023, by and between Madrigal Pharmaceuticals, Inc. and Cowen and Company, LLC.    8-K   001-33277    1.1   May 9, 2023   
  10.2    Registration Rights Agreement, dated August 7, 2023, by and among Madrigal Pharmaceuticals, Inc., 667, L.P. and Baker Brothers Life Sciences, L.P.                X  
  10.3    Form of RSU Agreement for Directors                X  
  10.4    Form of RSU Agreement for Executive Officers                X  
  10.5    Form of RSU Agreement for Employees                X  
  23.1    Consent of Hogan Lovells US LLP (included in Exhibit 5.1)                X  
  31.1    Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.                X  
  31.2    Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.                X  
  32.1*    Certifications of Principal Executive Officer and Principal Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.                X  
101.INS    Inline XBRL Instance Document.                X  
101.SCH    Inline XBRL Taxonomy Extension Schema Document.                X  
101.CAL    Inline XBRL Taxonomy Extension Calculation Linkbase Document.                X  
101.LAB    Inline XBRL Taxonomy Extension Label Linkbase Document.                X  
101.PRE    Inline XBRL Taxonomy Extension Presentation Linkbase Document.                X  
101.DEF    Inline XBRL Taxonomy Extension Definition Linkbase Document.                X  
104    Inline XBRL for the cover page of this Quarterly Report on Form 10-Q, included in the Exhibit 101 Inline XBRL Document Set.             

 

*

The certifications attached as Exhibit 32.1 that accompany this Quarterly Report pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, shall not be deemed “filed” by the registrant for purposes of Section 18 of the Exchange Act and are not to be incorporated by reference into any of the registrant’s filings under the Securities Act or the Exchange Act, irrespective of any general incorporation language contained in any such filing.

 

28


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

    MADRIGAL PHARMACEUTICALS, INC.
Date: August 8, 2023     By:  

/s/ Paul A. Friedman, M.D.

      Paul A. Friedman, M.D.
      Chief Executive Officer and Chairman of the Board
      (Principal Executive Officer)
Date: August 8, 2023     By:  

/s/ Alex G. Howarth

      Alex G. Howarth
      Senior Vice President and Chief Financial Officer
      (Principal Financial and Accounting Officer)

 

29

EX-5.1 2 d530762dex51.htm EX-5.1 EX-5.1

Exhibit 5.1

 

LOGO  

Hogan Lovells US LLP

555 Thirteenth Street, NW

Washington, D.C. 20004

T +1 202 637 5600

F +1 202 637 5910

www.hoganlovells.com

August 8, 2023

Board of Directors

Madrigal Pharmaceuticals, Inc.

Four Tower Bridge

200 Barr Harbor Drive, Suite 200

West Conshohocken, PA 19428

Ladies and Gentlemen:

We are acting as counsel to Madrigal Pharmaceuticals, Inc., a Delaware corporation (the “Company”), in connection with the public offering by entities affiliated with Baker Bros. Advisors LP (collectively, the “Selling Stockholder”) of up to (i) 1,545,113 shares of the Company’s common stock, par value $0.01 per share (“Common Stock”) currently issued and outstanding (the “Outstanding Shares”), including 979,457 shares of Common Stock purchased by the Selling Stockholders in open market transactions (the “Open Market Shares”) and (ii) 1,969,797 shares of Common Stock issuable upon conversion (the “Series A Conversion Shares”) of the Company’s Series A Convertible Preferred Stock, par value $0.01 per share (the “Series A Preferred Shares”) and 400,000 shares of Common Stock issuable upon conversion (the “Series B Conversion Shares” and, together with the Series A Conversion Shares, the “Conversion Shares”) of the Company’s Series B Convertible Preferred Stock, par value $0.01 per share (the “Series B Preferred Shares”) owned by the Selling Stockholder pursuant to the prospectus supplement, dated August 8, 2023 (the “Prospectus Supplement”) to the Company’s registration statement on Form S-3 (the “Registration Statement”) filed with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Act”) on June 1, 2021, including a base prospectus (the “Base Prospectus” and together with the Prospectus Supplement, the “Prospectus”) that forms a part thereof. This opinion letter is furnished to you at your request to enable you to fulfill the requirements of Item 601(b)(5) of Regulation S-K, 17 C.F.R. § 229.601(b)(5), in connection with the Registration Statement.

For purposes of this opinion letter, we have examined copies of such agreements, instruments and documents as we have deemed an appropriate basis on which to render the opinions hereinafter expressed. In our examination of the aforesaid documents, we have assumed the genuineness of all signatures, the legal capacity of all natural persons, the accuracy and completeness of all documents submitted to us, the authenticity of all original documents, and the conformity to authentic original documents of all documents submitted to us as copies (including pdfs). As to all matters of fact, we have relied on the representations and statements of fact made in the documents so reviewed, and we have not independently established the facts so relied on. This opinion letter is given, and all statements herein are made, in the context of the foregoing. For purposes of our opinion, we assume that the Open Market Shares were, when originally issued, duly authorized,

 

Hogan Lovells US LLP is a limited liability partnership registered in the District of Columbia. “Hogan Lovells” is an international legal practice that includes Hogan Lovells US LLP and Hogan Lovells International LLP, with offices in: Alicante Amsterdam Baltimore Beijing Birmingham Boston Brussels Colorado Springs Denver Dubai Dusseldorf Frankfurt Hamburg Hanoi Ho Chi Minh City Hong Kong Houston Johannesburg London Los Angeles Luxembourg Madrid Mexico City Miami Milan Minneapolis Monterrey Munich New York Northern Virginia Paris Philadelphia Rome San Francisco São Paulo Shanghai Silicon Valley Singapore Sydney Tokyo Warsaw Washington, D.C. Associated Offices: Budapest Jakarta Riyadh Shanghai FTZ Ulaanbaatar. Business Service Centers: Johannesburg Louisville. Legal Services Center: Berlin. For more information see www.hoganlovells.com


 

  -2-   August 8, 2023

validly issued, fully-paid and non-assessable, and were the subject of a legal opinion issued prior to the date hereof by another firm of licensed attorneys to such effect.

This opinion letter is based as to matters of law solely on the Delaware General Corporation Law, as amended. We express no opinion herein as to any other statutes, rules or regulations.

Based upon, subject to and limited by the foregoing, we are of the opinion that (i) the Outstanding Shares are validly issued, fully paid, and nonassessable, and (ii) the Conversion Shares have been duly authorized and, if issued upon conversion of the Series A Preferred Shares and the Series B Preferred Shares on the date hereof in accordance with the Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock, the Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock and the Restated Certificate of Incorporation, as amended, of the Company, would be validly issued, fully paid and non-assessable.

This opinion letter has been prepared for use in connection with the filing by the Company of a Quarterly Report on Form 10-Q on the date hereof, which Form 10-Q will be incorporated by reference into the Registration Statement and Prospectus, and speaks as of the date hereof. We assume no obligation to advise of any changes in the foregoing subsequent to the delivery of this letter.

We hereby consent to the filing of this opinion letter as Exhibit 5.1 to the above-described Form 10-Q and to the reference to this firm under the caption “Legal Matters” in the Prospectus. In giving this consent, we do not thereby admit that we are an “expert” within the meaning of the Act.

Very truly yours,

/s/ Hogan Lovells US LLP

EX-10.2 3 d530762dex102.htm EX-10.2 EX-10.2

Exhibit 10.2

REGISTRATION RIGHTS AGREEMENT

This Registration Rights Agreement (this “Agreement”) is made as of August 7, 2023 by and between Madrigal Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.

RECITALS

WHEREAS, the Company and the Investors wish to provide for certain arrangements with respect to the registration of the Registrable Securities (as defined below) by the Company under the Securities Act (as defined below).

NOW, THEREFORE, in consideration of the mutual promises and covenants set forth herein, and other consideration, the receipt and adequacy of which are hereby acknowledged, the parties hereto agree as follows:

Section 1

Definitions

1.1. Certain Definitions. In addition to the terms defined elsewhere in this Agreement, as used in this Agreement, the following terms have the respective meanings set forth below:

(a) “Board” shall mean the Board of Directors of the Company.

(b) “Commission” shall mean the Securities and Exchange Commission or any other federal agency at the time administering the Securities Act.

(c) “Common Stock” shall mean the common stock of the Company, par value $0.0001 per share.

(d) “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended, or any similar successor federal statute and the rules and regulations thereunder, all as the same shall be in effect from time to time.

(e) “Other Securities” shall mean securities of the Company, other than Registrable Securities (as defined below), with respect to which registration rights have been granted by the Company from time to time.


(f) “Person” shall mean any individual, partnership, corporation, company, association, trust, joint venture, limited liability company, unincorporated organization, entity or division, or any government, governmental department or agency or political subdivision thereof.

(g) “Registrable Securities” shall mean shares of Common Stock and any Common Stock issuable upon the exercise or conversion of any other securities (whether equity, debt or otherwise) of the Company, including, but not limited to, the shares of Common Stock issued or issuable upon conversion of the Company’s Series A Convertible Preferred Stock, now owned or hereafter acquired by any of the Investors.

 

2


(h) The terms “register,” “registered” and “registration” shall refer to a registration effected by preparing and filing a Registration Statement in compliance with the Securities Act, and such Registration Statement becoming effective under the Securities Act.

(i) “Registration Expenses” shall mean all expenses incurred by the Company in effecting any registration pursuant to this Agreement, including, without limitation, all registration, qualification, and filing fees, printing expenses, escrow fees, fees and disbursements of counsel for the Company and up to $50,000 of reasonable legal expenses of one special counsel for Investors (if different from the Company’s counsel and if such counsel is reasonably approved by the Company) for underwritten public offerings, blue sky fees and expenses, and expenses of any regular or special audits incident to or required by any such registration, but shall not include Selling Expenses.

(j) “Registration Statement” means any registration statement of the Company filed with, or to be filed with, the Commission under the Securities Act, including the related prospectus, amendments and supplements to such registration statement, including pre- and post-effective amendments, and all exhibits and all material incorporated by reference in such registration statement as may be necessary to comply with applicable securities laws other than a registration statement (and related prospectus) filed on Form S-4 or Form S-8 or any successor forms thereto.

(k) “Rule 144” shall mean Rule 144 as promulgated by the Commission under the Securities Act, as such rule may be amended from time to time, or any similar successor rule that may be promulgated by the Commission.

(l) “Securities Act” shall mean the Securities Act of 1933, as amended, or any similar successor federal statute and the rules and regulations thereunder, all as the same shall be in effect from time to time.

(m) “Selling Expenses” shall mean all underwriting discounts and selling commissions applicable to the sale of Registrable Securities, the fees and expenses of any legal counsel and any other advisors any of the Investors engage and all similar fees and commissions relating to the Investors’ disposition of the Registrable Securities.

(n) “Series A Convertible Preferred Stock” shall mean the Series A Convertible Preferred Stock, par value $0.0001 per share, issued by the Company pursuant to the terms and conditions of that certain Securities Purchase Agreement dated as of June 20, 2017, by and among the Company and the parties signatory thereto.

Section 2

Resale Registration Rights

2.1. Resale Registration Rights.

(a) Following demand by any Investor, the Company shall file with the Commission a Registration Statement on Form S-3 (except if the Company is not then eligible to register for resale the Registrable Securities on Form S-3, in which case such registration shall be on another appropriate form in accordance with the Securities Act) covering the resale of the Registrable Securities by the Investors (the “Resale Registration Shelf”), and the Company shall file such Resale Registration Shelf as promptly as reasonably practicable following such demand, and in any event within sixty (60) days of such demand. Such Resale Registration Shelf shall include a “final” prospectus, including the information required by Item 507 of Regulation S-K of the Securities Act, as provided by the Investors in accordance with Section 2.7. Notwithstanding the foregoing, before filing the Resale Registration Shelf,

 

3


the Company shall furnish to the Investors a copy of the Resale Registration Shelf and afford the Investors an opportunity to review and comment on the Resale Registration Shelf. The Company’s obligation pursuant to this Section 2.1(a) is conditioned upon the Investors providing the information contemplated in Section 2.7.

(b) The Company shall use its reasonable best efforts to cause the Resale Registration Shelf and related prospectuses to become effective as promptly as practicable after filing. The Company shall use its reasonable best efforts to cause such Registration Statement to remain effective under the Securities Act until the earlier of the date (i) all Registrable Securities covered by the Resale Registration Shelf have been sold or may be sold freely without limitations or restrictions as to volume or manner of sale pursuant to Rule 144 or (ii) all Registrable Securities covered by the Resale Registration Shelf otherwise cease to be Registrable Securities pursuant to Section 2.9 hereof. The Company shall promptly, and within two (2) business days after the Company confirms effectiveness of the Resale Registration Shelf with the Commission, notify the Investors of the effectiveness of the Resale Registration Shelf.

(c) Notwithstanding anything contained herein to the contrary, the Company shall not be obligated to effect, or to take any action to effect, a registration pursuant to Section 2.1(a):

(i) if the Company has and maintains an effective Registration Statement on Form S-3ASR that provides for the resale of an unlimited number of securities by selling stockholders (a “Company Registration Shelf”); or

(ii) during the period forty-five (45) days prior to the Company’s good faith estimate of the date of filing of a Company Registration Shelf; or

(iii) if the Company has caused a Registration Statement to become effective pursuant to this Section 2.1 during the prior twelve (12) month period.

(d) If the Company has a Company Registration Shelf in place at any time in which the Investors make a demand pursuant to Section 2.1(a), the Company shall file with the Commission, as promptly as practicable, and in any event within fifteen (15) business days after such demand, a “final” prospectus supplement to its Company Registration Shelf covering the resale of the Registrable Securities by the Investors (the “Prospectus”); provided, however, that the Company shall not be obligated to file more than one Prospectus pursuant to this Section 2.1(d) in any six month period to add additional Registrable Securities to the Company Registration Shelf that were acquired by the Investors other than directly from the Company or in an underwritten public offering by the Company. The Prospectus shall include the information required under Item 507 of Regulation S-K of the Securities Act, which information shall be provided by the Investors in accordance with Section 2.7. Notwithstanding the foregoing, before filing the Prospectus, the Company shall furnish to the Investors a copy of the Prospectus and afford the Investors an opportunity to review and comment on the Prospectus. The Company’s obligation pursuant to this Section 2.1(d) is conditioned upon the Investors providing the information contemplated in Section 2.7.

(e) Deferral and Suspension. At any time after being obligated to file a Resale Registration Shelf or Prospectus, or after any Resale Registration Shelf has become effective or a Prospectus filed with the Commission, the Company may defer the filing of or suspend the use of any such Resale Registration Shelf or Prospectus, upon giving written notice of such action to the Investors with a certificate signed by the Principal Executive Officer of the Company stating that in the good faith judgment of the Board, the filing or use of any such Resale Registration Shelf or Prospectus covering the Registrable Securities would be seriously detrimental to the Company or its stockholders at such time and

 

4


that the Board concludes, as a result, that it is in the best interests of the Company and its stockholders to defer the filing or suspend the use of such Resale Registration Shelf or Prospectus at such time. The Company shall have the right to defer the filing of or suspend the use of such Resale Registration Shelf or Prospectus for a period of not more than one hundred twenty (120) days from the date the Company notifies the Investors of such deferral or suspension; provided that the Company shall not exercise the right contained in this Section 2.1(e) more than once in any twelve month period. In the case of the suspension of use of any effective Resale Registration Shelf or Prospectus, the Investors, immediately upon receipt of notice thereof from the Company, shall discontinue any offers or sales of Registrable Securities pursuant to such Resale Registration Shelf or Prospectus until advised in writing by the Company that the use of such Resale Registration Shelf or Prospectus may be resumed. In the case of a deferred Prospectus or Resale Registration Shelf filing, the Company shall provide prompt written notice to the Investors of (i) the Company’s decision to file or seek effectiveness of the Prospectus or Resale Registration Shelf, as the case may be, following such deferral and (ii) in the case of a Resale Registration Shelf, the effectiveness of such Resale Registration Shelf. In the case of either a suspension of use of, or deferred filing of, any Resale Registration Shelf or Prospectus, the Company shall not, during the pendency of such suspension or deferral, be required to take any action hereunder (including any action pursuant to Section 2.2 hereof) with respect to the registration or sale of any Registrable Securities pursuant to any such Resale Registration Shelf, Company Registration Shelf or Prospectus.

(f) Other Securities. Subject to Section 2.2(e) below, any Resale Registration Shelf or Prospectus may include Other Securities, and may include securities of the Company being sold for the account of the Company; provided such Other Securities are excluded first from such Registration Statement in order to comply with any applicable laws or request from any Government Entity, Nasdaq or any applicable listing agency. For the avoidance of doubt, no Other Securities may be included in an underwritten offering pursuant to Section 2.2 without the consent of the Investors.

2.2. Sales and Underwritten Offerings of the Registrable Securities.

(a) Notwithstanding any provision contained herein to the contrary, the Investors, collectively, shall, subject to the limitations set forth in this Section 2.2, be permitted one underwritten public offering per calendar year, but no more than three underwritten public offerings in total, to effect the sale or distribution of Registrable Securities.

(b) If the Investors intend to effect an underwritten public offering pursuant to a Resale Registration Shelf or Company Registration Shelf to sell or otherwise distribute Registrable Securities, they shall so advise the Company and provide as much notice to the Company as reasonably practicable (and in any event not less than fifteen (15) business days prior to the Investors’ request that the Company file a prospectus supplement to a Resale Registration Shelf or Company Registration Shelf).

(c) In connection with any offering initiated by the Investors pursuant to this Section 2.2 involving an underwriting of shares of Registrable Securities, the Investors shall be entitled to select the underwriter or underwriters for such offering, subject to the consent of the Company, such consent not to be unreasonably withheld, conditioned or delayed.

(d) In connection with any offering initiated by the Investors pursuant to this Section 2.2 involving an underwriting of shares of Registrable Securities, the Company shall not be required to include any of the Registrable Securities in such underwriting unless the Investors (i) enter into an underwriting agreement in customary form with the underwriter or underwriters, (ii) accept customary terms in such underwriting agreement with regard to representations and warranties relating to ownership of the Registrable Securities and authority and power to enter into such underwriting agreement and (iii) complete and execute all questionnaires, powers of attorney, custody agreements, indemnities and other

 

5


documents as may be requested by such underwriter or underwriters. Further, the Company shall not be required to include any of the Registrable Securities in such underwriting if (Y) the underwriting agreement proposed by the underwriter or underwriters contains representations, warranties or conditions that are not reasonable in light of the Company’s then-current business or (Z) the underwriter, underwriters or the Investors require the Company to participate in any marketing, road show or comparable activity that may be required to complete the orderly sale of shares by the underwriter or underwriters.

(e) If the total amount of securities to be sold in any offering initiated by the Investors pursuant to this Section 2.2 involving an underwriting of shares of Registrable Securities exceeds the amount that the underwriters determine in their sole discretion is compatible with the success of the offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities (subject in each case to the cutback provisions set forth in this Section 2.2(e)), that the underwriters and the Company determine in their sole discretion shall not jeopardize the success of the offering. If the underwritten public offering has been requested pursuant to Section 2.2(a) hereof, the number of shares that are entitled to be included in the registration and underwriting shall be allocated in the following manner: (a) first, shares of Company equity securities that the Company desires to include in such registration shall be excluded and (b) second, Registrable Securities requested to be included in such registration by the Investors shall be excluded. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round down the number of shares allocated to any of the Investors to the nearest 100 shares.

2.3. Fees and Expenses. Except as otherwise may be agreed upon between the Investors and the Company, all Registration Expenses incurred in connection with registrations pursuant to this Agreement shall be borne by the Company. All Selling Expenses relating to securities registered on behalf of the Investors shall be borne by the Investors.

2.4. Registration Procedures. In the case of each registration of Registrable Securities effected by the Company pursuant to Section 2.1 hereof, the Company shall keep the Investors advised as to the initiation of each such registration and as to the status thereof. The Company shall use its reasonable best efforts, within the limits set forth in this Section 2.4, to:

(a) prepare and file with the Commission such amendments and supplements to such Registration Statement and the prospectuses used in connection with such Registration Statement as may be necessary to keep such Registration Statement effective and current and comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such Registration Statement;

(b) furnish to the Investors such numbers of copies of a prospectus, including preliminary prospectuses, in conformity with the requirements of the Securities Act, and such other documents as the Investors may reasonably request in order to facilitate the disposition of Registrable Securities;

(c) use its reasonable best efforts to register and qualify the Registrable Securities covered by such Registration Statement under such other securities or blue sky laws of such jurisdictions in the United States as shall be reasonably requested by the Investors, provided that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a general consent to service of process in any such states or jurisdictions;

(d) in the event of any underwritten public offering, and subject to Section 2.2(d), enter into and perform its obligations under an underwriting agreement, in usual and customary form,with the managing underwriter of such offering and take such other usual and customary action as the Investors may reasonably request in order to facilitate the disposition of such Registrable Securities;

 

6


(e) notify the Investors at any time when a prospectus relating to a Registration Statement covering any Registrable Securities is required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus included in such Registration Statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing. The Company shall use its reasonable best efforts to amend or supplement such prospectus in order to cause such prospectus not to include any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing;

(f) provide a transfer agent and registrar for all Registrable Securities registered pursuant to such Registration Statement and, if required, a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration;

(g) if requested by an Investor, use reasonable best efforts to cause the Company’s transfer agent to remove any restrictive legend from any Registrable Securities being transferred by an Investor pursuant to a Resale Registration Shelf or Company Registration Shelf, within two business days following such request;

(h) cause to be furnished, at the request of the Investors, on the date that Registrable Securities are delivered to underwriters for sale in connection with an underwritten offering pursuant to this Agreement, (i) an opinion, dated such date, of the counsel representing the Company for the purposes of such registration, in form and substance as is customarily given to underwriters in an underwritten public offering, addressed to the underwriters, and (ii) a letter or letters from the independent certified public accountants of the Company, in form and substance as is customarily given by independent certified public accountants to underwriters in an underwritten public offering, addressed to the underwriters; and

(i) cause all such Registrable Securities included in a Registration Statement pursuant to this Agreement to be listed on each securities exchange or other securities trading markets on which Common Stock is then listed.

2.5. The Investors Obligations.

(a) Discontinuance of Distribution. The Investors agree that, upon receipt of any notice from the Company of the occurrence of any event of the kind described in Section 2.4(e) hereof, the Investors shall immediately discontinue disposition of Registrable Securities pursuant to any Registration Statement covering such Registrable Securities until the Investors’ receipt of the copies of the supplemented or amended prospectus contemplated by Section 2.4(e) hereof or receipt of notice that no supplement or amendment is required and that the Investors’ disposition of the Registrable Securities may be resumed. The Company may provide appropriate stop orders to enforce the provisions of this Section 2.5(a).

(b) Compliance with Prospectus Delivery Requirements. The Investors covenant and agree that they shall comply with the prospectus delivery requirements of the Securities Act as applicable to them or an exemption therefrom in connection with sales of Registrable Securities pursuant to any Registration Statement filed by the Company pursuant to this Agreement.

 

7


(c) Notification of Sale of Registrable Securities. The Investors covenant and agree that they shall notify the Company following the sale of Registrable Securities to a third party as promptly as reasonably practicable, and in any event within thirty (30) days, following the sale of such Registrable Securities.

2.6. Indemnification.

(a) To the extent permitted by law, the Company shall indemnify the Investors, and, as applicable, their officers, directors, and constituent partners, legal counsel for each Investor and each Person controlling the Investors, with respect to which registration, related qualification, or related compliance of Registrable Securities has been effected pursuant to this Agreement, and each underwriter, if any, and each Person who controls any underwriter within the meaning of the Securities Act against all claims, losses, damages, or liabilities (or actions in respect thereof) to the extent such claims, losses, damages, or liabilities arise out of or are based upon (i) any untrue statement (or alleged untrue statement) of a material fact contained in any prospectus or other document (including any related Registration Statement) incident to any such registration, qualification, or compliance, or (ii) any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, or (iii) any violation or alleged violation by the Company of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act or any state securities law applicable to the Company and relating to action or inaction required of the Company in connection with any such registration, qualification, or compliance; and the Company shall pay as incurred to the Investors, each such underwriter, and each Person who controls the Investors or underwriter, any legal and any other expenses reasonably incurred in connection with investigating or defending any such claim, loss, damage, liability, or action; provided, however, that the indemnity contained in this Section 2.6(a) shall not apply to amounts paid in settlement of any such claim, loss, damage, liability, or action if settlement is effected without the consent of the Company (which consent shall not unreasonably be withheld); and provided, further, that the Company shall not be liable in any such case to the extent that any such claim, loss, damage, liability, or expense arises out of or is based upon any violation by such Investor of the obligations set forth in Section 2.5 hereof or any untrue statement or omission contained in such prospectus or other document based upon written information furnished to the Company by the Investors, such underwriter, or such controlling Person and stated to be for use therein.

(b) To the extent permitted by law, each Investor (severally and not jointly) shall, if Registrable Securities held by such Investor are included for sale in the registration and related qualification and compliance effected pursuant to this Agreement, indemnify the Company, each of its directors, each officer of the Company who signs the applicable Registration Statement, each legal counsel and each underwriter of the Company’s securities covered by such a Registration Statement, each Person who controls the Company or such underwriter within the meaning of the Securities Act against all claims, losses, damages, and liabilities (or actions in respect thereof) arising out of or based upon (i) any untrue statement (or alleged untrue statement) of a material fact contained in any such Registration Statement, or related document, or (ii) any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, or (iii) any violation or alleged violation by such Investor of Section 2.5 hereof, the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act or any state securities law applicable to such Investor and relating to action or inaction required of such Investor in connection with any such registration and related qualification and compliance, and shall pay as incurred to such persons, any legal and any other expenses reasonably incurred in connection with investigating or defending any such claim, loss, damage, liability, or action, in each case only to the extent that such untrue statement (or alleged untrue statement) or omission (or alleged omission) is made in (and such violation pertains to) such Registration Statement or related

 

8


document in reliance upon and in conformity with written information furnished to the Company by such Investor and stated to be specifically for use therein; provided, however, that the indemnity contained in this Section 2.6(b) shall not apply to amounts paid in settlement of any such claim, loss, damage, liability, or action if settlement is effected without the consent of such Investor (which consent shall not unreasonably be withheld); provided, further, that such Investor’s liability under this Section 2.6(b) (when combined with any amounts such Investor is liable for under Section 2.6(d)) shall not exceed such Investor’s net proceeds from the offering of securities made in connection with such registration.

(c) Promptly after receipt by an indemnified party under this Section 2.6 of notice of the commencement of any action, such indemnified party shall, if a claim in respect thereof is to be made against an indemnifying party under this Section 2.6, notify the indemnifying party in writing of the commencement thereof and generally summarize such action. The indemnifying party shall have the right to participate in and to assume the defense of such claim; provided, however, that the indemnifying party shall be entitled to select counsel for the defense of such claim with the approval of any parties entitled to indemnification, which approval shall not be unreasonably withheld; provided further, however, that if either party reasonably determines that there may be a conflict between the position of the Company and the Investors in conducting the defense of such action, suit, or proceeding by reason of recognized claims for indemnity under this Section 2.6, then counsel for such party shall be entitled to conduct the defense to the extent reasonably determined by such counsel to be necessary to protect the interest of such party. The failure to notify an indemnifying party promptly of the commencement of any such action, if prejudicial to the ability of the indemnifying party to defend such action, shall relieve such indemnifying party, to the extent so prejudiced, of any liability to the indemnified party under this Section 2.6, but the omission so to notify the indemnifying party shall not relieve such party of any liability that such party may have to any indemnified party otherwise than under this Section 2.6.

(d) If the indemnification provided for in this Section 2.6 is held by a court of competent jurisdiction to be unavailable to an indemnified party with respect to any loss, liability, claim, damage, or expense referred to therein, then the indemnifying party, in lieu of indemnifying such indemnified party hereunder, shall contribute to the amount paid or payable by such indemnified party as a result of such loss, liability, claim, damage, or expense in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and of the indemnified party on the other in connection with the statements or omissions that resulted in such loss, liability, claim, damage, or expense as well as any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission. In no event, however, shall (i) any amount due for contribution hereunder be in excess of the amount that would otherwise be due under Section 2.6(a) or Section 2.6(b), as applicable, based on the limitations of such provisions and (ii) a Person guilty of fraudulent misrepresentation (within the meaning of the Securities Act) be entitled to contribution from a Person who was not guilty of such fraudulent misrepresentation.

(e) Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting agreement entered into in connection with an underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control; provided, however, that the failure of the underwriting agreement to provide for or address a matter provided for or addressed by the foregoing provisions shall not be a conflict between the underwriting agreement and the foregoing provisions.

 

9


(f) The obligations of the Company and the Investors under this Section 2.6 shall survive the completion of any offering of Registrable Securities in a Registration Statement under this Agreement or otherwise.

2.7. Information. The Investors shall furnish to the Company such information regarding the Investors and the distribution proposed by the Investors as the Company may reasonably request and as shall be reasonably required in connection with any registration referred to in this Agreement. The Investors agree to, as promptly as practicable (and in any event prior to any sales made pursuant to a prospectus), furnish to the Company all information required to be disclosed in order to make the information previously furnished to the Company by the Investors not misleading. The Investors agree to keep confidential the receipt of any notice received pursuant to Section 2.4(e) and the contents thereof, except as required pursuant to applicable law. Notwithstanding anything to the contrary herein, the Company shall be under no obligation to name the Investors in any Registration Statement if the Investors have not provided the information required by this Section 2.7 with respect to the Investors as a selling securityholder in such Registration Statement or any related prospectus.

2.8. Rule 144 Requirements. With a view to making available to the Investors the benefits of Rule 144 promulgated under the Securities Act and any other rule or regulation of the Commission that may at any time permit the Investors to sell Registrable Securities to the public without registration, the Company agrees to use its reasonable best efforts to:

(a) make and keep public information available, as those terms are understood and defined in Rule 144 under the Securities Act at all times after the date hereof;

(b) file with the Commission in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act;

(c) prior to the filing of the Registration Statement or any amendment thereto (whether pre-effective or post-effective), and prior to the filing of any prospectus or prospectus supplement related thereto, to provide the Investors with copies of all of the pages thereof (if any) that reference the Investors; and

(d) furnish to any Investor, so long as the Investor owns any Registrable Securities, forthwith upon request (i) a written statement by the Company that it has complied with the reporting requirements of Rule 144, (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company, and (iii) such other information as may be reasonably requested by an Investor in availing itself of any rule or regulation of the Commission which permits an Investor to sell any such securities without registration.

2.9. Termination of Status as Registrable Securities. The Registrable Securities shall cease to be Registrable Securities upon the earliest to occur of the following events: (i) such Registrable Securities have been sold pursuant to an effective Registration Statement; (ii) such Registrable Securities have been sold by the Investors pursuant to Rule 144 (or other similar rule), (iii) such Registrable Securities may be resold by the Investor holding such Registrable Securities without limitations as to volume or manner of sale pursuant to Rule 144; or (iv) ten (10) years after the date of this Agreement.

Section 4

Miscellaneous

3.1. Amendment. No amendment, alteration or modification of any of the provisions of this Agreement shall be binding unless made in writing and signed by each of the Company and the Investors.

 

10


3.2. Injunctive Relief. It is hereby agreed and acknowledged that it shall be impossible to measure in money the damages that would be suffered if the parties fail to comply with any of the obligations herein imposed on them and that in the event of any such failure, an aggrieved Person shall be irreparably damaged and shall not have an adequate remedy at law. Any such Person shall, therefore, be entitled (in addition to any other remedy to which it may be entitled in law or in equity) to injunctive relief, including, without limitation, specific performance, to enforce such obligations, and if any action should be brought in equity to enforce any of the provisions of this Agreement, none of the parties hereto shall raise the defense that there is an adequate remedy at law.

3.3. Notices. All notices required or permitted under this Agreement must be in writing and sent to the address or facsimile number identified below. Notices must be given: (a) by personal delivery, with receipt acknowledged; (b) by facsimile followed by hard copy delivered by the methods under clause (c) or (d); (c) by prepaid certified or registered mail, return receipt requested; or (d) by prepaid reputable overnight delivery service. Notices shall be effective upon receipt. Either party may change its notice address by providing the other party written notice of such change. Notices shall be delivered as follows:

If to the Investors: At such Investor’s address as set forth on Schedule A hereto.

If to the Company: Four Tower Bridge

200 Barr Harbor Drive, Suite 200

West Conshohocken, Pennsylvania 19428 Attention: General Counsel

3.4. Governing Law; Jurisdiction; Venue; Jury Trial.

(a) This Agreement shall be governed by, and construed in accordance with, the law of the State of New York without giving effect to any choice or conflict of law provision or rule (whether of the State of New York or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of New York.

(b) Each of the Company and the Investors irrevocably and unconditionally submits, for itself and its property, to the nonexclusive jurisdiction of the courts of the State of New York sitting in the Borough of Manhattan, New York and of the United States District Court of the Southern District of New York, and any appellate court from any thereof, in any action or proceeding arising out of or relating to this Agreement and the transactions contemplated herein, or for recognition or enforcement of any judgment, and each of the Company and the Investors irrevocably and unconditionally agrees that all claims in respect of any such action or proceeding may be heard and determined in such New York state court or, to the fullest extent permitted by applicable law, in such federal court. Each of the Company and the Investors hereto agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law.

(c) Each of the Company and the Investors irrevocably and unconditionally waives, to the fullest extent permitted by applicable law, any objection that it may now or hereafter have to the laying of venue of any action or proceeding arising out of or relating to this Agreement and the transactions contemplated herein in any court referred to in Section 3.4(b) hereof. Each of the Company and the Investors hereby irrevocably waives, to the fullest extent permitted by applicable law, the defense of an inconvenient forum to the maintenance of such action or proceeding in any such court.

 

11


(d) EACH OF THE COMPANY AND THE INVESTORS HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY). EACH OF THE COMPANY AND THE INVESTORS (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PERSON HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PERSON WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT EACH OF THE COMPANY AND THE INVESTORS HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION.

3.5. Successors, Assigns and Transferees. Any and all rights, duties and obligations hereunder shall not be assigned, transferred, delegated or sublicensed by any party hereto without the prior written consent of the other party; provided, however, that the Investors shall be entitled to transfer Registrable Securities to one or more of their affiliates and, solely in connection therewith, may assign their rights hereunder in respect of such transferred Registrable Securities, in each case, so long as such Investor is not relieved of any liability or obligations hereunder, without the prior consent of the Company. Any transfer or assignment made other than as provided in the first sentence of this Section 3.5 shall be null and void. Subject to the foregoing and except as otherwise provided herein, the provisions of this Agreement shall inure to the benefit of, and be binding upon, the successors, permitted assigns, heirs, executors and administrators of the parties hereto.

3.6. Entire Agreement. This Agreement, together with any exhibits hereto, constitute the entire agreement between the parties relating to the subject matter hereof and all previous agreements or arrangements between the parties, written or oral, relating to the subject matter hereof are superseded.

3.7. Waiver. No failure on the part of either party hereto to exercise any power, right, privilege or remedy under this Agreement, and no delay on the part of either party hereto in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver thereof; and no single or partial exercise of any such power, right, privilege or remedy shall preclude any other or further exercise thereof or of any other power, right, privilege or remedy.

3.8. Severability. If any part of this Agreement is declared invalid or unenforceable by any court of competent jurisdiction, such declaration shall not affect the remainder of the Agreement and the invalidated provision shall be revised in a manner that shall render such provision valid while preserving the parties’ original intent to the maximum extent possible.

3.9. Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement. All references in this Agreement to sections, paragraphs and exhibits shall, unless otherwise provided, refer to sections and paragraphs hereof and exhibits attached hereto.

3.10. Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be enforceable against the parties that execute such counterparts (including by facsimile or other electronic means), and all of which together shall constitute one instrument.

3.11. Term and Termination. The Investors’ rights to demand the registration of the Registrable Securities under this Agreement, as well as the Company’s obligations under Section 2.2 hereof, shall terminate automatically once all Registrable Securities cease to be Registrable Securities pursuant to the terms of Section 2.9 of this Agreement.

 

12


IN WITNESS WHEREOF, the parties hereto have executed this Registration Rights Agreement effective as of the day, month and year first above written.

 

MADRIGAL PHARMACEUTICALS, INC.

a Delaware Corporation

By:    

Name:

  Brian J. Lynch
Title:   Senior Vice President and General Counsel

[Signature Page to Registration Rights Agreement]


667, L.P.
BY: BAKER BROS. ADVISORS LP, management company and investment adviser to 667, L.P., pursuant to authority granted to it by Baker Biotech Capital, L.P., general partner to 667, L.P., and not as the general partner.

 

By:    
Name:   Scott Lessing
Title   President

 

BAKER BROTHERS LIFE SCIENCES, L.P.
By: BAKER BROS. ADVISORS LP, management company and investment adviser to Baker Brothers Life Sciences, L.P., pursuant to authority granted to it by Baker Brothers Life Sciences Capital, L.P., general partner to Baker Brothers Life Sciences, L.P., and not as the general partner.

 

By:    
Name:   Scott Lessing
Title   President

[Signature Page to Registration Rights Agreement]


Schedule A

The Investors

667, L.P.

Baker Brothers Life Sciences, L.P.

To the above Investors:

Baker Bros. Advisors LP

860 Washington St. 3d Floor

New York, N.Y. 10014

Attention: Scott Lessing, President

EX-10.3 4 d530762dex103.htm EX-10.3 EX-10.3

Exhibit 10.3

MADRIGAL PHARMACEUTICALS, INC.

AMENDED 2015 STOCK PLAN

RESTRICTED STOCK UNIT AWARD

GRANT NOTICE

 

1.

  Name of Participant:     

2.

 

Grant Date of the RSUs

(the “Grant Date”):

    

3.

  Number of RSUs:     

 

4.

Vesting of Award: Subject to the Participant’s continuous employment or other service relationship with or to the Company or any of its Affiliates as an Employee, director, and/or Consultant from the Grant Date through the first anniversary of the Grant Date (the “Vesting Date”), the RSUs shall become 100 percent (100%) vested on such Vesting Date. Any terms used and not defined herein have the meanings ascribed to such terms in the Madrigal Pharmaceuticals, Inc. Amended 2015 Stock Plan (as it has been and may be amended and/or restated from time to time, the “Plan”).

By signing this Grant Notice or by electronic acknowledgment of this Grant Notice, the Participant acknowledges receipt of and agrees to all the terms and conditions described in this Restricted Stock Unit Award Grant Notice, the attached Restricted Stock Unit Agreement, and the Plan. The Participant acknowledges that he or she has carefully reviewed the Plan and agrees that the Plan will control in the event any provision of the Agreement should appear to be inconsistent with the Plan.

 

MADRIGAL PHARMACEUTICALS, INC.
By:    
Name:    
Title:    
 

PARTICIPANT

ATTACHMENT: Restricted Stock Unit Agreement


MADRIGAL PHARMACEUTICALS, INC.

AMENDED 2015 STOCK PLAN

RESTRICTED STOCK UNIT AGREEMENT

This RESTRICTED STOCK UNIT AGREEMENT (the “Agreement”) is made as of the “Grant Date” set forth in the Restricted Stock Unit Award Grant Notice (“Grant Notice”) between MADRIGAL PHARMACEUTICALS, INC. (the “Company”), a Delaware corporation, and the individual whose name appears on the Restricted Stock Unit Award Grant Notice (the “Participant”).

WHEREAS, the Company has adopted the Madrigal Pharmaceuticals, Inc. Amended 2015 Stock Plan (as it has been and may be amended and/or restated from time to time, the “Plan”) to promote the interests of the Company by providing an incentive for Employees, directors, and Consultants of the Company and its Affiliates;

WHEREAS, pursuant to the provisions of the Plan, and in consideration for the Participant’s past and future services to the Company, the Company desires to grant to the Participant restricted stock units (“RSUs”) related to the Company’s common stock, $0.0001 par value per share (“Common Stock”), in accordance with the provisions of the Plan, all on the terms and conditions hereinafter set forth; and

WHEREAS, the Company and the Participant understand and agree that any terms used and not defined herein have the meanings ascribed to such terms in the Plan.

NOW, THEREFORE, in consideration of the promises and the mutual covenants contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:

 

1.

Grant of Award. The Company hereby grants to the Participant a Stock-Based Award for the number of RSUs set forth in the Grant Notice (the “Award”). Each RSU represents a contingent entitlement of the Participant to receive one share of Common Stock, on the terms and conditions and subject to all the limitations set forth herein, in the Grant Notice, and in the Plan, which are incorporated herein by reference.

 

2.

Vesting of Award.

 

  a.

Subject to the terms and conditions set forth in this Agreement and the Plan: (i) the Award shall vest as set forth in the Grant Notice and is subject to the other terms and conditions of this Agreement and the Plan; and (ii) upon vesting, the Participant shall be entitled to receive such number of shares of Common Stock equivalent to the number of such vested RSUs.


  b.

Notwithstanding anything to the contrary in the Grant Notice or this Agreement, any fractional Shares resulting from the vesting schedule set forth in the Grant Notice will be rounded to the nearest whole Share and shall be rounded up or down as necessary as of the last Vesting Date; provided, in all cases, the Participant cannot vest in more than the number of RSUs set forth in the Grant Notice.

 

3.

Forfeiture of Unvested RSUs.

 

  a.

Except as otherwise set forth in this Agreement, the Grant Notice, the Plan, or a separate agreement between Participant and the Company, if the Participant ceases his or her continuous employment or other service relationship with or to the Company or any of its Affiliates as an Employee, director, and/or Consultant (“Termination”), then all then-unvested RSUs shall automatically and immediately be forfeited to the Company as of such Termination, and this Agreement and the Grant Notice shall automatically and immediately terminate and be of no further force or effect.

 

  b.

For purposes of this Agreement, the Participant’s continuous employment or other service relationship with or to the Company or any of its Affiliates as an Employee, director, and/or Consultant does not terminate when the Participant goes on a bona fide leave of absence that was approved by the Administrator in writing, if the terms of the leave provide for continued service crediting, or when continued service crediting is required by applicable law. The Participant’s continuous employment or other service relationship with or to the Company or any of its Affiliates as an Employee, director, and/or Consultant terminates in any event when the approved leave ends unless the Participant immediately returns to active work. The Administrator may determine, in its discretion, which leaves count for this purpose and when the Participant’s continuous employment or other service relationship with or to the Company or any of its Affiliates as an Employee, director, and/or Consultant terminates for all purposes under the Plan in accordance with the provisions of the Plan.

 

4.

Delivery of Award; Evidence of Issuance. Delivery of the Shares represented by the Participant’s vested RSUs shall be made as soon as practicable after the applicable Vesting Date and, in any event, by no later than sixty (60) days following each applicable Vesting Date. The issuance of the Shares represented by the Participant’s vested RSUs shall be evidenced in such a manner as the Administrator, in its discretion, deems appropriate, including, without limitation, by (i) book-entry registration or (ii) issuance of one or more share certificates.


5.

Prohibitions on Transfer and Sale. This Award (including any additional RSUs received by the Participant as a result of stock dividends, stock splits, or any other similar transaction affecting the Company’s securities without receipt of consideration) shall not be transferable, without the prior approval of the Administrator, by the Participant, by the Participant, other than by will or by the laws of descent and distribution. Except as provided in the previous sentence, the Shares to be issued pursuant to this Agreement shall be issued, during the Participant’s lifetime, only to the Participant (or, in the event of legal incapacity or incompetence, to the Participant’s guardian or representative), and this Award shall not be assigned, pledged, or hypothecated in any way (whether by operation of law or otherwise) and shall not be subject to execution, attachment, or similar process. Any attempted transfer, assignment, pledge, hypothecation, or other disposition of this Award or of any rights granted hereunder contrary to the provisions of this Section 5, or the levy of any attachment or similar process upon this Award, shall be null and void.

 

6.

Adjustments. The Plan contains provisions covering the treatment of RSUs and Shares in a number of contingencies, such as stock splits and Corporate Transactions. Provisions in the Plan for adjustment with respect to this Award and the related provisions with respect to successors to the business of the Company are hereby made applicable hereunder and are incorporated herein by reference.

 

7.

Securities Law Compliance. The Participant specifically acknowledges and agrees that any sales of Shares shall be made in accordance with the requirements of the Securities Act. The Company currently has an effective registration statement on file with the United States Securities and Exchange Commission with respect to the Shares to be granted hereunder. Despite registration, applicable securities laws may restrict the ability of the Participant to sell his or her Shares, including due to the Participant’s affiliation with the Company. The Company shall not be obligated to either issue the Shares or permit the resale of any Shares if such issuance or resale would violate any applicable securities law, rule, or regulation.

 

8.

Rights as a Stockholder. The Participant shall have no rights as a stockholder, including voting and dividend rights, with respect to the RSUs subject to this Agreement, unless and until Shares represented by the Participant’s vested RSUs have been issued to the Participant and either a certificate evidencing the Shares has been issued or an appropriate entry has been made on the Company’s books. No adjustments to Shares represented by the Participant’s vested RSUs shall be made for dividends, distributions, or other rights on or with respect to the Common Stock generally if the applicable record date for any such dividend, distribution, or right occurs before the Participant’s certificate is issued or an appropriate book entry is made, except as otherwise described in the Plan.

 

9.

Incorporation of the Plan; Clawback. The Participant specifically understands and agrees that the RSUs and the Shares to be issued under the Agreement will be issued to the Participant pursuant to the Plan, a copy of which Plan the Participant acknowledges he or she has received, has read, and understands and by which Plan he or she agrees to be


  bound. The provisions of the Plan are incorporated herein by reference. In addition, the RSUs (and any compensation paid or Shares issued pursuant to this Agreement) is subject to recoupment in accordance with The Sarbanes-Oxley Act, The Dodd-Frank Wall Street Reform and Consumer Protection Act and any implementing regulations thereunder, any clawback policy adopted by the Company, and any compensation recovery policy otherwise required by applicable law. No recovery of compensation under such a clawback policy will be an event giving rise to a right to resign for “good reason” or for a “constructive termination” (or similar terms) under any agreement between the Participant and the Company or any Affiliate.

 

10.

Tax Liability of the Participant and Payment of Taxes. The Participant acknowledges and agrees that any income or other taxes due from the Participant with respect to this Award or the Shares to be issued pursuant to this Agreement or otherwise sold shall be the Participant’s responsibility. In the event that the Company or an Affiliate determines that any federal, state, local, or foreign tax or withholding payment is required relating to the RSUs, or the delivery of Shares with respect to this Award, the Company or any Affiliate, subject to the proviso below, will have the right to withhold the delivery of vested Shares otherwise deliverable under this Agreement to meet such obligations, provided that, to the extent required to avoid adverse accounting consequences to the Company, the Shares so withheld will have an aggregate Fair Market Value not exceeding the minimum amount of tax required to be withheld by applicable laws and fractional Shares will not be retained to satisfy any portion of the Company’s withholding obligation (such process, “Net Settlement”); provided, however, the Administrator shall have the discretion to override Net Settlement, (i) provided ninety (90) days’ advance notice is given prior to a Vesting Date from the Company to the Participant, in which case such withholding shall be through a “same day sale” commitment with a broker-dealer that is a member of the Financial Industry Regulatory Authority (a “FINRA Dealer”), whereby the Participant irrevocably elects to sell a portion of the Shares to be delivered in connection with the RSUs to satisfy withholding obligations and whereby the FINRA Dealer irrevocably commits to forward the proceeds necessary to satisfy the withholding obligations directly to the Company or any Affiliate (“Sell to Cover”) or (ii)(A) in lieu of withholding (under Net Settlement) or selling (under Sell to Cover) a fractional vested Share or (B) in connection with withholding obligations arising outside the ordinary course, such as outside annual Vesting Dates of the RSUs, and in each case under (A) or (B) such withholding may be through deduction from payments of any kind otherwise due to the Participant.

The Participant hereby (i) agrees that the Company or any Affiliate shall be entitled to use the foregoing methods to recover such taxes and (ii) acknowledges that, absent further action by the Administrator, in the event that the Company or an Affiliate determines that any federal, state, local, or foreign tax or withholding payment is required relating to the RSUs, or the delivery of Shares with respect to this Award, the Company or any Affiliate will utilize Net Settlement.


The Participant further agrees that the Administrator may, as it reasonably considers necessary, amend or vary this Agreement due to changes in tax laws to facilitate such recovery of taxes.

 

11.

Participant Acknowledgements and Authorizations. The Participant hereby acknowledges the following:

 

  a.

Neither the Company nor any Affiliate is, by the Plan or this Award, obligated to continue the Participant as an Employee, director, or Consultant of the Company or an Affiliate. Unless otherwise specified in a written employment or other written compensatory agreement between the Participant and the Company or an Affiliate, the Company or any Affiliate, as applicable, reserves the right to terminate the Participant’s employment or other service relationship with the Company or an Affiliate at any time and for any reason.

 

  b.

The Plan is discretionary in nature and may be suspended or terminated by the Company at any time.

 

  c.

The grant of this Award is considered a one-time benefit and does not create a contractual or other right to receive any other award under the Plan, benefits in lieu of awards, or any other benefits in the future.

 

  d.

The Plan is a voluntary program of the Company and future awards, if any, will be at the sole discretion of the Company, including, but not limited to, the timing of any grant, the amount of any award, vesting provisions, and the purchase price, if any.

 

  e.

The Participant (i) authorizes the Company and each Affiliate and any agent of the Company or any Affiliate administering the Plan or providing Plan recordkeeping services to disclose to the Company or any of its Affiliates such information and data as the Company or any such Affiliate shall request in order to facilitate the grant of the Award and the administration of the Plan; and (ii) authorizes the Company and each Affiliate to store and transmit such information in electronic form for the purposes set forth in this Agreement.

 

  f.

The obligation of the Company to deliver Shares pursuant to this Award constitutes an unfunded and unsecured obligation of the Company. Until Shares are delivered, the Participant shall have no rights under this Agreement or the Plan, other than those of a general unsecured creditor of the Company. No assets of the Company shall be set aside for the settlement of the RSUs.


12.

Notices. By accepting the Award, the Participant agrees that notices may be given to the Participant in writing either at the Participant’s home or mailing address as shown in the records of the Company or an Affiliate or by electronic transmission (including e-mail or reference to a website or other URL) sent to the Participant through the normal process employed by the Company or the Affiliate, as applicable, for communicating electronically with its employees or other service providers.

 

13.

Assignment and Successors.

 

  a.

This Agreement is personal to the Participant and, without the prior approval of the Administrator, shall not be assignable by the Participant, other than by will or the laws of descent and distribution. This Agreement shall inure to the benefit of and be enforceable by the Participant’s legal representatives and beneficiaries.

 

  b.

This Agreement shall inure to the benefit of and be binding upon the Company and its successors and assigns.

 

14.

Governing Law. This Agreement shall be construed and enforced in accordance with the laws of the State of Delaware, without giving effect to the conflict of law principles thereof. For the purpose of litigating any dispute that arises under this Agreement, whether at law or in equity, the parties hereby consent to exclusive jurisdiction in the Commonwealth of Pennsylvania and agree that such litigation shall be conducted in the state courts of the Commonwealth of Pennsylvania or the federal courts of the United States for the Eastern District of Pennsylvania.

 

15.

Severability. If any provision of this Agreement is held to be invalid or unenforceable by a court of competent jurisdiction, then such provision or provisions shall be modified to the extent necessary to make such provision valid and enforceable, and to the extent that this is impossible, then such provision shall be deemed to be excised from this Agreement, and the validity, legality, and enforceability of the rest of this Agreement shall not be affected thereby.

 

16.

Entire Agreement. This Agreement, together with the Grant Notice and the Plan, constitutes the entire agreement and understanding between the parties hereto with respect to the subject matter hereof and supersedes all prior oral or written agreements and understandings relating to the subject matter hereof, including without limitation any offer letter provision related to the subject matter hereof. No statement, representation, warranty, covenant, or agreement not expressly set forth in this Agreement shall affect or be used to interpret, change, or restrict the express terms and provisions of this Agreement; provided, however, in any event, this Agreement shall be subject to and governed by the Plan.


17.

Modifications and Amendments; Waivers and Consents. The terms and provisions of this Agreement may be modified or amended as provided in the Plan. Except as provided in the Plan, the terms and provisions of this Agreement may be waived, or consent for the departure therefrom granted, only by written document executed by the party entitled to the benefits of such terms or provisions. No such waiver or consent shall be deemed to be or shall constitute a waiver or consent with respect to any other terms or provisions of this Agreement, whether or not similar. Each such waiver or consent shall be effective only in the specific instance and for the purpose for which it was given, and shall not constitute a continuing waiver or consent.

 

18.

Code Section 409A. The Award of RSUs evidenced by this Agreement is intended to be exempt from the nonqualified deferred compensation rules of Code Section 409A as a “short-term deferral” within the meaning of Code Section 409A and, to the maximum extent permitted, shall be construed accordingly. Notwithstanding anything to the contrary in the Plan or this Agreement, none of the Company, its Affiliates, the Board of Directors, the Administrator, or any of their respective agents or delegates will have any obligation to take any action to prevent the assessment of any excise tax or penalty on the Participant under Code Section 409A, and none of the Company, its Affiliates, the Board of Directors, the Administrator, or any of their respective agents or delegates will have any liability to the Participant or any other person for such tax or penalty.

To the extent that the RSUs constitute “deferred compensation” under Code Section 409A, a termination of Service occurs only upon an event that would be a “separation from service” within the meaning of Code Section 409A. If, at the time of the Participant’s “separation from service,” (i) the Participant is a “specified employee” within the meaning of Code Section 409A (and as applied according to procedures of the Company and its Affiliates), and (ii) the Administrator makes a good faith determination that an amount payable under this Agreement on account of the Participant’s separation from service constitutes deferred compensation (within the meaning of Code Section 409A), the payment of which is required to be delayed pursuant to the six (6)-month delay rule set forth in Code Section 409A to avoid taxes or penalties under Code Section 409A (the “Delay Period”), then the Company will not pay such amount on the otherwise scheduled payment date but will instead pay it in a lump sum on the first business day after the Delay Period (or upon the Participant’s death, if earlier), without interest. Each installment of RSUs that vest under this Agreement (if there is more than one installment) will be considered one of a series of separate payments for purposes of Code Section 409A.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

EX-10.4 5 d530762dex104.htm EX-10.4 EX-10.4

Exhibit 10.4

Section 16 Officer Form

MADRIGAL PHARMACEUTICALS, INC.

AMENDED 2015 STOCK PLAN

RESTRICTED STOCK UNIT AWARD

GRANT NOTICE

 

1.

  Name of Participant:     

2.

 

Grant Date of the RSUs

(the “Grant Date”):

    

3.

  Number of RSUs:     

 

4.

Vesting of Award: Subject to the Participant’s continuous employment or other service relationship with or to the Company or any of its Affiliates as an Employee, director, and/or Consultant from the Grant Date through each of the following applicable dates (each such date, a “Vesting Date”), the RSUs shall vest twenty-five percent (25%) of the Number of RSUs above on each of the first, second, third, and fourth anniversaries of the Grant Date. Any terms used and not defined herein have the meanings ascribed to such terms in the Madrigal Pharmaceuticals, Inc. Amended 2015 Stock Plan (as it has been and may be amended and/or restated from time to time, the “Plan”).

By signing this Grant Notice or by electronic acknowledgment of this Grant Notice, the Participant acknowledges receipt of and agrees to all the terms and conditions described in this Restricted Stock Unit Award Grant Notice, the attached Restricted Stock Unit Agreement (including the Restrictive Covenants Agreement attached thereto), and the Plan. The Participant acknowledges that he or she has carefully reviewed the Plan and agrees that the Plan will control in the event any provision of the Agreement should appear to be inconsistent with the Plan.

 

MADRIGAL PHARMACEUTICALS, INC.
By:    
Name:    
Title:    
 
PARTICIPANT

ATTACHMENT: Restricted Stock Unit Agreement & Restrictive Covenants Agreement


MADRIGAL PHARMACEUTICALS, INC.

AMENDED 2015 STOCK PLAN

RESTRICTED STOCK UNIT AGREEMENT

This RESTRICTED STOCK UNIT AGREEMENT (the “Agreement”) is made as of the “Grant Date” set forth in the Restricted Stock Unit Award Grant Notice (“Grant Notice”) between MADRIGAL PHARMACEUTICALS, INC. (the “Company”), a Delaware corporation, and the individual whose name appears on the Restricted Stock Unit Award Grant Notice (the “Participant”).

WHEREAS, the Company has adopted the Madrigal Pharmaceuticals, Inc. Amended 2015 Stock Plan (as it has been and may be amended and/or restated from time to time, the “Plan”) to promote the interests of the Company by providing an incentive for Employees, directors, and Consultants of the Company and its Affiliates;

WHEREAS, pursuant to the provisions of the Plan, and in consideration for the Participant’s past and future services to the Company and for compliance with certain Restrictive Covenants Agreement (as defined below) restrictions set forth herein, the Company desires to grant to the Participant restricted stock units (“RSUs”) related to the Company’s common stock, $0.0001 par value per share (“Common Stock”), in accordance with the provisions of the Plan, all on the terms and conditions hereinafter set forth; and

WHEREAS, the Company and the Participant understand and agree that any terms used and not defined herein have the meanings ascribed to such terms in the Plan.

NOW, THEREFORE, in consideration of the promises and the mutual covenants contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:

 

1.

Grant of Award. The Company hereby grants to the Participant a Stock-Based Award for the number of RSUs set forth in the Grant Notice (the “Award”). Each RSU represents a contingent entitlement of the Participant to receive one share of Common Stock, on the terms and conditions and subject to all the limitations set forth herein, in the Grant Notice, and in the Plan, which are incorporated herein by reference.

 

2.

Vesting of Award.

 

  a.

Subject to the terms and conditions set forth in this Agreement and the Plan: (i) the Award shall vest as set forth in the Grant Notice and is subject to the other terms and conditions of this Agreement and the Plan; and (ii) upon vesting, the Participant shall be entitled to receive such number of shares of Common Stock equivalent to the number of such vested RSUs.

 

1


  b.

Notwithstanding anything to the contrary in the Grant Notice or this Agreement, any fractional Shares resulting from the vesting schedule set forth in the Grant Notice will be rounded to the nearest whole Share and shall be rounded up or down as necessary as of the last Vesting Date; provided, in all cases, the Participant cannot vest in more than the number of RSUs set forth in the Grant Notice.

 

3.

Forfeiture of Unvested RSUs.

 

  a.

Except as otherwise set forth in this Agreement, the Grant Notice, the Plan, or a separate agreement between Participant and the Company, if the Participant ceases his or her continuous employment or other service relationship with or to the Company or any of its Affiliates as an Employee, director, and/or Consultant (“Termination”), then all then-unvested RSUs shall automatically and immediately be forfeited to the Company as of such Termination, and this Agreement and the Grant Notice shall automatically and immediately terminate and be of no further force or effect.

 

  b.

For purposes of this Agreement, the Participant’s continuous employment or other service relationship with or to the Company or any of its Affiliates as an Employee, director, and/or Consultant does not terminate when the Participant goes on a bona fide leave of absence that was approved by the Administrator in writing, if the terms of the leave provide for continued service crediting, or when continued service crediting is required by applicable law. The Participant’s continuous employment or other service relationship with or to the Company or any of its Affiliates as an Employee, director, and/or Consultant terminates in any event when the approved leave ends unless the Participant immediately returns to active work. The Administrator may determine, in its discretion, which leaves count for this purpose and when the Participant’s continuous employment or other service relationship with or to the Company or any of its Affiliates as an Employee, director, and/or Consultant terminates for all purposes under the Plan in accordance with the provisions of the Plan.

 

  c.

This Award is expressly granted as consideration for the Participant’s agreement to comply with the Confidentiality and Inventions and Restrictive Covenants Agreement attached as Exhibit A hereto (the “Restrictive Covenants Agreement”). Therefore, notwithstanding anything to the contrary contained in this Agreement, in the event that the Participant materially breaches the terms of the Restrictive Covenants Agreement, all of the Unvested RSUs then held by the Participant and all Common Stock issued upon the vesting of RSUs that are outstanding and held by the Participant shall be forfeited to the Company immediately upon written notice by the Company. No other awards granted to the Participant under the Plan shall be subject to the forfeiture and repayment obligation set forth in this Section 3.c unless they expressly provide for such obligation.

 

2


4.

Delivery of Award; Evidence of Issuance. Delivery of the Shares represented by the Participant’s vested RSUs shall be made as soon as practicable after the applicable Vesting Date and, in any event, by no later than sixty (60) days following each applicable Vesting Date. The issuance of the Shares represented by the Participant’s vested RSUs shall be evidenced in such a manner as the Administrator, in its discretion, deems appropriate, including, without limitation, by (i) book-entry registration or (ii) issuance of one or more share certificates.

 

5.

Prohibitions on Transfer and Sale. This Award (including any additional RSUs received by the Participant as a result of stock dividends, stock splits, or any other similar transaction affecting the Company’s securities without receipt of consideration) shall not be transferable, without the prior approval of the Administrator, by the Participant, other than by will or by the laws of descent and distribution. Except as provided in the previous sentence, the Shares to be issued pursuant to this Agreement shall be issued, during the Participant’s lifetime, only to the Participant (or, in the event of legal incapacity or incompetence, to the Participant’s guardian or representative), and this Award shall not be assigned, pledged, or hypothecated in any way (whether by operation of law or otherwise) and shall not be subject to execution, attachment, or similar process. Any attempted transfer, assignment, pledge, hypothecation, or other disposition of this Award or of any rights granted hereunder contrary to the provisions of this Section 5, or the levy of any attachment or similar process upon this Award, shall be null and void.

 

6.

Adjustments. The Plan contains provisions covering the treatment of RSUs and Shares in a number of contingencies, such as stock splits and Corporate Transactions. Provisions in the Plan for adjustment with respect to this Award and the related provisions with respect to successors to the business of the Company are hereby made applicable hereunder and are incorporated herein by reference.

 

7.

Securities Law Compliance. The Participant specifically acknowledges and agrees that any sales of Shares shall be made in accordance with the requirements of the Securities Act. The Company currently has an effective registration statement on file with the United States Securities and Exchange Commission with respect to the Shares to be granted hereunder. Despite registration, applicable securities laws may restrict the ability of the Participant to sell his or her Shares, including due to the Participant’s affiliation with the Company. The Company shall not be obligated to either issue the Shares or permit the resale of any Shares if such issuance or resale would violate any applicable securities law, rule, or regulation.

 

3


8.

Rights as a Stockholder. The Participant shall have no rights as a stockholder, including voting and dividend rights, with respect to the RSUs subject to this Agreement, unless and until Shares represented by the Participant’s vested RSUs have been issued to the Participant and either a certificate evidencing the Shares has been issued or an appropriate entry has been made on the Company’s books. No adjustments to Shares represented by the Participant’s vested RSUs shall be made for dividends, distributions, or other rights on or with respect to the Common Stock generally if the applicable record date for any such dividend, distribution, or right occurs before the Participant’s certificate is issued or an appropriate book entry is made, except as otherwise described in the Plan.

 

9.

Incorporation of the Plan; Clawback. The Participant specifically understands and agrees that the RSUs and the Shares to be issued under the Agreement will be issued to the Participant pursuant to the Plan, a copy of which Plan the Participant acknowledges he or she has received, has read, and understands and by which Plan he or she agrees to be bound. The provisions of the Plan are incorporated herein by reference. In addition, the RSUs (and any compensation paid or Shares issued pursuant to this Agreement) are subject to recoupment in accordance with The Sarbanes-Oxley Act, The Dodd-Frank Wall Street Reform and Consumer Protection Act and any implementing regulations thereunder, any clawback policy adopted by the Company, and any compensation recovery policy otherwise required by applicable law. No recovery of compensation under such a clawback policy will be an event giving rise to a right to resign for “good reason” or for a “constructive termination” (or similar terms) under any agreement between the Participant and the Company or any Affiliate.

 

10.

Tax Liability of the Participant and Payment of Taxes. The Participant acknowledges and agrees that any income or other taxes due from the Participant with respect to this Award or the Shares to be issued pursuant to this Agreement or otherwise sold shall be the Participant’s responsibility. In the event that the Company or an Affiliate determines that any federal, state, local, or foreign tax or withholding payment is required relating to the RSUs, or the delivery of Shares with respect to this Award, the Company or any Affiliate, subject to the proviso below, will have the right to withhold the delivery of vested Shares otherwise deliverable under this Agreement to meet such obligations, provided that, to the extent required to avoid adverse accounting consequences to the Company, the Shares so withheld will have an aggregate Fair Market Value not exceeding the minimum amount of tax required to be withheld by applicable laws and fractional Shares will not be retained to satisfy any portion of the Company’s withholding obligation (such process, “Net Settlement”); provided, however, the Administrator shall have the discretion to override Net Settlement, (i) provided ninety (90) days’ advance notice is given prior to a Vesting Date from the Company to the Participant, in which case such withholding shall be through a “same day sale” commitment with a broker-dealer that is a member of the Financial Industry Regulatory Authority (a “FINRA Dealer”), whereby the Participant irrevocably

 

4


  elects to sell a portion of the Shares to be delivered in connection with the RSUs to satisfy withholding obligations and whereby the FINRA Dealer irrevocably commits to forward the proceeds necessary to satisfy the withholding obligations directly to the Company or any Affiliate (“Sell to Cover”) or (ii)(A) in lieu of withholding (under Net Settlement) or selling (under Sell to Cover) a fractional vested Share or (B) in connection with withholding obligations arising outside the ordinary course, such as outside annual Vesting Dates of the RSUs, and in each case under (A) or (B) such withholding may be through deduction from payments of any kind otherwise due to the Participant.

The Participant hereby (i) agrees that the Company or any Affiliate shall be entitled to use the foregoing methods to recover such taxes and (ii) acknowledges that, absent further action by the Administrator, in the event that the Company or an Affiliate determines that any federal, state, local, or foreign tax or withholding payment is required relating to the RSUs, or the delivery of Shares with respect to this Award, the Company or any Affiliate will utilize Net Settlement.

The Participant further agrees that the Administrator may, as it reasonably considers necessary, amend or vary this Agreement due to changes in tax laws to facilitate such recovery of taxes.

 

11.

Participant Acknowledgements and Authorizations. The Participant hereby acknowledges the following:

 

  a.

Neither the Company nor any Affiliate is, by the Plan or this Award, obligated to continue the Participant as an Employee, director, or Consultant of the Company or an Affiliate. Unless otherwise specified in a written employment or other written compensatory agreement between the Participant and the Company or an Affiliate, the Company or any Affiliate, as applicable, reserves the right to terminate the Participant’s employment or other service relationship with the Company or an Affiliate at any time and for any reason.

 

  b.

The Plan is discretionary in nature and may be suspended or terminated by the Company at any time.

 

  c.

The grant of this Award is considered a one-time benefit and does not create a contractual or other right to receive any other award under the Plan, benefits in lieu of awards, or any other benefits in the future.

 

  d.

The Plan is a voluntary program of the Company and future awards, if any, will be at the sole discretion of the Company, including, but not limited to, the timing of any grant, the amount of any award, vesting provisions, and the purchase price, if any.

 

5


  e.

The value of this Award is an extraordinary item of compensation outside of the scope of the Participant’s employment or consulting contract, agreement, or arrangement. As such, the Award is not part of normal or expected compensation for purposes of calculating any severance, resignation, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits, or similar payments. The future value of the shares of Common Stock is unknown and cannot be predicted with certainty.

 

  f.

The Participant (i) authorizes the Company and each Affiliate and any agent of the Company or any Affiliate administering the Plan or providing Plan recordkeeping services to disclose to the Company or any of its Affiliates such information and data as the Company or any such Affiliate shall request in order to facilitate the grant of the Award and the administration of the Plan; and (ii) authorizes the Company and each Affiliate to store and transmit such information in electronic form for the purposes set forth in this Agreement.

 

  g.

The obligation of the Company to deliver Shares pursuant to this Award constitutes an unfunded and unsecured obligation of the Company. Until Shares are delivered, the Participant shall have no rights under this Agreement or the Plan, other than those of a general unsecured creditor of the Company. No assets of the Company shall be set aside for the settlement of the RSUs.

 

12.

Notices. By accepting the Award, the Participant agrees that notices may be given to the Participant in writing either at the Participant’s home or mailing address as shown in the records of the Company or an Affiliate or by electronic transmission (including e-mail or reference to a website or other URL) sent to the Participant through the normal process employed by the Company or the Affiliate, as applicable, for communicating electronically with its employees or other service providers.

 

13.

Assignment and Successors.

 

  a.

This Agreement is personal to the Participant and, without the prior approval of the Administrator, shall not be assignable by the Participant, other than by will or the laws of descent and distribution. This Agreement shall inure to the benefit of and be enforceable by the Participant’s legal representatives and beneficiaries.

 

  b.

This Agreement shall inure to the benefit of and be binding upon the Company and its successors and assigns.

 

6


14.

Governing Law. This Agreement shall be construed and enforced in accordance with the laws of the State of Delaware, without giving effect to the conflict of law principles thereof; provided that, for the avoidance of doubt, the Restrictive Covenants Agreement shall continue to be governed solely by Pennsylvania law. For the purpose of litigating any dispute that arises under this Agreement, whether at law or in equity, the parties hereby consent to exclusive jurisdiction in the Commonwealth of Pennsylvania and agree that such litigation shall be conducted in the state courts of the Commonwealth of Pennsylvania or the federal courts of the United States for the Eastern District of Pennsylvania.

 

15.

Severability. If any provision of this Agreement is held to be invalid or unenforceable by a court of competent jurisdiction, then such provision or provisions shall be modified to the extent necessary to make such provision valid and enforceable, and to the extent that this is impossible, then such provision shall be deemed to be excised from this Agreement, and the validity, legality, and enforceability of the rest of this Agreement shall not be affected thereby.

 

16.

Entire Agreement. This Agreement, together with the Grant Notice, the Restrictive Covenants Agreement, and the Plan, constitutes the entire agreement and understanding between the parties hereto with respect to the subject matter hereof and supersedes all prior oral or written agreements and understandings relating to the subject matter hereof, including without limitation any offer letter provision related to the subject matter hereof. No statement, representation, warranty, covenant, or agreement not expressly set forth in this Agreement shall affect or be used to interpret, change, or restrict the express terms and provisions of this Agreement; provided, however, in any event, this Agreement shall be subject to and governed by the Plan.

 

17.

Modifications and Amendments; Waivers and Consents. The terms and provisions of this Agreement may be modified or amended as provided in the Plan. Except as provided in the Plan, the terms and provisions of this Agreement may be waived, or consent for the departure therefrom granted, only by written document executed by the party entitled to the benefits of such terms or provisions. No such waiver or consent shall be deemed to be or shall constitute a waiver or consent with respect to any other terms or provisions of this Agreement, whether or not similar. Each such waiver or consent shall be effective only in the specific instance and for the purpose for which it was given, and shall not constitute a continuing waiver or consent.

 

18.

Code Section 409A. The Award of RSUs evidenced by this Agreement is intended to be exempt from the nonqualified deferred compensation rules of Code Section 409A as a “short-term deferral” within the meaning of Code Section 409A and, to the maximum extent permitted, shall be construed accordingly. Notwithstanding anything to the contrary in the Plan or this Agreement, none of the Company, its Affiliates, the Board of Directors, the Administrator, or any of their respective agents or delegates will have any obligation to take any action to prevent the assessment of any excise tax or penalty on the Participant under Code Section 409A, and none of the Company, its Affiliates, the Board of Directors, the Administrator, or any of their respective agents or delegates will have any liability to the Participant or any other person for such tax or penalty.

 

7


To the extent that the RSUs constitute “deferred compensation” under Code Section 409A, a termination of Service occurs only upon an event that would be a “separation from service” within the meaning of Code Section 409A. If, at the time of the Participant’s “separation from service,” (i) the Participant is a “specified employee” within the meaning of Code Section 409A (and as applied according to procedures of the Company and its Affiliates), and (ii) the Administrator makes a good faith determination that an amount payable under this Agreement on account of the Participant’s separation from service constitutes deferred compensation (within the meaning of Code Section 409A), the payment of which is required to be delayed pursuant to the six (6)-month delay rule set forth in Code Section 409A to avoid taxes or penalties under Code Section 409A (the “Delay Period”), then the Company will not pay such amount on the otherwise scheduled payment date but will instead pay it in a lump sum on the first business day after the Delay Period (or upon the Participant’s death, if earlier), without interest. Each installment of RSUs that vest under this Agreement (if there is more than one installment) will be considered one of a series of separate payments for purposes of Code Section 409A.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

 

8


Exhibit A

Restrictive Covenants Agreement

[see attached]

EX-10.5 6 d530762dex105.htm EX-10.5 EX-10.5

Exhibit 10.5

Non-Section 16 Officer Form

MADRIGAL PHARMACEUTICALS, INC.

AMENDED 2015 STOCK PLAN

RESTRICTED STOCK UNIT AWARD

GRANT NOTICE

 

1.

  Name of Participant:     

2.

 

Grant Date of the RSUs

(the “Grant Date”):

    

3.

  Number of RSUs:     

 

4.

ting of Award: Subject to the Participant’s continuous employment or other service relationship with or to the Company or any of its Affiliates as an Employee, director, and/or Consultant from the Grant Date through each of the following applicable dates (each such date, a “Vesting Date”), the RSUs shall vest twenty-five percent (25%) of the Number of RSUs above on each of the first, second, third, and fourth anniversaries of the Grant Date. Any terms used and not defined herein have the meanings ascribed to such terms in the Madrigal Pharmaceuticals, Inc. Amended 2015 Stock Plan (as it has been and may be amended and/or restated from time to time, the “Plan”).

By signing this Grant Notice or by electronic acknowledgment of this Grant Notice, the Participant acknowledges receipt of and agrees to all the terms and conditions described in this Restricted Stock Unit Award Grant Notice, the attached Restricted Stock Unit Agreement, and the Plan. The Participant acknowledges that he or she has carefully reviewed the Plan and agrees that the Plan will control in the event any provision of the Agreement should appear to be inconsistent with the Plan.

 

MADRIGAL PHARMACEUTICALS, INC.
By:    
Name:    
Title:    

 

PARTICIPANT

ATTACHMENT: Restricted Stock Unit Agreement


MADRIGAL PHARMACEUTICALS, INC.

AMENDED 2015 STOCK PLAN

RESTRICTED STOCK UNIT AGREEMENT

This RESTRICTED STOCK UNIT AGREEMENT (the “Agreement”) is made as of the “Grant Date” set forth in the Restricted Stock Unit Award Grant Notice (“Grant Notice”) between MADRIGAL PHARMACEUTICALS, INC. (the “Company”), a Delaware corporation, and the individual whose name appears on the Restricted Stock Unit Award Grant Notice (the “Participant”).

WHEREAS, the Company has adopted the Madrigal Pharmaceuticals, Inc. Amended 2015 Stock Plan (as it has been and may be amended and/or restated from time to time, the “Plan”) to promote the interests of the Company by providing an incentive for Employees, directors, and Consultants of the Company and its Affiliates;

WHEREAS, pursuant to the provisions of the Plan, the Company desires to grant to the Participant restricted stock units (“RSUs”) related to the Company’s common stock, $0.0001 par value per share (“Common Stock”), in accordance with the provisions of the Plan, all on the terms and conditions hereinafter set forth; and

WHEREAS, the Company and the Participant understand and agree that any terms used and not defined herein have the meanings ascribed to such terms in the Plan.

NOW, THEREFORE, in consideration of the promises and the mutual covenants contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:

 

1.

Grant of Award. The Company hereby grants to the Participant a Stock-Based Award for the number of RSUs set forth in the Grant Notice (the “Award”). Each RSU represents a contingent entitlement of the Participant to receive one share of Common Stock, on the terms and conditions and subject to all the limitations set forth herein, in the Grant Notice, and in the Plan, which are incorporated herein by reference.

 

2.

Vesting of Award.

 

  a.

Subject to the terms and conditions set forth in this Agreement and the Plan: (i) the Award shall vest as set forth in the Grant Notice and is subject to the other terms and conditions of this Agreement and the Plan; and (ii) upon vesting, the Participant shall be entitled to receive such number of shares of Common Stock equivalent to the number of such vested RSUs.

 

1


  b.

Notwithstanding anything to the contrary in the Grant Notice or this Agreement, any fractional Shares resulting from the vesting schedule set forth in the Grant Notice will be rounded to the nearest whole Share and shall be rounded up or down as necessary as of the last Vesting Date; provided, in all cases, the Participant cannot vest in more than the number of RSUs set forth in the Grant Notice.

 

3.

Forfeiture of Unvested RSUs.

 

  a.

Except as otherwise set forth in this Agreement, the Grant Notice, the Plan, or a separate agreement between Participant and the Company, if the Participant ceases his or her continuous employment or other service relationship with or to the Company or any of its Affiliates as an Employee, director, and/or Consultant (“Termination”), then all then-unvested RSUs shall automatically and immediately be forfeited to the Company as of such Termination, and this Agreement and the Grant Notice shall automatically and immediately terminate and be of no further force or effect.

 

  b.

For purposes of this Agreement, the Participant’s continuous employment or other service relationship with or to the Company or any of its Affiliates as an Employee, director, and/or Consultant does not terminate when the Participant goes on a bona fide leave of absence that was approved by the Administrator in writing, if the terms of the leave provide for continued service crediting, or when continued service crediting is required by applicable law. The Participant’s continuous employment or other service relationship with or to the Company or any of its Affiliates as an Employee, director, and/or Consultant terminates in any event when the approved leave ends unless the Participant immediately returns to active work. The Administrator may determine, in its discretion, which leaves count for this purpose and when the Participant’s continuous employment or other service relationship with or to the Company or any of its Affiliates as an Employee, director, and/or Consultant terminates for all purposes under the Plan in accordance with the provisions of the Plan.

 

4.

Delivery of Award; Evidence of Issuance. Delivery of the Shares represented by the Participant’s vested RSUs shall be made as soon as practicable after the applicable Vesting Date and, in any event, by no later than sixty (60) days following each applicable Vesting Date. The issuance of the Shares represented by the Participant’s vested RSUs shall be evidenced in such a manner as the Administrator, in its discretion, deems appropriate, including, without limitation, by (i) book-entry registration or (ii) issuance of one or more share certificates.

 

2


5.

Prohibitions on Transfer and Sale. This Award (including any additional RSUs received by the Participant as a result of stock dividends, stock splits, or any other similar transaction affecting the Company’s securities without receipt of consideration) shall not be transferable, without the prior approval of the Administrator, by the Participant, other than by will or by the laws of descent and distribution. Except as provided in the previous sentence, the Shares to be issued pursuant to this Agreement shall be issued, during the Participant’s lifetime, only to the Participant (or, in the event of legal incapacity or incompetence, to the Participant’s guardian or representative), and this Award shall not be assigned, pledged, or hypothecated in any way (whether by operation of law or otherwise) and shall not be subject to execution, attachment, or similar process. Any attempted transfer, assignment, pledge, hypothecation, or other disposition of this Award or of any rights granted hereunder contrary to the provisions of this Section 5, or the levy of any attachment or similar process upon this Award, shall be null and void.

 

6.

Adjustments. The Plan contains provisions covering the treatment of RSUs and Shares in a number of contingencies, such as stock splits and Corporate Transactions. Provisions in the Plan for adjustment with respect to this Award and the related provisions with respect to successors to the business of the Company are hereby made applicable hereunder and are incorporated herein by reference.

 

7.

Securities Law Compliance. The Participant specifically acknowledges and agrees that any sales of Shares shall be made in accordance with the requirements of the Securities Act. The Company currently has an effective registration statement on file with the United States Securities and Exchange Commission with respect to the Shares to be granted hereunder.

 

8.

Rights as a Stockholder. The Participant shall have no rights as a stockholder, including voting and dividend rights, with respect to the RSUs subject to this Agreement, unless and until Shares represented by the Participant’s vested RSUs have been issued to the Participant and either a certificate evidencing the Shares has been issued or an appropriate entry has been made on the Company’s books. No adjustments to Shares represented by the Participant’s vested RSUs shall be made for dividends, distributions, or other rights on or with respect to the Common Stock generally if the applicable record date for any such dividend, distribution, or right occurs before the Participant’s certificate is issued or an appropriate book entry is made, except as otherwise described in the Plan.

 

9.

Incorporation of the Plan; Clawback. The Participant specifically understands and agrees that the RSUs and the Shares to be issued under the Agreement will be issued to the Participant pursuant to the Plan, a copy of which Plan the Participant acknowledges he or she has received, has read, and understands and by which Plan he or she agrees to be bound. The provisions of the Plan are incorporated herein by reference. In addition, the RSUs (and any compensation paid or Shares issued pursuant to this Agreement) are subject to recoupment in accordance with The Sarbanes-Oxley Act, The Dodd-Frank Wall Street Reform and Consumer Protection Act and any implementing regulations thereunder, any

 

3


  clawback policy adopted by the Company, and any compensation recovery policy otherwise required by applicable law. No recovery of compensation under such a clawback policy will be an event giving rise to a right to resign for “good reason” or for a “constructive termination” (or similar terms) under any agreement between the Participant and the Company or any Affiliate.

 

10.

Tax Liability of the Participant and Payment of Taxes. The Participant acknowledges and agrees that any income or other taxes due from the Participant with respect to this Award or the Shares to be issued pursuant to this Agreement or otherwise sold shall be the Participant’s responsibility. In the event that the Company or an Affiliate determines that any federal, state, local, or foreign tax or withholding payment is required relating to the RSUs, or the delivery of Shares with respect to this Award, the Company or any Affiliate will have the right, and Participant agrees, that the Company shall cause Participant to, and Participant shall, enter into a “same day sale” commitment with a broker-dealer that is a member of the Financial Industry Regulatory Authority (a “FINRA Dealer”), whereby the Participant irrevocably elects to sell a portion of the Shares to be delivered in connection with the RSUs to satisfy withholding obligations and whereby the FINRA Dealer irrevocably commits to forward the proceeds necessary to satisfy the withholding obligations directly to the Company or any Affiliate (such process, “Sell to Cover”); provided, however, the Administrator shall have the discretion to override Sell to Cover, (i) in lieu of selling a fractional vested Share or (ii) in connection with withholding obligations arising outside the ordinary course, such as outside annual Vesting Dates of the RSUs, and in each case such withholding may be through deduction from payments of any kind otherwise due to the Participant.

The Participant hereby agrees and acknowledges that, in the event that the Company or an Affiliate determines that any federal, state, local, or foreign tax or withholding payment is required relating to the RSUs, or the delivery of Shares with respect to this Award, the Company or any Affiliate will utilize Sell to Cover, and that, in the event Sell to Cover is unavailable for any reason, the Company or any Affiliate shall be entitled to use whatever method it may deem appropriate to recover such taxes (including, without limitation, through deduction from payments of any kind otherwise due to the Participant).

The Participant further agrees that the Administrator may, as it reasonably considers necessary, amend or vary this Agreement due to changes in tax laws to facilitate such recovery of taxes.

 

4


11.

Participant Acknowledgements and Authorizations. The Participant hereby acknowledges the following:

 

  a.

Neither the Company nor any Affiliate is, by the Plan or this Award, obligated to continue the Participant as an Employee, director, or Consultant of the Company or an Affiliate. Unless otherwise specified in a written employment or other written compensatory agreement between the Participant and the Company or an Affiliate, the Company or any Affiliate, as applicable, reserves the right to terminate the Participant’s employment or other service relationship with the Company or an Affiliate at any time and for any reason.

 

  b.

The Plan is discretionary in nature and may be suspended or terminated by the Company at any time.

 

  c.

The grant of this Award is considered a one-time benefit and does not create a contractual or other right to receive any other award under the Plan, benefits in lieu of awards, or any other benefits in the future.

 

  d.

The Plan is a voluntary program of the Company and future awards, if any, will be at the sole discretion of the Company, including, but not limited to, the timing of any grant, the amount of any award, vesting provisions, and the purchase price, if any.

 

  e.

The value of this Award is an extraordinary item of compensation outside of the scope of the Participant’s employment or consulting contract, agreement, or arrangement. As such, the Award is not part of normal or expected compensation for purposes of calculating any severance, resignation, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits, or similar payments. The future value of the shares of Common Stock is unknown and cannot be predicted with certainty.

 

  f.

The Participant (i) authorizes the Company and each Affiliate and any agent of the Company or any Affiliate administering the Plan or providing Plan recordkeeping services to disclose to the Company or any of its Affiliates such information and data as the Company or any such Affiliate shall request in order to facilitate the grant of the Award and the administration of the Plan; and (ii) authorizes the Company and each Affiliate to store and transmit such information in electronic form for the purposes set forth in this Agreement.

 

  g.

The obligation of the Company to deliver Shares pursuant to this Award constitutes an unfunded and unsecured obligation of the Company. Until Shares are delivered, the Participant shall have no rights under this Agreement or the Plan, other than those of a general unsecured creditor of the Company. No assets of the Company shall be set aside for the settlement of the RSUs.

 

5


12.

Notices. By accepting the Award, the Participant agrees that notices may be given to the Participant in writing either at the Participant’s home or mailing address as shown in the records of the Company or an Affiliate or by electronic transmission (including e-mail or reference to a website or other URL) sent to the Participant through the normal process employed by the Company or the Affiliate, as applicable, for communicating electronically with its employees or other service providers.

 

13.

Assignment and Successors.

 

  a.

This Agreement is personal to the Participant and, without the prior written approval of the Administrator, shall not be assignable by the Participant, other than by will or the laws of descent and distribution. This Agreement shall inure to the benefit of and be enforceable by the Participant’s legal representatives and beneficiaries.

 

  b.

This Agreement shall inure to the benefit of and be binding upon the Company and its successors and assigns.

 

14.

Governing Law. This Agreement shall be construed and enforced in accordance with the laws of the State of Delaware, without giving effect to the conflict of law principles thereof. For the purpose of litigating any dispute that arises under this Agreement, whether at law or in equity, the parties hereby consent to exclusive jurisdiction in the Commonwealth of Pennsylvania and agree that such litigation shall be conducted in the state courts of the Commonwealth of Pennsylvania or the federal courts of the United States for the Eastern District of Pennsylvania.

 

15.

Severability. If any provision of this Agreement is held to be invalid or unenforceable by a court of competent jurisdiction, then such provision or provisions shall be modified to the extent necessary to make such provision valid and enforceable, and to the extent that this is impossible, then such provision shall be deemed to be excised from this Agreement, and the validity, legality, and enforceability of the rest of this Agreement shall not be affected thereby.

 

16.

Entire Agreement. This Agreement, together with the Grant Notice and the Plan, constitutes the entire agreement and understanding between the parties hereto with respect to the subject matter hereof and supersedes all prior oral or written agreements and understandings relating to the subject matter hereof, including without limitation any offer letter provision related to the subject matter hereof. No statement, representation, warranty, covenant, or agreement not expressly set forth in this Agreement shall affect or be used to interpret, change, or restrict the express terms and provisions of this Agreement; provided, however, in any event, this Agreement shall be subject to and governed by the Plan.

 

6


17.

Modifications and Amendments; Waivers and Consents. The terms and provisions of this Agreement may be modified or amended as provided in the Plan. Except as provided in the Plan, the terms and provisions of this Agreement may be waived, or consent for the departure therefrom granted, only by written document executed by the party entitled to the benefits of such terms or provisions. No such waiver or consent shall be deemed to be or shall constitute a waiver or consent with respect to any other terms or provisions of this Agreement, whether or not similar. Each such waiver or consent shall be effective only in the specific instance and for the purpose for which it was given, and shall not constitute a continuing waiver or consent.

 

18.

Code Section 409A. The Award of RSUs evidenced by this Agreement is intended to be exempt from the nonqualified deferred compensation rules of Code Section 409A as a “short-term deferral” within the meaning of Code Section 409A and, to the maximum extent permitted, shall be construed accordingly. Notwithstanding anything to the contrary in the Plan or this Agreement, none of the Company, its Affiliates, the Board of Directors, the Administrator, or any of their respective agents or delegates will have any obligation to take any action to prevent the assessment of any excise tax or penalty on the Participant under Code Section 409A, and none of the Company, its Affiliates, the Board of Directors, the Administrator, or any of their respective agents or delegates will have any liability to the Participant or any other person for such tax or penalty.

To the extent that the RSUs constitute “deferred compensation” under Code Section 409A, a termination of Service occurs only upon an event that would be a “separation from service” within the meaning of Code Section 409A. If, at the time of the Participant’s “separation from service,” (i) the Participant is a “specified employee” within the meaning of Code Section 409A (and as applied according to procedures of the Company and its Affiliates), and (ii) the Administrator makes a good faith determination that an amount payable under this Agreement on account of the Participant’s separation from service constitutes deferred compensation (within the meaning of Code Section 409A), the payment of which is required to be delayed pursuant to the six (6)-month delay rule set forth in Code Section 409A to avoid taxes or penalties under Code Section 409A (the “Delay Period”), then the Company will not pay such amount on the otherwise scheduled payment date but will instead pay it in a lump sum on the first business day after the Delay Period (or upon the Participant’s death, if earlier), without interest. Each installment of RSUs that vest under this Agreement (if there is more than one installment) will be considered one of a series of separate payments for purposes of Code Section 409A.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

 

7

EX-31.1 7 d530762dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Paul A. Friedman, M.D., certify that:

 

  1.

I have reviewed this Quarterly Report on Form 10-Q of Madrigal Pharmaceuticals, Inc.;

 

  2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

  3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

  4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  (a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  (b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  (c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  (d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

  5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  (b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

/s/ Paul A. Friedman, M.D.

Paul A. Friedman, M.D.
Chief Executive Officer and Chairman of the Board
(Principal Executive Officer)
Date: August 8, 2023
EX-31.2 8 d530762dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Alex G. Howarth, certify that:

 

  1.

I have reviewed this Quarterly Report on Form 10-Q of Madrigal Pharmaceuticals, Inc.;

 

  2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

  3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

  4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  (a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  (b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  (c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  (d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

  5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  (b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

/s/ Alex G. Howarth

Alex G. Howarth
Senior Vice President and Chief Financial Officer
(Principal Financial and Accounting Officer)
Date: August 8, 2023
EX-32.1 9 d530762dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

CERTIFICATIONS PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. Section 1350)), each of the undersigned officers of Madrigal Pharmaceuticals, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:

The Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2023 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Dated: August 8, 2023      

/s/ Paul A. Friedman, M.D.

      Paul A. Friedman, M.D.
      Chief Executive Officer and Chairman of the Board
      (Principal Executive Officer)
Dated: August 8, 2023      

/s/ Alex G. Howarth

      Alex G. Howarth
      Senior Vice President and Chief Financial Officer
      (Principal Financial and Accounting Officer)

These certifications accompany the Form 10-Q, are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

EX-101.SCH 10 mdgl-20230630.xsd XBRL TAXONOMY EXTENSION SCHEMA 1001 - Document - Cover Page link:presentationLink link:definitionLink link:calculationLink 1002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 1003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 1004 - Statement - Condensed Consolidated Statements Of Operations link:presentationLink link:definitionLink link:calculationLink 1005 - Statement - Condensed Consolidated Statements Of Comprehensive Loss link:presentationLink link:definitionLink link:calculationLink 1006 - Statement - Condensed Consolidated Statements Of Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 1007 - Statement - Condensed Consolidated Statements Of Cash Flows link:presentationLink link:definitionLink link:calculationLink 1008 - Disclosure - Organization, Business and Basis of Presentation link:presentationLink link:definitionLink link:calculationLink 1009 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 1010 - Disclosure - Liquidity and Uncertainties link:presentationLink link:definitionLink link:calculationLink 1011 - Disclosure - Cash, Cash Equivalents and Marketable Securities link:presentationLink link:definitionLink link:calculationLink 1012 - Disclosure - Accrued Liabilities link:presentationLink link:definitionLink link:calculationLink 1013 - Disclosure - Long Term Debt link:presentationLink link:definitionLink link:calculationLink 1014 - Disclosure - Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 1015 - Disclosure - Stock-based Compensation link:presentationLink link:definitionLink link:calculationLink 1016 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 1017 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 1018 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 1019 - Disclosure - Cash, Cash Equivalents and Marketable Securities (Tables) link:presentationLink link:definitionLink link:calculationLink 1020 - Disclosure - Accrued Liabilities (Tables) link:presentationLink link:definitionLink link:calculationLink 1021 - Disclosure - Long Term Debt (Tables) link:presentationLink link:definitionLink link:calculationLink 1022 - Disclosure - Stock-based Compensation (Tables) link:presentationLink link:definitionLink link:calculationLink 1023 - Disclosure - Summary of Significant Accounting Policies - Income Taxes (Details) link:presentationLink link:definitionLink link:calculationLink 1024 - Disclosure - Summary of Significant Accounting Policies - Basic and Diluted Loss Per Common Share (Details) link:presentationLink link:definitionLink link:calculationLink 1025 - Disclosure - Liquidity and Uncertainties (Details) link:presentationLink link:definitionLink link:calculationLink 1026 - Disclosure - Cash, Cash Equivalents and Marketable Securities (Details) link:presentationLink link:definitionLink link:calculationLink 1027 - Disclosure - Accrued Liabilities (Details) link:presentationLink link:definitionLink link:calculationLink 1028 - Disclosure - Long Term Debt - Schedule of Maturities of Long-Term Debt (Details) link:presentationLink link:definitionLink link:calculationLink 1029 - Disclosure - Long Term Debt (Details) link:presentationLink link:definitionLink link:calculationLink 1030 - Disclosure - Stockholders' Equity (Deficit) - Common Stock (Details) link:presentationLink link:definitionLink link:calculationLink 1031 - Disclosure - Stockholders' Equity (Deficit) - Preferred Stock (Details) link:presentationLink link:definitionLink link:calculationLink 1032 - Disclosure - Stockholders' Equity (Deficit) - Registered Offering (Details) link:presentationLink link:definitionLink link:calculationLink 1033 - Disclosure - Stockholders' Equity (Deficit) - At The Market Issuances (Details) link:presentationLink link:definitionLink link:calculationLink 1034 - Disclosure - Stock-based Compensation - Stock Option (Details) link:presentationLink link:definitionLink link:calculationLink 1035 - Disclosure - Stock-based Compensation - Expense (Details) link:presentationLink link:definitionLink link:calculationLink 1036 - Disclosure - Stock-based Compensation - Unrecognized Expense (Details) link:presentationLink link:definitionLink link:calculationLink 1037 - Disclosure - Stock-based Compensation - Restricted Stock Units (Details) link:presentationLink link:definitionLink link:calculationLink 1038 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 11 mdgl-20230630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 12 mdgl-20230630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 13 mdgl-20230630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 14 mdgl-20230630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 15 g530762g0808005346480.jpg GRAPHIC begin 644 g530762g0808005346480.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#N:***_(SL M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M**Y'4O%&J6/C"R\/I963M>HTD4IFM;T,/.NW&'17^2$W8ZZ MBL'Q/K-]X?\ #[ZI';VTWD(#/&TC#DE1\IQSR3UQ5CPYJ5WK&C6^HW,,$(N8 MUDC2)RV 1WR!S]*'AIJC[;3EO;?J*ZO8UJ***P*"BBB@ HHHH **** "O./% M#SI\7O#C6T*33"T?:DDA13_K.K8./RKT>N UJTU2X^).DZS#H]Y)9V,3Q2,# M'EC\X!4%N1\PZXKT\J:563=OAEOYHB>Q)X^N-8?P/JBW.FVD4)1=SI>L[#YU MZ+Y0S^8K/FU^ZTGP'X3T_3Y!#>:HL5NLQ4'REX#, >_S"ND\=V]YJ/A.ZTZQ ML)[BXND 4(5 3#*?FR1[],]*Y^?PUJ>H^$=!6*QD@U;0VC=(KAE"S8QN4$$_ MW1R<=*[\).B\/#VB27.W:_\ =LF[MZ7)=[Z%WQ9=7'@BVT_5[6^O;B'[4L%U M;W,YE$J,I)(W?=8;>V!STJSJ]]=WGQ#L/#_VJ:WL#9M=2""0QO,V6 &X<@#& M>,=ZA\3Z??>-H+#2QIEU96B7*SW<]R44JH##:H!.XG<>>@XJEXE.HQ>+9KJ; MPW>ZO!$J"QFL;MXFMOE&\?N^023U/;':E0C":BIV]I:7;R4>J5UKUO;Y _P+ MWA2YU"7Q=X@TZ;4[JXM-.=%@20JPPX)PS%=Q(QQSVK&UW5#IOA&2^@\275QK M]N(WF,-P9(0Y9=R%5_=@#) &!T%6M/U"._TO5/#EKH=YH6JWMM-+&+HDF=B, M$F1OF8\]3^=5+C3M>N?AA_PC=OX?F@N845)3))&%?$@;]WAOF)/)R .O)XSO M"$574II+6*M[JNK:R>]TWNE]XNAK^--3O8_A_#KUI>7%I=&&%P(7POSE6 I1D)). M[H<'&/3M65%Q@J#\IXYKJ:\^U_P#Y+-X9_P"O1_Y2UUY?2IU9 MR517M%OKNE?H3)M'H )*@D8..1GI2T5R!UN]UKQQ=Z!8W;65KI\(>XGB1&DD MC0E6Y@\V/ MH>%+G4Y%E6(7-G?+#'YC+QE&7;M.,]0!]TTG@ M;6]1U2SU>WUK4'&I6$S0S#9&JQ 9PZX7U#=NR.$K482J1DFK+SNI;/5 M=_FF3=,WK71[@ZO'JFI7D=Q<0Q-% D,/EQQAB-QP68DG &<_A6O7GVH^*-1T M3PS:WLM^TUYJTVRS%VD:I!$2<2-M5)IIO$]S MH,FF^7=0VIN583AE<9 Z<9S^%.\.^)_[>U'5K%K)K:;3)5BES('#$EAP<#^ M[^M8UO\ \EIO/^P0/_0UK.\+7\<2J!D;U"[0X R M<-N.<=\UW->9B<-+#RY9/7Y_JE\BD[A7GFN>?)\4=&U..PU![*RA>*>9+*4A M6_>#C"_,.1R,CFO0Z*>%Q/U>3E:]TU]^@-7..\3>(;V:SCLM&TK5I)IY4#W' MV.2-8DW MRP!R1Q^)YJ".PF\-_$/4=7DMYY=-U.$?O8(FD,4@QPRJ"<'!YQW MKN**VAC8PA[.,-&FGKJ[VZ^5@Y>IQ6DZ9<:I\0KSQ-+;S06,5N+>T$Z&-Y#@ M9;:>0/O=0,Y%4_$'AO43X\BN--5A9:S ;;4F4$A%7&XY[%E ]\^M>@T4XYE M4C4YXK3EY;>73\=?47*K'&_$#0KW4-/TZ^TJ'S;O2KA9XX%XWJ,9 ]_E7CZU MK0^(I=3^SQZ;97@E=U,S7=M)$L"9^;);&6QD *3R<]*W**S^MWI1ISC?EO;Y M]^X^76YP,,8/:-]W= )Z]+]NPTK'__9 end XML 16 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover Page - shares
6 Months Ended
Jun. 30, 2023
Aug. 03, 2023
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Transition Report false  
Entity Interactive Data Current Yes  
Amendment Flag false  
Document Fiscal Year Focus 2023  
Document Period End Date Jun. 30, 2023  
Document Fiscal Period Focus Q2  
Entity Registrant Name MADRIGAL PHARMACEUTICALS, INC.  
Entity Central Index Key 0001157601  
Entity File Number 001-33277  
Current Fiscal Year End Date --12-31  
Entity Tax Identification Number 04-3508648  
Entity Incorporation, State or Country Code DE  
Entity Current Reporting Status Yes  
Entity Filer Category Large Accelerated Filer  
Entity Emerging Growth Company false  
Entity Small Business false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   18,471,233
City Area Code 267  
Local Phone Number 824-2827  
Trading Symbol MDGL  
Security Exchange Name NASDAQ  
Title of 12(b) Security Common Stock, $0.0001 Par Value Per Share  
Entity Address, Address Line One Four Tower Bridge  
Entity Address, Address Line Two 200 Barr Harbor Drive, Suite 200  
Entity Address, City or Town West Conshohocken  
Entity Address, Postal Zip Code 19428  
Entity Address, State or Province PA  
XML 17 R2.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 77,196 $ 331,549
Marketable securities 221,222 27,225
Prepaid expenses and other current assets 3,177 2,595
Total current assets 301,595 361,369
Property and equipment, net 455 601
Right-of-use asset 411 602
Total assets 302,461 362,572
Current liabilities:    
Accounts payable 17,534 23,831
Accrued expenses 81,761 91,461
Lease liability 411 602
Total current liabilities 99,706 115,894
Long term liabilities:    
Loan payable, net of discount 99,249 49,289
Total long term liabilities 99,249 49,289
Total liabilities 198,955 165,183
Stockholders' equity:    
Preferred stock, par value $0.0001 per share authorized: 5,000,000 shares at June 30, 2023 and December 31, 2022; 2,369,797 and 2,369,797 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively
Common stock, par value $0.0001 per share authorized: 200,000,000 at June 30, 2023 and December 31, 2022; 18,459,033 and 18,102,523 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively 2 2
Additional paid-in-capital 1,228,949 1,160,079
Accumulated other comprehensive loss (89) (32)
Accumulated deficit (1,125,356) (962,660)
Total stockholders' equity 103,506 197,389
Total liabilities and stockholders' equity $ 302,461 $ 362,572
XML 18 R3.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Jun. 30, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized 5,000,000 5,000,000
Preferred stock, shares issued 2,369,797 2,369,797
Preferred stock, shares outstanding 2,369,797 2,369,797
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized 200,000,000 200,000,000
Common stock, shares issued 18,459,033 18,102,523
Common stock, shares outstanding 18,459,033 18,102,523
XML 19 R4.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements Of Operations - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenues:        
Total revenues
Operating expenses:        
Research and development 68,605 58,499 130,759 106,428
General and administrative 17,845 11,774 34,027 21,432
Total operating expenses 86,450 70,273 164,786 127,860
Loss from operations (86,450) (70,273) (164,786) (127,860)
Interest income 3,551 323 7,327 392
Interest expense (2,901) (780) (5,237) (780)
Net loss $ (85,800) $ (70,730) $ (162,696) $ (128,248)
Net loss per common share:        
Basic net loss per common share $ (4.69) $ (4.14) $ (8.91) $ (7.5)
Diluted net loss per common share $ (4.69) $ (4.14) $ (8.91) $ (7.5)
Basic weighted average number of common shares outstanding 18,310,952 17,103,395 18,249,778 17,103,395
Diluted weighted average number of common shares outstanding 18,310,952 17,103,395 18,249,778 17,103,395
XML 20 R5.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements Of Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Statement of Comprehensive Income [Abstract]        
Net Loss $ (85,800) $ (70,730) $ (162,696) $ (128,248)
Other comprehensive income (loss):        
Unrealized loss on available-for-sale securities (3) (45) (57) (367)
Comprehensive loss $ (85,803) $ (70,775) $ (162,753) $ (128,615)
XML 21 R6.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements Of Stockholders' Equity - USD ($)
$ in Thousands
Total
Preferred Stock
Common stock
Additional paid-in Capital
Accumulated other comprehensive income (loss)
Accumulated deficit
Balance at Dec. 31, 2021 $ 196,107   $ 2 $ 863,495 $ (80) $ (667,310)
Balance (in shares) at Dec. 31, 2021   1,969,797 17,103,395      
Increase (Decrease) in Stockholders' Equity            
Compensation expense related to stock options for services 7,477     7,477    
Unrealized loss on marketable securities (322)       (322)  
Net loss (57,518)         (57,518)
Balance at Mar. 31, 2022 145,744   $ 2 870,972 (402) (724,828)
Balance (in shares) at Mar. 31, 2022   1,969,797 17,103,395      
Balance at Dec. 31, 2021 196,107   $ 2 863,495 (80) (667,310)
Balance (in shares) at Dec. 31, 2021   1,969,797 17,103,395      
Increase (Decrease) in Stockholders' Equity            
Unrealized loss on marketable securities (367)          
Net loss (128,248)          
Balance at Jun. 30, 2022 83,535   $ 2 879,538 (447) (795,558)
Balance (in shares) at Jun. 30, 2022   1,969,797 17,103,395      
Balance at Mar. 31, 2022 145,744   $ 2 870,972 (402) (724,828)
Balance (in shares) at Mar. 31, 2022   1,969,797 17,103,395      
Increase (Decrease) in Stockholders' Equity            
Compensation expense related to stock options for services 7,944     7,944    
Unrealized loss on marketable securities (45)       (45)  
Hercules warrant 622     622    
Net loss (70,730)         (70,730)
Balance at Jun. 30, 2022 83,535   $ 2 879,538 (447) (795,558)
Balance (in shares) at Jun. 30, 2022   1,969,797 17,103,395      
Balance at Dec. 31, 2022 $ 197,389   $ 2 1,160,079 (32) (962,660)
Balance (in shares) at Dec. 31, 2022 18,102,523 2,369,797 18,102,523      
Increase (Decrease) in Stockholders' Equity            
Sale of common shares to related parties and exercise of common stock options, net of transaction cost $ 17,903     17,903    
Sale of common shares to related parties and exercise of common stock options, net of transaction cost ( in shares)     180,551      
Compensation expense related to stock options for services 11,250     11,250    
Unrealized loss on marketable securities (54)       (54)  
Hercules warrant 544     544    
Net loss (76,896)         (76,896)
Balance at Mar. 31, 2023 150,136   $ 2 1,189,776 (86) (1,039,556)
Balance (in shares) at Mar. 31, 2023   2,369,797 18,283,074      
Balance at Dec. 31, 2022 $ 197,389   $ 2 1,160,079 (32) (962,660)
Balance (in shares) at Dec. 31, 2022 18,102,523 2,369,797 18,102,523      
Increase (Decrease) in Stockholders' Equity            
Unrealized loss on marketable securities $ (57)          
Net loss (162,696)          
Balance at Jun. 30, 2023 $ 103,506   $ 2 1,228,949 (89) (1,125,356)
Balance (in shares) at Jun. 30, 2023 18,459,033 2,369,797 18,459,033      
Balance at Mar. 31, 2023 $ 150,136   $ 2 1,189,776 (86) (1,039,556)
Balance (in shares) at Mar. 31, 2023   2,369,797 18,283,074      
Increase (Decrease) in Stockholders' Equity            
Issuance of common and preferred shares in equity offerings, excluding to related parties, net of transaction costs 21,754     21,754    
Issuance of common and preferred shares in equity offerings, excluding to related parties, net of transaction costs (in shares)     85,901      
Sale of common shares to related parties and exercise of common stock options, net of transaction cost 6,251     6,251    
Sale of common shares to related parties and exercise of common stock options, net of transaction cost ( in shares)     90,058      
Compensation expense related to stock options for services 10,973     10,973    
Unrealized loss on marketable securities (3)       (3)  
Hercules warrant 195     195    
Net loss (85,800)         (85,800)
Balance at Jun. 30, 2023 $ 103,506   $ 2 $ 1,228,949 $ (89) $ (1,125,356)
Balance (in shares) at Jun. 30, 2023 18,459,033 2,369,797 18,459,033      
XML 22 R7.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements Of Cash Flows - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Cash flows from operating activities:    
Net loss $ (162,696) $ (128,248)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation expense 22,223 15,421
Depreciation and amortization expense 250 217
Amortization of debt issuance costs and discount 987 178
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets (582) (1,442)
Accounts payable (6,297) (10,086)
Accrued expense (9,700) 16,788
Accrued interest, net of interest received on maturity of investments (3,562) (101)
Net cash used in operating activities (159,377) (107,273)
Cash flows from investing activities:    
Purchases of marketable securities (290,696) (116,496)
Sales and maturities of marketable securities 100,204 191,813
Purchases of property and equipment, net of disposals (104) (155)
Net cash provided by (used in) investing activities (190,596) 75,162
Cash flows from financing activities:    
Proceeds from issuances of stock, excluding related parties, net of transaction costs 21,754 0
Proceeds from the sale of related party stock and exercise of common stock options, net of transaction costs 24,154 0
Proceeds from issuance of loan payable 50,000 50,000
Payment of debt issuance costs (288) (886)
Net cash provided by financing activities 95,620 49,114
Net increase (decrease) in cash and cash equivalents (254,353) 17,003
Cash and cash equivalents at beginning of period 331,549 36,269
Cash and cash equivalents at end of period 77,196 53,272
Supplemental disclosure of cash flow information:    
Obtaining a right-of-use asset in exchange for a lease liability $ 0 $ 583
XML 23 R8.htm IDEA: XBRL DOCUMENT v3.23.2
Organization, Business and Basis of Presentation
6 Months Ended
Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization, Business and Basis of Presentation
1. Organization, Business, and Basis of Presentation
Organization and Business
Madrigal Pharmaceuticals, Inc. (the “Company” or “Madrigal”) is a clinical-stage pharmaceutical company developing novel, high-quality, small-molecule drugs addressing major unmet needs in cardiovascular, metabolic, and liver diseases. The Company’s lead compound, resmetirom, is being advanced for
non-alcoholic
steatohepatitis (“NASH”), a liver disease that commonly affects people with metabolic diseases such as obesity and diabetes, and
non-alcoholic
fatty liver disease (“NAFLD”). The Company initiated two Phase 3 studies of resmetirom in NASH in 2019 that are ongoing. The Company announced certain topline results from the
MAESTRO-NAFLD-1
safety study of resmetirom in January 2022 and the MAESTRO-NASH study in December 2022. In August 2022, Madrigal initiated a third study, MAESTRO-NASH-OUTCOMES.
Basis of Presentation
Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) have been condensed or omitted. Accordingly, the unaudited condensed consolidated financial statements do not include all information and footnotes required by GAAP for complete annual financial statements. However, we believe that the disclosures included in these financial statements are adequate to make the information presented not misleading. The unaudited condensed consolidated financial statements, in the opinion of management, reflect all adjustments, which include normal recurring adjustments, necessary for a fair statement of such interim results. The interim results are not necessarily indicative of the results that we will have for the full year ending December 31, 2023 or any subsequent period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes to those statements for the year ended December 31, 2022.
XML 24 R9.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Significant Accounting Policies
6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies
2. Summary of Significant Accounting Policies
Principle of Consolidation
The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries. All significant intercompany balances have been eliminated in consolidation.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities, and the reported amounts of revenues and expenses during the reporting periods. The Company bases its estimates on historical experience and various other assumptions that management believes to be reasonable under the circumstances. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.
Cash and Cash Equivalents
The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. The Company maintains its cash in bank accounts, the balance of which, at times, exceeds Federal Deposit Insurance Corporation insured limits.
The primary objective of the Company’s investment activities is to preserve its capital for the purpose of funding operations and the Company does not enter into investments for trading or speculative purposes. The Company’s cash is deposited in highly rated financial institutions in the United States. The Company invests in money market funds and high-grade, commercial paper and corporate bonds, which management believes are subject to minimal credit and market risk.
Marketable Securities
Marketable securities consist of investments in high-grade corporate obligations and government and government agency obligations that are classified as
available-for-sale.
Since these securities are available to fund current operations, they are classified as current assets on the consolidated balance sheets.
 
The Company adjusts the cost of
available-for-sale
debt securities for amortization of premiums and accretion of discounts to maturity. The Company includes such amortization and accretion as a component of interest income, net. Realized gains and losses and declines in value, if any, that the Company judges to be the result of impairment or as a result of recognizing an allowance for credit losses on
available-for-sale
securities are reported as a component of interest income. To determine whether an impairment exists, the Company considers whether it intends to sell the debt security and, if the Company does not intend to sell the debt security, it considers available evidence to assess whether it is more likely than not that it will be required to sell the security before the recovery of its amortized cost basis. During the six months ended June 30, 2023 and 2022, the Company determined it did not have any securities that were other-than-temporarily impaired.
Marketable securities are stated at fair value, including accrued interest, with their unrealized gains and losses included as a component of accumulated other comprehensive income or loss, which is a separate component of stockholders’ equity. The fair value of these securities is based on quoted prices and observable inputs on a recurring basis. Realized gains and losses are determined on the specific identification method. During the six months ended June 30, 2023 and 2022, the Company did not have any realized gains or losses on marketable
securitie
s.
Fair Value of Financial Instruments
The carrying amounts of the Company’s financial instruments, which include cash equivalents and marketable securities, approximate their fair values. The fair value of the Company’s financial instruments reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels:
Level 1—quoted prices in active markets for identical assets and liabilities.
Level 2—observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.
Level 3—unobservable inputs that reflect the Company’s own assumptions about the assumptions market participants would use in pricing the asset or liability.
Financial assets and liabilities are classified in their entirety within the fair value hierarchy based on the lowest level of input that is significant to the fair value measurement. The Company measures the fair value of its marketable securities by taking into consideration valuations obtained from third- party pricing sources. The pricing services utilize industry standard valuation models, including both income and market based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker-dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities and other observable inputs.
As of June 30, 2023, the Company’s financial assets valued based on Level 1 inputs consisted of cash and cash equivalents in a money market fund, its financial assets valued based on Level 2 inputs consisted of high-grade corporate and government agency bonds and commercial paper, and it had no financial assets valued based on Level 3 inputs. During the six months ended June 30, 2023 and 2022, the Company did not have any transfers of financial assets between Levels 1 and 2. As of June 30, 2023 and December 31, 2022, the Company did not have any financial liabilities that were recorded at fair value on a recurring basis on the balance sheet.
Research and Development Costs
Research and development costs are expensed as incurred. Research and development costs are comprised of costs incurred in performing research and development activities, including internal costs (including stock-based compensation), costs for consultants, milestone payments under licensing agreements, and other costs associated with the Company’s preclinical and clinical programs. In particular, the Company has conducted safety studies in animals, optimized and implemented the manufacturing of our drug, and conducted clinical trials, all of which are considered research and development expenditures. Management uses significant judgment in estimating the amount of research and development costs recognized in each reporting period. Management analyzes and estimates the progress of its clinical trials, completion of milestone events per underlying agreements, invoices received and contracted costs when estimating the research and development costs to accrue in each reporting period. Actual results could differ from the Company’s estimates.
Patents
Costs to secure and defend patents are expensed as incurred and are classified as general and administrative expense in the Company’s consolidated statements of operations.
 
Stock-Based Compensation
The Company recognizes stock-based compensation expense based on the grant date fair value of stock options and restricted stock units granted to employees, officers, and directors. Awards that vest as the recipient provides service are expensed on a straight-line basis over the requisite service period. The Company uses the Black-Scholes option pricing model to determine the grant date fair value of stock options as management believes it is the most appropriate valuation method for its option grants. The Black-Scholes model requires inputs for risk-free interest rate, dividend yield, volatility and expected lives of the options. The expected lives for options granted represent the period of time that options granted are expected to be outstanding. The Company uses the simplified method for determining the expected lives of options. Expected volatility is based upon an industry estimate or blended rate including the Company’s historical trading activity. The risk-free rate for periods within the expected life of the option is based on the U.S. Treasury yield curve in effect at the time of the grant. The Company estimates the forfeiture rate based on historical data. This analysis is
re-evaluated
at least annually and the forfeiture rate is adjusted as necessary.
Income Taxes
The Company uses the asset and liability method to account for income taxes. Deferred tax assets and liabilities are determined based on the expected future tax consequences of temporary differences between the Company’s financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates expected to be in effect in the years in which the differences are expected to reverse. The Company currently maintains a 100% valuation allowance on its deferred tax assets.
Comprehensive Loss
Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from
non-owner
sources. Changes in unrealized gains and losses on marketable securities represent the only difference between the Company’s net loss and comprehensive loss.
Basic and Diluted Loss Per Common Share
Basic net loss per share is computed using the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed using the weighted average number of common shares outstanding and the weighted average dilutive potential common shares outstanding using the treasury stock method. However, for the six months ended June 30, 2023 and 2022, diluted net loss per share is the same as basic net loss per share because the inclusion of weighted average shares of common stock issuable upon the exercise of stock options and warrants or vesting of restricted stock units, and common stock issuable upon the conversion of preferred stock would be anti-dilutive. The following table summarizes outstanding securities not included in the computation of diluted net loss per common share, as their inclusion would be anti-dilutive:
 
    
Six Months Ended June 30,
 
    
2023
    
2022
 
Common stock options
     2,583,540        2,976,545  
Restricted stock units
     222,300        —    
Preferred stock
     2,369,797        1,969,797  
Warrants
     18,403        14,899  
Recent Accounting Pronouncements
None
XML 25 R10.htm IDEA: XBRL DOCUMENT v3.23.2
Liquidity and Uncertainties
6 Months Ended
Jun. 30, 2023
Liquidity and Uncertainties  
Liquidity and Uncertainties
3. Liquidity and Uncertainties
The Company is subject to risks common to development stage companies in the biopharmaceutical industry including, but not limited to, uncertainty of product development and commercialization, dependence on key personnel, uncertainty of market acceptance of products and product reimbursement, product liability, uncertain protection of proprietary technology, potential inability to raise additional financing necessary for development and commercialization, and compliance with the U.S. Food and Drug Administration (FDA) and other government regulations.
 
The Company has incurred losses since inception, including approximately $162.7 million for the six months ended June 30, 2023, resulting in an accumulated deficit of approximately $1,125 million as of June 30, 2023. Management expects to incur losses for the foreseeable future. To date, the Company has funded its operations primarily through proceeds from sales of the Company’s capital stock and debt financings. The Company believes that its cash, cash equivalents and marketable securities at June 30, 2023 will be sufficient to fund operations past one year from the issuance of these financial statements. To meet its future capital needs, the Company intends to raise additional capital through debt or equity financings, collaborations, partnerships or other strategic transactions. However, there can be no assurance that the Company will be able to complete any such transactions on acceptable terms or otherwise. The inability of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations and financial condition. The Company has the ability to delay certain research activities and related clinical expenses if necessary due to liquidity concerns until a date when those concerns are
relieved
.
XML 26 R11.htm IDEA: XBRL DOCUMENT v3.23.2
Cash, Cash Equivalents and Marketable Securities
6 Months Ended
Jun. 30, 2023
Cash and Cash Equivalents [Abstract]  
Cash, Cash Equivalents and Marketable Securities
4. Cash, Cash Equivalents and Marketable Securities
A summary of cash, cash equivalents and
available-for-sale
marketable securities held by the Company as of June 30, 2023 and December 31, 2022 is as follows (in thousands):
 
    
June 30, 2023
 
    
Cost
    
Unrealized

gains
    
Unrealized

losses
    
Fair

value
 
Cash and cash equivalents:
           
Cash (Level 1)
   $ 8,185      $  —        $ —        $ 8,185  
Money market funds (Level 1)
     69,011        —          —          69,011  
  
 
 
    
 
 
    
 
 
    
 
 
 
Total cash and cash equivalents
     77,196        —          —          77,196  
Marketable securities:
           
Corporate debt securities due within
1
 
year of date of purchase (Level 2)
     144,036        13        (105      143,944  
U.S. government and government sponsored entities due within 1 year of date of purchase (Level 2)
     77,275        6        (3      77,278  
  
 
 
    
 
 
    
 
 
    
 
 
 
Total cash, cash equivalents and marketable securities
   $ 298,507      $ 19      $ (108    $  298,418  
  
 
 
    
 
 
    
 
 
    
 
 
 
 
    
December 31, 2022
 
    
Cost
    
Unrealized

gains
    
Unrealized

losses
    
Fair

value
 
Cash and cash equivalents:
           
Cash (Level 1)
   $ 15,100      $  —        $  —        $ 15,100  
Money market funds (Level 1)
     316,449        —          —          316,449  
  
 
 
    
 
 
    
 
 
    
 
 
 
Total cash and cash equivalents
     331,549        —          —          331,549  
Marketable securities:
           
Corporate debt securities due within 1 year of date of purchase (Level 2)
     27,257        7        (39      27,225  
  
 
 
    
 
 
    
 
 
    
 
 
 
Total cash, cash equivalents and marketable securities
   $  358,806      $ 7      $ (39    $  358,774  
  
 
 
    
 
 
    
 
 
    
 
 
 
XML 27 R12.htm IDEA: XBRL DOCUMENT v3.23.2
Accrued Liabilities
6 Months Ended
Jun. 30, 2023
Accrued Liabilities, Current [Abstract]  
Accrued Liabilities
5. Accrued Liabilities
Accrued liabilities as of June 30, 2023 and December 31, 2022 consisted of the following (in thousands):
 
    
June 30,
2023
    
December 31,
2022
 
Contract research organization costs
   $  58,050      $  53,119  
Other clinical study related costs
     3,605        6,582  
Manufacturing and drug supply
     3,556        11,262  
Compensation and benefits
     5,453        14,864  
Professional fees
     9,494        4,867  
Other
     1,603        767  
    
 
 
    
 
 
 
Total accrued liabilities
   $ 81,761      $ 91,461  
    
 
 
    
 
 
 
XML 28 R13.htm IDEA: XBRL DOCUMENT v3.23.2
Long Term Debt
6 Months Ended
Jun. 30, 2023
Debt Disclosure [Abstract]  
Long Term Debt
6. Long Term Debt
In May 2022 the Company and its wholly-owned subsidiary, Canticle Pharmaceuticals, Inc., entered into the $250.0 million Loan Facility with the several banks and other financial institutions or entities party thereto (each, a “Lender” and collectively referred to as the “Lenders”), and Hercules Capital, Inc. (“Hercules”), in its capacity as administrative agent and collateral agent for itself and the Lenders. Under the terms of the Loan Facility, the first $50.0 million tranche was drawn at closing. The Company also could draw up to an additional $125.0 million in two separate tranches upon achievement of certain resmetirom clinical and regulatory milestones. A fourth tranche of $75.0 million could be drawn by the Company, subject to the approval of Hercules. The Loan Facility had a minimum interest rate of 7.45% and adjusts with changes in the prime rate. The Company will pay interest-only monthly payments of accrued interest under the Loan Facility for a period of 30 months, which period may be extended to 36, 48, and 60 months upon the successive achievement of certain clinical and regulatory milestones and if the Company maintains compliance with applicable covenants. The Loan Facility matures in May 2026 and may be extended an additional year upon the achievement of certain clinical and regulatory milestones. The Loan Facility is secured by a security interest in substantially all of the Company’s assets, other than intellectual property. It includes an end of term charge of 5.35% of the aggregate principal amount, which is accounted for in the loan discount. In connection with the first tranche drawn at closing, the Company issued Hercules a warrant to purchase 14,899 shares of Company common stock, which had a Black-Scholes value of $0.6 million.
On February 3, 2023, the Company entered into the First Amendment (the “Amendment”) to the Loan Facility (as amended, the “Amended Loan Facility”). Under the Amended Loan Facility, an additional $35.0 million was drawn under a second, expanded, $65.0 million tranche (“Tranche 2”) in February of 2023 following the Company’s achievement of the Phase 3 clinical development milestone. An additional $15.0 million was drawn under Tranche 2 in June of 2023. The Company has the ability to draw the remaining $15.0 million available under Tranche 2 by September 30, 2023
 
in accordance with the Amended Loan Facility.
The third tranche (“Tranche 3”) of $75.0 million remains unchanged by the Amendment, and such borrowings are available subject to the Company obtaining a certain FDA approval for resmetirom. Coincident with the expansion of Tranche 2 borrowing capacity by $15 million, the Amendment reduced the fourth tranche under the Loan Facility (“Tranche 4”) by $15.0 million to $60.0 million , which amount is available subject to Hercules’ sole discretion. In connection with the $35.0 million drawn under
Tranche 2
at the closing of the Amendment and $15.0 million drawn in June of 2023, the Company issued to Hercules and affiliates Tranche 2 Warrants to purchase 3,504 shares of common stock, which had a Black-Scholes value of $0.7 million. The Amendment reduced the interest rate under the Amended Loan Facility to the greater of (i) the prime rate as reported in The Wall Street Journal plus 2.45% and (ii) 8.25%. The Amendment and the Amended Loan Facility summary terms were disclosed in the Company’s Current Report on Form
8-K
filed with the Securities and Exchange Commission on February 9, 2023.
The Loan Facility includes affirmative and restrictive financial covenants commencing on January 1, 2023, including maintenance of a minimum cash, cash equivalents and liquid funds covenant of $35.0 million, which may decrease in certain circumstances if the Company achieves certain clinical milestones and a revenue milestone, and a revenue-based covenant that could apply commencing at or after the time that financial reporting is due for the quarter ending September 30, 2024. The Loan Facility contains event of default provisions for: the Company’s failure to make required payments or maintain compliance with covenants under the Loan Facility; the Company’s breach of certain representations or default under certain obligations outside the Loan Facility; insolvency, attachment or judgment events affecting the Company; and any circumstance which has occurred or could reasonably be expected to have a material adverse effect on the Company, provided that, any failure to achieve a clinical milestone or approval milestone under the Loan Facility shall not in and of itself constitute a material adverse effect. The Loan Facility also includes customary covenants associated with a secured loan facility, including covenants concerning financial reporting obligations, and certain limitations on indebtedness, liens (including a negative pledge on intellectual property and other assets), investments, distributions (including dividends), collateral, investments, distributions, transfers, mergers or acquisitions, taxes, corporate changes, and deposit accounts.
 
As of June 30, 2023, the outstanding principal under the Loan Facility was $100.0 million. The interest rate as of June 30, 2023 was 10.70%. As of June 30, 2023, the Company was in compliance with all loan covenants and provisions.
Future minimum payments, including interest and principal, under the loans payable outstanding as of June 30, 2023 are as follows (in thousands):
 
Period Ending June 30, 2023:
  
Amount
 
2023 (remaining six months)
   $ 5,372  
2024
     10,878  
2025
     69,044  
Thereafter
     46,363  
    
 
 
 
     $ 131,657  
Less amount representing interest
     (26,307
Less unamortized discount
     (6,101
    
 
 
 
Loans payable, net of discount
   $ 99,249  
    
 
 
 
XML 29 R14.htm IDEA: XBRL DOCUMENT v3.23.2
Stockholders' Equity
6 Months Ended
Jun. 30, 2023
Stockholders' Equity Note [Abstract]  
Stockholders' Equity
7. Stockholders’ Equity
Common Stock
Each common stockholder is entitled to one vote for each share of common stock held. The common stock will vote together with all other classes and series of stock of the Company as a single class on all actions to be taken by the Company’s stockholders. Each share of common stock is entitled to receive dividends, as and when declared by the Company’s board of directors. The Company has never declared cash dividends on its common stock and does not expect to do so in the foreseeable future.
Preferred Stock
The Series A and B Preferred Stock have a par value of $0.0001 per share and are convertible into shares of the common stock at a
one-to-one
ratio, subject to adjustment as provided in the Certificates of Designation of Preferences, Rights and Limitations of Series A Preferred Stock and Series B Preferred Stock that the Company filed with the Secretary of State of the State of Delaware on June 21, 2017 and December 22, 2022, respectively. The terms of the Series A and B Preferred Stock are set forth in such Certificates of Designation. Each share of the Series A and B Preferred Stock is convertible into shares of Common Stock following notice that may be given at the holder’s option. Upon any liquidation, dissolution or
winding-up
of the Company, whether voluntary or involuntary, after the satisfaction in full of the debts of the Company and the payment of any liquidation preference owed to the holders of shares of capital stock of the Company ranking prior to the Series A and B Preferred Stock upon liquidation, the holders of the Series A and B Preferred Stock shall participate pari passu with the holders of the Common Stock (on an
as-if-converted-to-Common-Stock
basis) in the net assets of the Company. Shares of the Series A and B Preferred Stock will generally have no voting rights, except as required by law. Shares of the Series A and B Preferred Stock will be entitled to receive dividends before shares of any other class or series of capital stock of the Company (other than dividends in the form of the Common Stock) equal to the dividend payable on each share of the Common Stock, on an
as-converted
basis.
December 2022 Registered Direct Offering
In December 2022, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with a group of institutional accredited investors, who were existing,
non-controlling
stockholders of the Company, pursuant to which the Company sold securities to the Investors in an offering that was registered under the Company’s existing shelf registration statement (the “2022 Registered Direct Offering”). Under the terms of the Purchase Agreement, the Company sold 44,444 shares of its common stock at a price of $225 per share, and 400,000 shares of its Series B Convertible Preferred Stock at a price of $225 per share. The 2022 Registered Direct Offering resulted in gross proceeds to the Company of approximately $100.0 million, and net proceeds to the Company of approximately $99.5 million. The 2022 Registered Direct Offering closed on December 23, 2022.
 
At-The-Market
Issuance Sales Agreement
In June 2021, the Company entered into an
at-the-market
sales agreement (the “2021 Sales Agreement”) with Cowen and Company, LLC (“Cowen”), pursuant to which the Company could, from time to time, issue and sell shares of its common stock. The 2021 Sales Agreement
 initially
authorized an aggregate offering of up to $200 million in shares of our common stock, at the Company’s option, through Cowen as its sales agent. Sales of common stock through Cowen could be made by any method that is deemed an
“at-the-market”
offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, including by means of ordinary brokers’ transactions at market prices, in block transactions or as otherwise agreed by the Company and Cowen. Subject to the terms and conditions of the 2021 Sales Agreement, Cowen would use commercially reasonable efforts consistent with its normal trading and sales practices to sell the common stock based upon the Company’s instructions (including any price, time or size limits or other customary parameters or conditions the Company imposed).
In December 2022, the Company sold 738,900 shares
 of common stock
under the 2021 Sales Agreement for an aggregate of $159.1 million in gross proceeds, with net proceeds to the Company of $155.9 million after deducting commissions and other transaction costs. In total, under the 2021 Sales Agreement the Company sold 1,235,943 shares for an aggregate of $199.9 million in gross proceeds, with net proceeds to the Company of approximately $195.8 million after deducting commissions and other transaction costs
 through December 31, 2022.
Of those shares sold, 738,900 were sold in 2022, and 497,043 were sold in 2021. All shares were sold pursuant to the Company’s effective shelf registration statement
on Form S-3 (the “Registration Statement”) and
 the prospectus supplement relating thereto. As of June 30, 2023, no amounts remained reserved and available for sale under the 2021 Sales Agreement and the related prospectus supplement.
In May 2023, the Company amended the 2021 Agreement (the “Sales Agreement
 Amendment
”), with Cowen, pursuant to which the Company may, from time to time, issue and sell
 in additional $200 million in
shares of its common stock. The Company is not obligated to make any sales of its common stock under this arrangement. Any shares sold will be sold pursuant to the Company’s effective
Registration Statement
on Form
S-3
(the “Registration Statement”) and prospectus supplement filed pursuant to the Registration Statement. The Sales Agreement Amendment authorizes
sales of
shares of our common stock, from time to time, at the Company’s option, through Cowen as its sales agent. Sales of common stock through Cowen may be made by any method that is deemed an
“at-the-market”
offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, and as described in the prospectus supplement. In total, under the Sales Agreement
 Amendment,
the Company sold 85,901 shares for an aggregate of $22.4 million in gross proceeds, with net proceeds to the Company of approximately $21.8 million after deducting commissions and other transaction costs. All shares were sold pursuant to the Company’s effective
Registration Statement
and the prospectus supplement relating thereto. As of June 30, 2023, $177.6 million remained reserved and available for sale under the 2023 Sales Agreement
 
Amendment 
and the Company’s related prospectus supplement.
XML 30 R15.htm IDEA: XBRL DOCUMENT v3.23.2
Stock-based Compensation
6 Months Ended
Jun. 30, 2023
Share-based Payment Arrangement [Abstract]  
Stock-based Compensation
8. Stock-based Compensation
The Company’s 2015 Stock Plan, as amended, is our primary equity incentive compensation plan through which equity based grants are awarded. The 2015 Stock Plan provides for the grant of incentive stock options,
non-statutory
stock options, restricted stock, restricted stock units and other stock-based compensation awards to employees, officers, directors, and consultants of the Company. The administration of the 2015 Stock Plan is under the general supervision of the Compensation Committee of the Board of Directors. The terms of stock options awarded under the 2015 Stock Plan, in general, are determined by the Compensation Committee, provided the exercise price per share generally shall not be set at less than the fair market value of a share of the common stock on the date of grant and the term shall not be greater than ten years from the date the option is granted. As of June 30, 2023, the Company had restricted stock units and options outstanding to purchase
 an aggregate of
2,805,840 shares of its common stock, which includes options outstanding under its prior incentive compensation plan, the 2006 Stock Plan. As of June 30, 2023, 670,634 shares were available for future issuance under the 2015 Stock Plan.
Stock Options
The following table summarizes stock option activity during the six months ended June 30, 2023:
 
    
Shares
    
Weighted
average exercise
price
 
Outstanding at January 1, 2023
     2,857,054      $ 81.78  
Options granted
     5,205        283.08  
Options exercised
     (270,609      89.26  
Options cancelled
     (8,110      84.12  
    
 
 
    
 
 
 
Outstanding at June 30, 2023
     2,583,540      $ 81.40  
    
 
 
    
 
 
 
Exercisable at June 30, 2023
     1,719,944      $ 76.62  
 
The total cash received by the Company as a result of stock option exercises was $21.8 million and $0 million, respectively, for the six months ended June 30, 2023 and 2022. The total intrinsic value of options exercised was $48.9 million and $0 million, respectively, for the six months ended June 30, 2023 and 2022. The weighted-average grant date fair values, based on the Black-Scholes option model, of options granted during the six months ended June 30, 2023 and 2022 were $219.02 and $55.84, respectively.
Restricted Stock Units
The Company’s share-based compensation plan provides for awards of restricted stock units to employees, officers, directors and consultants to the Company. Restricted stock units vest over the service period, and are subject to forfeiture if employment or service terminates before vesting. As of June 30, 2023, the Company had 222,300 restricted stock units outstanding, with a weighted average grant date fair value of $294.19 per unit.
Stock-Based Compensation Expense
Stock-based compensation expense during the six months ended June 30, 2023 and 2022 was as follows (in thousands):
 
    
Three Months Ended June 30,
    
Six Months Ended June 30,
 
    
2023
    
2022
    
2023
    
2022
 
Stock-based compensation expense by type of award:
                                   
Stock options
   $ 7,431      $ 7,944      $ 16,029      $ 15,421  
Restricted stock units
     3,542        —          6,194        —    
    
 
 
    
 
 
    
 
 
    
 
 
 
Total stock-based compensation expense
   $ 10,973      $ 7,944      $ 22,223      $ 15,421  
    
 
 
    
 
 
    
 
 
    
 
 
 
Effect of stock-based compensation expense by line item:
                                   
Research and development
   $ 5,184      $ 3,301      $ 10,570      $ 6,488  
General and administrative
     5,789        4,643        11,653        8,933  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total stock-based compensation expense included in net loss
   $ 10,973      $ 7,944      $ 22,223      $ 15,421  
    
 
 
    
 
 
    
 
 
    
 
 
 
Unrecognized stock-based compensation expense as of June 30, 2023 was $98.2 million with a weighted average remaining period of 2.90 years.
XML 31 R16.htm IDEA: XBRL DOCUMENT v3.23.2
Commitments and Contingencies
6 Months Ended
Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
9. Commitments and Contingencies
The Company has a Research, Development and Commercialization Agreement with
Hoffmann-La
Roche (“Roche”) which grants the Company a sole and exclusive license to develop, use, sell, offer for sale and import any Licensed Product as defined by the agreement.
The agreement requires future milestone payments to Roche. Remaining milestones under the agreement total $8 million and are payable upon Madrigal achieving specified objectives related to future regulatory approval in the United States and Europe of resmetirom or a product developed from resmetirom. Furthermore, a tiered single-digit royalty is payable on net sales of resmetirom or a product developed from resmetirom, subject to certain reductions. The Company has not achieved any additional product development or regulatory milestones and had no Licensed Product sales for the six months ended June 30, 2023 and 2022.
The Company has entered into customary contractual arrangements and letters of intent in preparation for and in support of the clinical trials.
XML 32 R17.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Significant Accounting Policies (Policies)
6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Principle of Consolidation
Principle of Consolidation
The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries. All significant intercompany balances have been eliminated in consolidation.
Use of Estimates
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities, and the reported amounts of revenues and expenses during the reporting periods. The Company bases its estimates on historical experience and various other assumptions that management believes to be reasonable under the circumstances. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.
Cash and Cash Equivalents
Cash and Cash Equivalents
The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. The Company maintains its cash in bank accounts, the balance of which, at times, exceeds Federal Deposit Insurance Corporation insured limits.
The primary objective of the Company’s investment activities is to preserve its capital for the purpose of funding operations and the Company does not enter into investments for trading or speculative purposes. The Company’s cash is deposited in highly rated financial institutions in the United States. The Company invests in money market funds and high-grade, commercial paper and corporate bonds, which management believes are subject to minimal credit and market risk.
Marketable Securities
Marketable Securities
Marketable securities consist of investments in high-grade corporate obligations and government and government agency obligations that are classified as
available-for-sale.
Since these securities are available to fund current operations, they are classified as current assets on the consolidated balance sheets.
 
The Company adjusts the cost of
available-for-sale
debt securities for amortization of premiums and accretion of discounts to maturity. The Company includes such amortization and accretion as a component of interest income, net. Realized gains and losses and declines in value, if any, that the Company judges to be the result of impairment or as a result of recognizing an allowance for credit losses on
available-for-sale
securities are reported as a component of interest income. To determine whether an impairment exists, the Company considers whether it intends to sell the debt security and, if the Company does not intend to sell the debt security, it considers available evidence to assess whether it is more likely than not that it will be required to sell the security before the recovery of its amortized cost basis. During the six months ended June 30, 2023 and 2022, the Company determined it did not have any securities that were other-than-temporarily impaired.
Marketable securities are stated at fair value, including accrued interest, with their unrealized gains and losses included as a component of accumulated other comprehensive income or loss, which is a separate component of stockholders’ equity. The fair value of these securities is based on quoted prices and observable inputs on a recurring basis. Realized gains and losses are determined on the specific identification method. During the six months ended June 30, 2023 and 2022, the Company did not have any realized gains or losses on marketable
securitie
s.
Fair Value of Financial Instruments
Fair Value of Financial Instruments
The carrying amounts of the Company’s financial instruments, which include cash equivalents and marketable securities, approximate their fair values. The fair value of the Company’s financial instruments reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels:
Level 1—quoted prices in active markets for identical assets and liabilities.
Level 2—observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.
Level 3—unobservable inputs that reflect the Company’s own assumptions about the assumptions market participants would use in pricing the asset or liability.
Financial assets and liabilities are classified in their entirety within the fair value hierarchy based on the lowest level of input that is significant to the fair value measurement. The Company measures the fair value of its marketable securities by taking into consideration valuations obtained from third- party pricing sources. The pricing services utilize industry standard valuation models, including both income and market based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker-dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities and other observable inputs.
As of June 30, 2023, the Company’s financial assets valued based on Level 1 inputs consisted of cash and cash equivalents in a money market fund, its financial assets valued based on Level 2 inputs consisted of high-grade corporate and government agency bonds and commercial paper, and it had no financial assets valued based on Level 3 inputs. During the six months ended June 30, 2023 and 2022, the Company did not have any transfers of financial assets between Levels 1 and 2. As of June 30, 2023 and December 31, 2022, the Company did not have any financial liabilities that were recorded at fair value on a recurring basis on the balance sheet.
Research and Development Costs
Research and Development Costs
Research and development costs are expensed as incurred. Research and development costs are comprised of costs incurred in performing research and development activities, including internal costs (including stock-based compensation), costs for consultants, milestone payments under licensing agreements, and other costs associated with the Company’s preclinical and clinical programs. In particular, the Company has conducted safety studies in animals, optimized and implemented the manufacturing of our drug, and conducted clinical trials, all of which are considered research and development expenditures. Management uses significant judgment in estimating the amount of research and development costs recognized in each reporting period. Management analyzes and estimates the progress of its clinical trials, completion of milestone events per underlying agreements, invoices received and contracted costs when estimating the research and development costs to accrue in each reporting period. Actual results could differ from the Company’s estimates.
Patents
Patents
Costs to secure and defend patents are expensed as incurred and are classified as general and administrative expense in the Company’s consolidated statements of operations.
Stock-Based Compensation
Stock-Based Compensation
The Company recognizes stock-based compensation expense based on the grant date fair value of stock options and restricted stock units granted to employees, officers, and directors. Awards that vest as the recipient provides service are expensed on a straight-line basis over the requisite service period. The Company uses the Black-Scholes option pricing model to determine the grant date fair value of stock options as management believes it is the most appropriate valuation method for its option grants. The Black-Scholes model requires inputs for risk-free interest rate, dividend yield, volatility and expected lives of the options. The expected lives for options granted represent the period of time that options granted are expected to be outstanding. The Company uses the simplified method for determining the expected lives of options. Expected volatility is based upon an industry estimate or blended rate including the Company’s historical trading activity. The risk-free rate for periods within the expected life of the option is based on the U.S. Treasury yield curve in effect at the time of the grant. The Company estimates the forfeiture rate based on historical data. This analysis is
re-evaluated
at least annually and the forfeiture rate is adjusted as necessary.
Income Taxes
Income Taxes
The Company uses the asset and liability method to account for income taxes. Deferred tax assets and liabilities are determined based on the expected future tax consequences of temporary differences between the Company’s financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates expected to be in effect in the years in which the differences are expected to reverse. The Company currently maintains a 100% valuation allowance on its deferred tax assets.
Comprehensive Loss
Comprehensive Loss
Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from
non-owner
sources. Changes in unrealized gains and losses on marketable securities represent the only difference between the Company’s net loss and comprehensive loss.
Basic and Diluted Loss Per Common Share
Basic and Diluted Loss Per Common Share
Basic net loss per share is computed using the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed using the weighted average number of common shares outstanding and the weighted average dilutive potential common shares outstanding using the treasury stock method. However, for the six months ended June 30, 2023 and 2022, diluted net loss per share is the same as basic net loss per share because the inclusion of weighted average shares of common stock issuable upon the exercise of stock options and warrants or vesting of restricted stock units, and common stock issuable upon the conversion of preferred stock would be anti-dilutive. The following table summarizes outstanding securities not included in the computation of diluted net loss per common share, as their inclusion would be anti-dilutive:
 
    
Six Months Ended June 30,
 
    
2023
    
2022
 
Common stock options
     2,583,540        2,976,545  
Restricted stock units
     222,300        —    
Preferred stock
     2,369,797        1,969,797  
Warrants
     18,403        14,899  
Recent Accounting Pronouncements
Recent Accounting Pronouncements
None
XML 33 R18.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Significant Accounting Policies (Tables)
6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Summary of the outstanding securities not included in the computation of diluted net loss per common share as their inclusion would be anti-dilutive The following table summarizes outstanding securities not included in the computation of diluted net loss per common share, as their inclusion would be anti-dilutive:
 
    
Six Months Ended June 30,
 
    
2023
    
2022
 
Common stock options
     2,583,540        2,976,545  
Restricted stock units
     222,300        —    
Preferred stock
     2,369,797        1,969,797  
Warrants
     18,403        14,899  
XML 34 R19.htm IDEA: XBRL DOCUMENT v3.23.2
Cash, Cash Equivalents and Marketable Securities (Tables)
6 Months Ended
Jun. 30, 2023
Cash and Cash Equivalents [Abstract]  
Summary of cash, cash equivalents and available-for-sale marketable securities
A summary of cash, cash equivalents and
available-for-sale
marketable securities held by the Company as of June 30, 2023 and December 31, 2022 is as follows (in thousands):
 
    
June 30, 2023
 
    
Cost
    
Unrealized

gains
    
Unrealized

losses
    
Fair

value
 
Cash and cash equivalents:
           
Cash (Level 1)
   $ 8,185      $  —        $ —        $ 8,185  
Money market funds (Level 1)
     69,011        —          —          69,011  
  
 
 
    
 
 
    
 
 
    
 
 
 
Total cash and cash equivalents
     77,196        —          —          77,196  
Marketable securities:
           
Corporate debt securities due within
1
 
year of date of purchase (Level 2)
     144,036        13        (105      143,944  
U.S. government and government sponsored entities due within 1 year of date of purchase (Level 2)
     77,275        6        (3      77,278  
  
 
 
    
 
 
    
 
 
    
 
 
 
Total cash, cash equivalents and marketable securities
   $ 298,507      $ 19      $ (108    $  298,418  
  
 
 
    
 
 
    
 
 
    
 
 
 
 
    
December 31, 2022
 
    
Cost
    
Unrealized

gains
    
Unrealized

losses
    
Fair

value
 
Cash and cash equivalents:
           
Cash (Level 1)
   $ 15,100      $  —        $  —        $ 15,100  
Money market funds (Level 1)
     316,449        —          —          316,449  
  
 
 
    
 
 
    
 
 
    
 
 
 
Total cash and cash equivalents
     331,549        —          —          331,549  
Marketable securities:
           
Corporate debt securities due within 1 year of date of purchase (Level 2)
     27,257        7        (39      27,225  
  
 
 
    
 
 
    
 
 
    
 
 
 
Total cash, cash equivalents and marketable securities
   $  358,806      $ 7      $ (39    $  358,774  
  
 
 
    
 
 
    
 
 
    
 
 
 
XML 35 R20.htm IDEA: XBRL DOCUMENT v3.23.2
Accrued Liabilities (Tables)
6 Months Ended
Jun. 30, 2023
Accrued Liabilities, Current [Abstract]  
Schedule of Accrued Liabilities
Accrued liabilities as of June 30, 2023 and December 31, 2022 consisted of the following (in thousands):
 
    
June 30,
2023
    
December 31,
2022
 
Contract research organization costs
   $  58,050      $  53,119  
Other clinical study related costs
     3,605        6,582  
Manufacturing and drug supply
     3,556        11,262  
Compensation and benefits
     5,453        14,864  
Professional fees
     9,494        4,867  
Other
     1,603        767  
    
 
 
    
 
 
 
Total accrued liabilities
   $ 81,761      $ 91,461  
    
 
 
    
 
 
 
XML 36 R21.htm IDEA: XBRL DOCUMENT v3.23.2
Long Term Debt (Tables)
6 Months Ended
Jun. 30, 2023
Debt Disclosure [Abstract]  
Schedule of Maturities of Long-Term Debt [Table Text Block]
Future minimum payments, including interest and principal, under the loans payable outstanding as of June 30, 2023 are as follows (in thousands):
 
Period Ending June 30, 2023:
  
Amount
 
2023 (remaining six months)
   $ 5,372  
2024
     10,878  
2025
     69,044  
Thereafter
     46,363  
    
 
 
 
     $ 131,657  
Less amount representing interest
     (26,307
Less unamortized discount
     (6,101
    
 
 
 
Loans payable, net of discount
   $ 99,249  
    
 
 
 
XML 37 R22.htm IDEA: XBRL DOCUMENT v3.23.2
Stock-based Compensation (Tables)
6 Months Ended
Jun. 30, 2023
Share-based Payment Arrangement [Abstract]  
Summary of stock option activity
The following table summarizes stock option activity during the six months ended June 30, 2023:
 
    
Shares
    
Weighted
average exercise
price
 
Outstanding at January 1, 2023
     2,857,054      $ 81.78  
Options granted
     5,205        283.08  
Options exercised
     (270,609      89.26  
Options cancelled
     (8,110      84.12  
    
 
 
    
 
 
 
Outstanding at June 30, 2023
     2,583,540      $ 81.40  
    
 
 
    
 
 
 
Exercisable at June 30, 2023
     1,719,944      $ 76.62  
Schedule of stock-based compensation expense
Stock-based compensation expense during the six months ended June 30, 2023 and 2022 was as follows (in thousands):
 
    
Three Months Ended June 30,
    
Six Months Ended June 30,
 
    
2023
    
2022
    
2023
    
2022
 
Stock-based compensation expense by type of award:
                                   
Stock options
   $ 7,431      $ 7,944      $ 16,029      $ 15,421  
Restricted stock units
     3,542        —          6,194        —    
    
 
 
    
 
 
    
 
 
    
 
 
 
Total stock-based compensation expense
   $ 10,973      $ 7,944      $ 22,223      $ 15,421  
    
 
 
    
 
 
    
 
 
    
 
 
 
Effect of stock-based compensation expense by line item:
                                   
Research and development
   $ 5,184      $ 3,301      $ 10,570      $ 6,488  
General and administrative
     5,789        4,643        11,653        8,933  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total stock-based compensation expense included in net loss
   $ 10,973      $ 7,944      $ 22,223      $ 15,421  
    
 
 
    
 
 
    
 
 
    
 
 
 
XML 38 R23.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Significant Accounting Policies - Income Taxes (Details)
6 Months Ended
Jun. 30, 2023
Income Taxes  
Valuation allowance on deferred tax assets (as a percent) 100.00%
XML 39 R24.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Significant Accounting Policies - Basic and Diluted Loss Per Common Share (Details) - shares
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Stock options    
Anti-dilutive securities    
Outstanding securities not included in the computation of diluted net loss per common share as their inclusion would be anti-dilutive (in shares) 2,583,540 2,976,545
Restricted stock units    
Anti-dilutive securities    
Outstanding securities not included in the computation of diluted net loss per common share as their inclusion would be anti-dilutive (in shares) 222,300 0
Preferred Stock    
Anti-dilutive securities    
Outstanding securities not included in the computation of diluted net loss per common share as their inclusion would be anti-dilutive (in shares) 2,369,797 1,969,797
Warrants    
Anti-dilutive securities    
Outstanding securities not included in the computation of diluted net loss per common share as their inclusion would be anti-dilutive (in shares) 18,403 14,899
XML 40 R25.htm IDEA: XBRL DOCUMENT v3.23.2
Liquidity and Uncertainties (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Liquidity and Uncertainties              
Net loss $ (85,800) $ (76,896) $ (70,730) $ (57,518) $ (162,696) $ (128,248)  
Accumulated deficit $ (1,125,356)       $ (1,125,356)   $ (962,660)
XML 41 R26.htm IDEA: XBRL DOCUMENT v3.23.2
Cash, Cash Equivalents and Marketable Securities (Details) - USD ($)
$ in Thousands
6 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Cash, Cash Equivalents and Marketable Securities    
Total cash, cash equivalents and marketable securities, Unrealized gains $ 19 $ 7
Total cash, cash equivalents and marketable securities, Unrealized losses (108) (39)
Carrying value    
Cash, Cash Equivalents and Marketable Securities    
Cash and cash equivalents 77,196 331,549
Total cash, cash equivalents and marketable securities, Cost 298,507 358,806
Fair value    
Cash, Cash Equivalents and Marketable Securities    
Cash and cash equivalents 77,196 331,549
Total cash, cash equivalents and marketable securities, Fair value $ 298,418 $ 358,774
Corporate debt securities due within 1 year of date of purchase    
Cash, Cash Equivalents and Marketable Securities    
Maturity period from date of purchase to classify an investment as marketable securities 1 year 1 year
Corporate debt securities due within 1 year of date of purchase | Level 2    
Cash, Cash Equivalents and Marketable Securities    
Marketable securities, unrealized gains $ 13 $ 7
Marketable securities, unrealized losses (105) (39)
Corporate debt securities due within 1 year of date of purchase | Carrying value | Level 2    
Cash, Cash Equivalents and Marketable Securities    
Marketable securities, cost 144,036 27,257
Corporate debt securities due within 1 year of date of purchase | Fair value | Level 2    
Cash, Cash Equivalents and Marketable Securities    
Marketable securities, fair value $ 143,944 27,225
U.S. government and government sponsored entities due within 1 year of date of purchase    
Cash, Cash Equivalents and Marketable Securities    
Maturity period from date of purchase to classify an investment as marketable securities 1 year  
U.S. government and government sponsored entities due within 1 year of date of purchase | Level 2    
Cash, Cash Equivalents and Marketable Securities    
Marketable securities, unrealized gains $ 6  
Marketable securities, unrealized losses (3)  
U.S. government and government sponsored entities due within 1 year of date of purchase | Carrying value | Level 2    
Cash, Cash Equivalents and Marketable Securities    
Marketable securities, cost 77,275  
U.S. government and government sponsored entities due within 1 year of date of purchase | Fair value | Level 2    
Cash, Cash Equivalents and Marketable Securities    
Marketable securities, fair value 77,278  
Cash | Carrying value | Level 1    
Cash, Cash Equivalents and Marketable Securities    
Cash and cash equivalents 8,185 15,100
Cash | Fair value | Level 1    
Cash, Cash Equivalents and Marketable Securities    
Cash and cash equivalents 8,185 15,100
Money market funds | Carrying value | Level 1    
Cash, Cash Equivalents and Marketable Securities    
Cash and cash equivalents 69,011 316,449
Money market funds | Fair value | Level 1    
Cash, Cash Equivalents and Marketable Securities    
Cash and cash equivalents $ 69,011 $ 316,449
XML 42 R27.htm IDEA: XBRL DOCUMENT v3.23.2
Accrued Liabilities (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Accrued Liabilities, Current [Abstract]    
Contract research organization costs $ 58,050 $ 53,119
Other clinical study related costs 3,605 6,582
Manufacturing and drug supply 3,556 11,262
Compensation and benefits 5,453 14,864
Professional fees 9,494 4,867
Other 1,603 767
Total accrued liabilities $ 81,761 $ 91,461
XML 43 R28.htm IDEA: XBRL DOCUMENT v3.23.2
Long Term Debt - Schedule of Maturities of Long-Term Debt (Details)
$ in Thousands
6 Months Ended
Jun. 30, 2023
USD ($)
Long-Term Debt, Fiscal Year Maturity [Abstract]  
2023 (remaining six months) $ 5,372
2024 10,878
2025 69,044
Thereafter 46,363
Long-Term Debt 131,657
Less amount representing interest (26,307)
Less unamortized discount (6,101)
Loans payable, net of discount $ 99,249
XML 44 R29.htm IDEA: XBRL DOCUMENT v3.23.2
Long Term Debt (Details) - USD ($)
$ in Millions
1 Months Ended
Feb. 03, 2023
Jan. 02, 2023
May 09, 2022
May 01, 2022
May 31, 2022
Sep. 30, 2023
Jun. 30, 2023
Jun. 19, 2023
Jan. 01, 2023
Debt instrument, Face amount             $ 100.0    
Interest rate             10.70%    
Percenatge of Term charges on aggregate principal amount         5.35%        
Debt conversion, converted instrument, warrants or options issued       14,899          
Debt conversion, converted instrument, amount     $ 0.6            
Loan Facility [Member]                  
Line of credit facility, maximum borrowing capacity                 $ 35.0
Line of credit facility, expiration date   Sep. 30, 2024              
Loan Facility And Amended Loan Facility [Member]                  
Long term debt floor interest rate percentage 8.25%                
Loan Facility And Amended Loan Facility [Member] | Prime Rate [Member]                  
Long term debt floor interest rate percentage 2.45%                
Loan Facility And Amended Loan Facility [Member] | Tranche Two [Member]                  
Proceeds from issuance of debt $ 35.0                
Line of credit facility, maximum borrowing capacity $ 65.0           $ 15.0 $ 15.0  
Debt conversion, converted instrument, warrants or options issued 3,504                
Debt conversion, converted instrument, amount $ 0.7                
Line of Credit Facility, Current Borrowing Capacity 15.0                
Loan Facility And Amended Loan Facility [Member] | Tranche three [Member]                  
Line of Credit Facility, Remaining Borrowing Capacity 75.0                
Loan Facility And Amended Loan Facility [Member] | Tranche fouth [Member]                  
Line of Credit Facility, Remaining Borrowing Capacity 15.0                
Loan Facility And Amended Loan Facility [Member] | Subsequent Event [Member] | Tranche Two [Member]                  
Line of credit facility, maximum borrowing capacity           $ 15.0      
Loan Facility And Amended Loan Facility One [Member] | Tranche fouth [Member]                  
Line of Credit Facility, Remaining Borrowing Capacity 60.0                
Drawn In Two Separate Tranches Upon Achievement of Resmetirom Clinical And Regulatory Milestone                  
Unused borrowing capacity that can be drawn         $ 125.0        
Term Loan [Member]                  
Debt instrument, Face amount         250.0        
Proceeds from issuance of debt         $ 50.0        
Long term debt floor interest rate percentage         7.45%        
Debt Instrument Interest Payments Terms         The Company will pay interest-only monthly payments of accrued interest under the Loan Facility for a period of 30 months, which period may be extended to 36, 48, and 60 months upon the successive achievement of certain clinical and regulatory milestones        
Term Loan [Member] | Loan Facility And Amended Loan Facility [Member]                  
Proceeds from issuance of debt $ 35.0                
Term Loan [Member] | Drawn In Two Separate Tranches Upon Achievement of Resmetirom Clinical And Regulatory Milestone                  
Unused borrowing capacity that can be drawn         $ 75.0        
XML 45 R30.htm IDEA: XBRL DOCUMENT v3.23.2
Stockholders' Equity (Deficit) - Common Stock (Details)
6 Months Ended
Jun. 30, 2023
Vote
Stockholders' Equity Note [Abstract]  
Number of votes per share that common stockholders are entitled to receive 1
XML 46 R31.htm IDEA: XBRL DOCUMENT v3.23.2
Stockholders' Equity (Deficit) - Preferred Stock (Details)
1 Months Ended
Jun. 30, 2017
Vote
$ / shares
shares
Jun. 30, 2023
$ / shares
Dec. 31, 2022
$ / shares
Stockholders' Equity (Deficit)      
Preferred stock, par value (in dollars per share)   $ 0.0001 $ 0.0001
Convertible Series A and B Preferred Stock      
Stockholders' Equity (Deficit)      
Preferred stock, par value (in dollars per share) $ 0.0001    
Preferred stock conversion ratio | shares 1    
Preferred shares number voting rights | Vote 0    
XML 47 R32.htm IDEA: XBRL DOCUMENT v3.23.2
Stockholders' Equity (Deficit) - Registered Offering (Details) - 2022 Registered Direct Offering - Purchase Agreement
$ / shares in Units, $ in Millions
1 Months Ended
Dec. 23, 2022
USD ($)
$ / shares
shares
Stockholders' Equity (Deficit)  
Proceeds from issuance or sale of equity, Gross | $ $ 100.0
Proceeds from issuance or sale of equity | $ $ 99.5
Common stock  
Stockholders' Equity (Deficit)  
Stock Issued During Period, Shares, New Issues | shares 44,444
Shares issued, Price per share | $ / shares $ 225
Series B Preferred Stock  
Stockholders' Equity (Deficit)  
Stock Issued During Period, Shares, New Issues | shares 400,000
Shares issued, Price per share | $ / shares $ 225
XML 48 R33.htm IDEA: XBRL DOCUMENT v3.23.2
Stockholders' Equity (Deficit) - At The Market Issuances (Details) - At-The-Market Issuance Sales Agreement - USD ($)
$ in Millions
1 Months Ended 6 Months Ended 12 Months Ended 24 Months Ended
May 31, 2023
Jun. 30, 2021
Jun. 30, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2022
2021 Sales Agreement            
Stockholders' Equity (Deficit)            
Number of shares sold by the entity       738,900 497,043 1,235,943
Value of shares sold by the entity       $ 159.1   $ 199.9
Net proceeds after deducting commissions and other transactions costs       $ 155.9   $ 195.8
Remaining reserved amount under shelf registration     $ 0.0      
2023 Sales Agreement            
Stockholders' Equity (Deficit)            
Number of shares sold by the entity     85,901      
Value of shares sold by the entity     $ 22.4      
Net proceeds after deducting commissions and other transactions costs     21.8      
Remaining reserved amount under shelf registration     $ 177.6      
Cowen & Co. LLC | Maximum            
Stockholders' Equity (Deficit)            
Maximum aggregate offering price $ 200.0 $ 200.0        
XML 49 R34.htm IDEA: XBRL DOCUMENT v3.23.2
Stock-based Compensation - Stock Option (Details) - USD ($)
$ / shares in Units, $ in Millions
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Stock-based compensation expense    
Options outstanding to purchase of common stock 2,805,840  
Maximum    
Stock-based compensation expense    
Expiration period 10 years  
Stock options    
Stock-based compensation expense    
Shares available for future issuance 670,634  
Shares    
Outstanding at the beginning of the year (in shares) 2,857,054  
Options granted (in shares) 5,205  
Options exercised (in shares) (270,609)  
Options cancelled (in shares) (8,110)  
Outstanding at the end of the year (in shares) 2,583,540  
Exercisable at the end of the year (in shares) 1,719,944  
Weighted average exercise price    
Outstanding at the beginning of the year (in dollars per share) $ 81.78  
Options granted (in dollars per share) 283.08  
Options exercised (in dollars per share) 89.26  
Options cancelled (in dollars per share) 84.12  
Outstanding at the end of the year (in dollars per share) 81.4  
Exercisable at the end of the year (in dollars per share) $ 76.62  
Additional disclosures    
Total intrinsic value of options exercised $ 48.9 $ 0.0
Proceeds resulting from exercise of stock options $ 21.8 $ 0.0
Weighted-average grant date fair value of options (in dollars per share) $ 219.02 $ 55.84
XML 50 R35.htm IDEA: XBRL DOCUMENT v3.23.2
Stock-based Compensation - Expense (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Stock-based compensation expense        
Stock-based compensation expense $ 10,973 $ 7,944 $ 22,223 $ 15,421
Research and development        
Stock-based compensation expense        
Stock-based compensation expense 5,184 3,301 10,570 6,488
General and administrative        
Stock-based compensation expense        
Stock-based compensation expense 5,789 4,643 11,653 8,933
Stock options        
Stock-based compensation expense        
Stock-based compensation expense 7,431 7,944 16,029 15,421
Restricted Stock Units (RSUs)        
Stock-based compensation expense        
Stock-based compensation expense $ 3,542 $ 0 $ 6,194 $ 0
XML 51 R36.htm IDEA: XBRL DOCUMENT v3.23.2
Stock-based Compensation - Unrecognized Expense (Details) - Stock options
$ in Millions
6 Months Ended
Jun. 30, 2023
USD ($)
Unrecognized stock-based compensation expense  
Unrecognized stock compensation expense $ 98.2
Weighted average remaining period (in years) 2 years 10 months 24 days
XML 52 R37.htm IDEA: XBRL DOCUMENT v3.23.2
Stock-based Compensation - Restricted Stock Units (Details) - Restricted Stock Units (RSUs)
Jun. 30, 2023
$ / shares
shares
Stock-based compensation expense  
Outstanding restricted units | shares 222,300
Weighted average grant date fair value | $ / shares $ 294.19
XML 53 R38.htm IDEA: XBRL DOCUMENT v3.23.2
Commitments and Contingencies (Details) - USD ($)
$ in Millions
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Commitments and Contingencies    
Licensed product sales $ 0 $ 0
Research, Development and Commercialization Agreement | Hoffmann-La Roche ("Roche")    
Commitments and Contingencies    
Remainder of future milestone payments $ 8  
XML 54 d530762d10q_htm.xml IDEA: XBRL DOCUMENT 0001157601 2023-06-30 0001157601 2022-12-31 0001157601 2023-01-01 2023-06-30 0001157601 2022-01-01 2022-06-30 0001157601 2023-04-01 2023-06-30 0001157601 2022-04-01 2022-06-30 0001157601 2023-01-01 2023-03-31 0001157601 2022-01-01 2022-03-31 0001157601 2023-08-03 0001157601 2022-05-01 2022-05-31 0001157601 2022-05-01 2022-05-01 0001157601 2022-05-09 2022-05-09 0001157601 2021-12-31 0001157601 2022-06-30 0001157601 2023-03-31 0001157601 2022-03-31 0001157601 us-gaap:CashMember us-gaap:FairValueInputsLevel1Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-06-30 0001157601 us-gaap:CashMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-06-30 0001157601 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-06-30 0001157601 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-06-30 0001157601 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-06-30 0001157601 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-06-30 0001157601 us-gaap:EmployeeStockOptionMember 2023-06-30 0001157601 mdgl:HoffmanLaRocheMember mdgl:ResearchDevelopmentAndCommercializationAgreementMember 2023-06-30 0001157601 us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember 2023-06-30 0001157601 us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:AgencySecuritiesMember 2023-06-30 0001157601 us-gaap:FairValueInputsLevel2Member us-gaap:AgencySecuritiesMember 2023-06-30 0001157601 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2023-06-30 0001157601 mdgl:AtTheMarketIssuanceSalesAgreementMember mdgl:TwoThousandAndTwentyThreeSalesAgreementMember 2023-06-30 0001157601 mdgl:AtTheMarketIssuanceSalesAgreementMember mdgl:TwoThousandAndTwentyOneSalesAgreementMember 2023-06-30 0001157601 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember 2023-06-30 0001157601 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:AgencySecuritiesMember 2023-06-30 0001157601 mdgl:LoanFacilityAndAmendedLoanFacilityMember mdgl:TrancheTwoMember 2023-06-30 0001157601 us-gaap:RestrictedStockUnitsRSUMember 2023-06-30 0001157601 us-gaap:CashMember us-gaap:FairValueInputsLevel1Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2022-12-31 0001157601 us-gaap:CashMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-12-31 0001157601 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2022-12-31 0001157601 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-12-31 0001157601 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2022-12-31 0001157601 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-12-31 0001157601 us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001157601 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001157601 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001157601 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001157601 us-gaap:EmployeeStockOptionMember 2023-04-01 2023-06-30 0001157601 us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0001157601 us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-01 2023-06-30 0001157601 us-gaap:RestrictedStockUnitsRSUMember 2023-04-01 2023-06-30 0001157601 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001157601 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001157601 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001157601 us-gaap:EmployeeStockOptionMember 2022-04-01 2022-06-30 0001157601 us-gaap:ResearchAndDevelopmentExpenseMember 2022-04-01 2022-06-30 0001157601 us-gaap:GeneralAndAdministrativeExpenseMember 2022-04-01 2022-06-30 0001157601 us-gaap:RestrictedStockUnitsRSUMember 2022-04-01 2022-06-30 0001157601 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001157601 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001157601 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001157601 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-06-30 0001157601 us-gaap:PreferredStockMember 2022-01-01 2022-06-30 0001157601 us-gaap:WarrantMember 2022-01-01 2022-06-30 0001157601 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-06-30 0001157601 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-06-30 0001157601 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-06-30 0001157601 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-06-30 0001157601 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-06-30 0001157601 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001157601 us-gaap:PreferredStockMember 2023-01-01 2023-06-30 0001157601 us-gaap:WarrantMember 2023-01-01 2023-06-30 0001157601 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-06-30 0001157601 mdgl:AtTheMarketIssuanceSalesAgreementMember mdgl:TwoThousandAndTwentyThreeSalesAgreementMember 2023-01-01 2023-06-30 0001157601 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001157601 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30 0001157601 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-06-30 0001157601 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-06-30 0001157601 srt:MaximumMember 2023-01-01 2023-06-30 0001157601 us-gaap:CorporateDebtSecuritiesMember 2023-01-01 2023-06-30 0001157601 us-gaap:AgencySecuritiesMember 2023-01-01 2023-06-30 0001157601 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001157601 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001157601 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001157601 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001157601 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001157601 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001157601 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001157601 mdgl:TermLoanMember 2022-05-01 2022-05-31 0001157601 mdgl:TermLoanMember 2022-05-31 0001157601 mdgl:TermLoanMember mdgl:DrawnInTwoSeparateTranchesUponAchievementOfResmetiromClinicalAndRegulatoryMilestoneMember 2022-05-31 0001157601 mdgl:DrawnInTwoSeparateTranchesUponAchievementOfResmetiromClinicalAndRegulatoryMilestoneMember 2022-05-31 0001157601 mdgl:LoanFacilityAndAmendedLoanFacilityMember mdgl:TermLoanMember 2023-02-03 2023-02-03 0001157601 mdgl:LoanFacilityAndAmendedLoanFacilityMember mdgl:TrancheTwoMember 2023-02-03 2023-02-03 0001157601 mdgl:LoanFacilityAndAmendedLoanFacilityMember us-gaap:PrimeRateMember 2023-02-03 0001157601 mdgl:LoanFacilityAndAmendedLoanFacilityMember 2023-02-03 0001157601 mdgl:LoanFacilityAndAmendedLoanFacilityMember mdgl:TrancheTwoMember 2023-02-03 0001157601 mdgl:LoanFacilityAndAmendedLoanFacilityMember mdgl:TrancheThreeMember 2023-02-03 0001157601 mdgl:LoanFacilityAndAmendedLoanFacilityMember mdgl:TrancheFouthMember 2023-02-03 0001157601 mdgl:LoanFacilityAndAmendedLoanFacilityOneMember mdgl:TrancheFouthMember 2023-02-03 0001157601 mdgl:LoanFacilityAndAmendedLoanFacilityMember mdgl:TrancheTwoMember 2023-06-19 0001157601 mdgl:LoanFacilityAndAmendedLoanFacilityMember us-gaap:SubsequentEventMember mdgl:TrancheTwoMember 2023-09-30 0001157601 mdgl:LoanFacilityMember 2023-01-01 0001157601 mdgl:ConvertibleSeriesAAndBPreferredStockMember 2017-06-30 0001157601 us-gaap:SeriesBPreferredStockMember mdgl:TwoThousandAndTwentyTwoRegisteredDirectOfferingMember mdgl:PurchaseAgreementMember 2022-12-01 2022-12-23 0001157601 us-gaap:CommonStockMember mdgl:TwoThousandAndTwentyTwoRegisteredDirectOfferingMember mdgl:PurchaseAgreementMember 2022-12-01 2022-12-23 0001157601 mdgl:TwoThousandAndTwentyTwoRegisteredDirectOfferingMember mdgl:PurchaseAgreementMember 2022-12-01 2022-12-23 0001157601 us-gaap:SeriesBPreferredStockMember mdgl:TwoThousandAndTwentyTwoRegisteredDirectOfferingMember mdgl:PurchaseAgreementMember 2022-12-23 0001157601 us-gaap:CommonStockMember mdgl:TwoThousandAndTwentyTwoRegisteredDirectOfferingMember mdgl:PurchaseAgreementMember 2022-12-23 0001157601 mdgl:AtTheMarketIssuanceSalesAgreementMember mdgl:TwoThousandAndTwentyOneSalesAgreementMember 2021-01-01 2021-12-31 0001157601 mdgl:CowenCo.LlcMember srt:MaximumMember mdgl:AtTheMarketIssuanceSalesAgreementMember 2021-06-01 2021-06-30 0001157601 mdgl:AtTheMarketIssuanceSalesAgreementMember mdgl:TwoThousandAndTwentyOneSalesAgreementMember 2022-01-01 2022-12-31 0001157601 us-gaap:CorporateDebtSecuritiesMember 2022-01-01 2022-12-31 0001157601 mdgl:CowenCo.LlcMember srt:MaximumMember mdgl:AtTheMarketIssuanceSalesAgreementMember 2023-05-01 2023-05-31 0001157601 mdgl:ConvertibleSeriesAAndBPreferredStockMember 2017-06-01 2017-06-30 0001157601 mdgl:LoanFacilityMember 2023-01-01 2023-01-02 0001157601 mdgl:AtTheMarketIssuanceSalesAgreementMember mdgl:TwoThousandAndTwentyOneSalesAgreementMember 2021-01-01 2022-12-31 0001157601 us-gaap:CommonStockMember 2023-06-30 0001157601 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001157601 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001157601 us-gaap:RetainedEarningsMember 2023-06-30 0001157601 us-gaap:PreferredStockMember 2023-06-30 0001157601 us-gaap:CommonStockMember 2022-06-30 0001157601 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001157601 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001157601 us-gaap:RetainedEarningsMember 2022-06-30 0001157601 us-gaap:PreferredStockMember 2022-06-30 0001157601 us-gaap:EmployeeStockOptionMember 2022-12-31 0001157601 us-gaap:RetainedEarningsMember 2021-12-31 0001157601 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001157601 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001157601 us-gaap:CommonStockMember 2021-12-31 0001157601 us-gaap:PreferredStockMember 2021-12-31 0001157601 us-gaap:CommonStockMember 2022-03-31 0001157601 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001157601 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001157601 us-gaap:RetainedEarningsMember 2022-03-31 0001157601 us-gaap:PreferredStockMember 2022-03-31 0001157601 us-gaap:RetainedEarningsMember 2022-12-31 0001157601 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001157601 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001157601 us-gaap:CommonStockMember 2022-12-31 0001157601 us-gaap:PreferredStockMember 2022-12-31 0001157601 us-gaap:CommonStockMember 2023-03-31 0001157601 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001157601 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001157601 us-gaap:RetainedEarningsMember 2023-03-31 0001157601 us-gaap:PreferredStockMember 2023-03-31 iso4217:USD shares pure utr:Year iso4217:USD shares mdgl:Vote false Q2 0001157601 --12-31 10-Q true 2023-06-30 2023 false 001-33277 MADRIGAL PHARMACEUTICALS, INC. DE 04-3508648 Four Tower Bridge 200 Barr Harbor Drive, Suite 200 West Conshohocken PA 19428 267 824-2827 Common Stock, $0.0001 Par Value Per Share MDGL NASDAQ Yes Yes Large Accelerated Filer false false false 18471233 77196000 331549000 221222000 27225000 3177000 2595000 301595000 361369000 455000 601000 411000 602000 302461000 362572000 17534000 23831000 81761000 91461000 411000 602000 99706000 115894000 99249000 49289000 99249000 49289000 198955000 165183000 0.0001 0.0001 5000000 5000000 2369797 2369797 2369797 2369797 0.0001 0.0001 200000000 200000000 18459033 18459033 18102523 18102523 2000 2000 1228949000 1160079000 -89000 -32000 -1125356000 -962660000 103506000 197389000 302461000 362572000 68605000 58499000 130759000 106428000 17845000 11774000 34027000 21432000 86450000 70273000 164786000 127860000 -86450000 -70273000 -164786000 -127860000 3551000 323000 7327000 392000 2901000 780000 5237000 780000 -85800000 -70730000 -162696000 -128248000 -4.69 -4.69 -4.14 -4.14 -8.91 -8.91 -7.5 -7.5 18310952 18310952 17103395 17103395 18249778 18249778 17103395 17103395 -85800000 -70730000 -162696000 -128248000 -3000 -45000 -57000 -367000 -85803000 -70775000 -162753000 -128615000 2369797 18102523 2000 1160079000 -32000 -962660000 197389000 180551 17903000 17903000 11250000 11250000 -54000 -54000 544000 544000 -76896000 -76896000 2369797 18283074 2000 1189776000 -86000 -1039556000 150136000 85901 21754000 21754000 90058 6251000 6251000 10973000 10973000 -3000 -3000 195000 195000 -85800000 -85800000 2369797 18459033 2000 1228949000 -89000 -1125356000 103506000 1969797 17103395 2000 863495000 -80000 -667310000 196107000 7477000 7477000 -322000 -322000 -57518000 -57518000 1969797 17103395 2000 870972000 -402000 -724828000 145744000 7944000 7944000 -45000 -45000 622000 622000 -70730000 -70730000 1969797 17103395 2000 879538000 -447000 -795558000 83535000 -162696000 -128248000 22223000 15421000 250000 217000 987000 178000 582000 1442000 -6297000 -10086000 -9700000 16788000 -3562000 -101000 -159377000 -107273000 290696000 116496000 100204000 191813000 104000 155000 -190596000 75162000 21754000 0 24154000 0 50000000 50000000 288000 886000 95620000 49114000 -254353000 17003000 331549000 36269000 77196000 53272000 0 583000 <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">1. Organization, Business, and Basis of Presentation </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Organization and Business </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Madrigal Pharmaceuticals, Inc. (the “Company” or “Madrigal”) is a clinical-stage pharmaceutical company developing novel, high-quality, small-molecule drugs addressing major unmet needs in cardiovascular, metabolic, and liver diseases. The Company’s lead compound, resmetirom, is being advanced for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-alcoholic</div> steatohepatitis (“NASH”), a liver disease that commonly affects people with metabolic diseases such as obesity and diabetes, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-alcoholic</div> fatty liver disease (“NAFLD”). The Company initiated two Phase 3 studies of resmetirom in NASH in 2019 that are ongoing. The Company announced certain topline results from the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">MAESTRO-NAFLD-1</div> safety study of resmetirom in January 2022 and the MAESTRO-NASH study in December 2022. In August 2022, Madrigal initiated a third study, MAESTRO-NASH-OUTCOMES. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Basis of Presentation </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) have been condensed or omitted. Accordingly, the unaudited condensed consolidated financial statements do not include all information and footnotes required by GAAP for complete annual financial statements. However, we believe that the disclosures included in these financial statements are adequate to make the information presented not misleading. The unaudited condensed consolidated financial statements, in the opinion of management, reflect all adjustments, which include normal recurring adjustments, necessary for a fair statement of such interim results. The interim results are not necessarily indicative of the results that we will have for the full year ending December 31, 2023 or any subsequent period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes to those statements for the year ended December 31, 2022. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">2. Summary of Significant Accounting Policies </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Principle of Consolidation </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries. All significant intercompany balances have been eliminated in consolidation. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Use of Estimates </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities, and the reported amounts of revenues and expenses during the reporting periods. The Company bases its estimates on historical experience and various other assumptions that management believes to be reasonable under the circumstances. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Cash and Cash Equivalents </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. The Company maintains its cash in bank accounts, the balance of which, at times, exceeds Federal Deposit Insurance Corporation insured limits. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The primary objective of the Company’s investment activities is to preserve its capital for the purpose of funding operations and the Company does not enter into investments for trading or speculative purposes. The Company’s cash is deposited in highly rated financial institutions in the United States. The Company invests in money market funds and high-grade, commercial paper and corporate bonds, which management believes are subject to minimal credit and market risk. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Marketable Securities </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Marketable securities consist of investments in high-grade corporate obligations and government and government agency obligations that are classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale.</div></div> Since these securities are available to fund current operations, they are classified as current assets on the consolidated balance sheets. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company adjusts the cost of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities for amortization of premiums and accretion of discounts to maturity. The Company includes such amortization and accretion as a component of interest income, net. Realized gains and losses and declines in value, if any, that the Company judges to be the result of impairment or as a result of recognizing an allowance for credit losses on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities are reported as a component of interest income. To determine whether an impairment exists, the Company considers whether it intends to sell the debt security and, if the Company does not intend to sell the debt security, it considers available evidence to assess whether it is more likely than not that it will be required to sell the security before the recovery of its amortized cost basis. During the six months ended June 30, 2023 and 2022, the Company determined it did not have any securities that were other-than-temporarily impaired. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Marketable securities are stated at fair value, including accrued interest, with their unrealized gains and losses included as a component of accumulated other comprehensive income or loss, which is a separate component of stockholders’ equity. The fair value of these securities is based on quoted prices and observable inputs on a recurring basis. Realized gains and losses are determined on the specific identification method. During the six months ended June 30, 2023 and 2022, the Company did not have any realized gains or losses on marketable <div style="display:inline;">securitie</div>s. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Fair Value of Financial Instruments </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The carrying amounts of the Company’s financial instruments, which include cash equivalents and marketable securities, approximate their fair values. The fair value of the Company’s financial instruments reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels: </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level 1—quoted prices in active markets for identical assets and liabilities. </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level 2—observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level 3—unobservable inputs that reflect the Company’s own assumptions about the assumptions market participants would use in pricing the asset or liability. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial assets and liabilities are classified in their entirety within the fair value hierarchy based on the lowest level of input that is significant to the fair value measurement. The Company measures the fair value of its marketable securities by taking into consideration valuations obtained from third- party pricing sources. The pricing services utilize industry standard valuation models, including both income and market based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker-dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities and other observable inputs. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June 30, 2023, the Company’s financial assets valued based on Level 1 inputs consisted of cash and cash equivalents in a money market fund, its financial assets valued based on Level 2 inputs consisted of high-grade corporate and government agency bonds and commercial paper, and it had no financial assets valued based on Level 3 inputs. During the six months ended June 30, 2023 and 2022, the Company did not have any transfers of financial assets between Levels 1 and 2. As of June 30, 2023 and December 31, 2022, the Company did not have any financial liabilities that were recorded at fair value on a recurring basis on the balance sheet. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Research and Development Costs </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development costs are expensed as incurred. Research and development costs are comprised of costs incurred in performing research and development activities, including internal costs (including stock-based compensation), costs for consultants, milestone payments under licensing agreements, and other costs associated with the Company’s preclinical and clinical programs. In particular, the Company has conducted safety studies in animals, optimized and implemented the manufacturing of our drug, and conducted clinical trials, all of which are considered research and development expenditures. Management uses significant judgment in estimating the amount of research and development costs recognized in each reporting period. Management analyzes and estimates the progress of its clinical trials, completion of milestone events per underlying agreements, invoices received and contracted costs when estimating the research and development costs to accrue in each reporting period. Actual results could differ from the Company’s estimates. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Patents </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Costs to secure and defend patents are expensed as incurred and are classified as general and administrative expense in the Company’s consolidated statements of operations. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Stock-Based Compensation </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes stock-based compensation expense based on the grant date fair value of stock options and restricted stock units granted to employees, officers, and directors. Awards that vest as the recipient provides service are expensed on a straight-line basis over the requisite service period. The Company uses the Black-Scholes option pricing model to determine the grant date fair value of stock options as management believes it is the most appropriate valuation method for its option grants. The Black-Scholes model requires inputs for risk-free interest rate, dividend yield, volatility and expected lives of the options. The expected lives for options granted represent the period of time that options granted are expected to be outstanding. The Company uses the simplified method for determining the expected lives of options. Expected volatility is based upon an industry estimate or blended rate including the Company’s historical trading activity. The risk-free rate for periods within the expected life of the option is based on the U.S. Treasury yield curve in effect at the time of the grant. The Company estimates the forfeiture rate based on historical data. This analysis is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluated</div> at least annually and the forfeiture rate is adjusted as necessary. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Income Taxes </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company uses the asset and liability method to account for income taxes. Deferred tax assets and liabilities are determined based on the expected future tax consequences of temporary differences between the Company’s financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates expected to be in effect in the years in which the differences are expected to reverse. The Company currently maintains a 100% valuation allowance on its deferred tax assets. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Comprehensive Loss </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-owner</div> sources. Changes in unrealized gains and losses on marketable securities represent the only difference between the Company’s net loss and comprehensive loss. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Basic and Diluted Loss Per Common Share </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic net loss per share is computed using the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed using the weighted average number of common shares outstanding and the weighted average dilutive potential common shares outstanding using the treasury stock method. However, for the six months ended June 30, 2023 and 2022, diluted net loss per share is the same as basic net loss per share because the inclusion of weighted average shares of common stock issuable upon the exercise of stock options and warrants or vesting of restricted stock units, and common stock issuable upon the conversion of preferred stock would be anti-dilutive. The following table summarizes outstanding securities not included in the computation of diluted net loss per common share, as their inclusion would be anti-dilutive: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:76%"></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended June 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Common stock options</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,583,540</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,976,545</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted stock units</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">222,300</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Preferred stock</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,369,797</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,969,797</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Warrants</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,403</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,899</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr></table><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Recent Accounting Pronouncements </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None </div> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Principle of Consolidation </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries. All significant intercompany balances have been eliminated in consolidation. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Use of Estimates </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities, and the reported amounts of revenues and expenses during the reporting periods. The Company bases its estimates on historical experience and various other assumptions that management believes to be reasonable under the circumstances. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Cash and Cash Equivalents </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. The Company maintains its cash in bank accounts, the balance of which, at times, exceeds Federal Deposit Insurance Corporation insured limits. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The primary objective of the Company’s investment activities is to preserve its capital for the purpose of funding operations and the Company does not enter into investments for trading or speculative purposes. The Company’s cash is deposited in highly rated financial institutions in the United States. The Company invests in money market funds and high-grade, commercial paper and corporate bonds, which management believes are subject to minimal credit and market risk. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Marketable Securities </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Marketable securities consist of investments in high-grade corporate obligations and government and government agency obligations that are classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale.</div></div> Since these securities are available to fund current operations, they are classified as current assets on the consolidated balance sheets. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company adjusts the cost of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities for amortization of premiums and accretion of discounts to maturity. The Company includes such amortization and accretion as a component of interest income, net. Realized gains and losses and declines in value, if any, that the Company judges to be the result of impairment or as a result of recognizing an allowance for credit losses on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities are reported as a component of interest income. To determine whether an impairment exists, the Company considers whether it intends to sell the debt security and, if the Company does not intend to sell the debt security, it considers available evidence to assess whether it is more likely than not that it will be required to sell the security before the recovery of its amortized cost basis. During the six months ended June 30, 2023 and 2022, the Company determined it did not have any securities that were other-than-temporarily impaired. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Marketable securities are stated at fair value, including accrued interest, with their unrealized gains and losses included as a component of accumulated other comprehensive income or loss, which is a separate component of stockholders’ equity. The fair value of these securities is based on quoted prices and observable inputs on a recurring basis. Realized gains and losses are determined on the specific identification method. During the six months ended June 30, 2023 and 2022, the Company did not have any realized gains or losses on marketable <div style="display:inline;">securitie</div>s. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Fair Value of Financial Instruments </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The carrying amounts of the Company’s financial instruments, which include cash equivalents and marketable securities, approximate their fair values. The fair value of the Company’s financial instruments reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels: </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level 1—quoted prices in active markets for identical assets and liabilities. </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level 2—observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level 3—unobservable inputs that reflect the Company’s own assumptions about the assumptions market participants would use in pricing the asset or liability. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial assets and liabilities are classified in their entirety within the fair value hierarchy based on the lowest level of input that is significant to the fair value measurement. The Company measures the fair value of its marketable securities by taking into consideration valuations obtained from third- party pricing sources. The pricing services utilize industry standard valuation models, including both income and market based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker-dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities and other observable inputs. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June 30, 2023, the Company’s financial assets valued based on Level 1 inputs consisted of cash and cash equivalents in a money market fund, its financial assets valued based on Level 2 inputs consisted of high-grade corporate and government agency bonds and commercial paper, and it had no financial assets valued based on Level 3 inputs. During the six months ended June 30, 2023 and 2022, the Company did not have any transfers of financial assets between Levels 1 and 2. As of June 30, 2023 and December 31, 2022, the Company did not have any financial liabilities that were recorded at fair value on a recurring basis on the balance sheet. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Research and Development Costs </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development costs are expensed as incurred. Research and development costs are comprised of costs incurred in performing research and development activities, including internal costs (including stock-based compensation), costs for consultants, milestone payments under licensing agreements, and other costs associated with the Company’s preclinical and clinical programs. In particular, the Company has conducted safety studies in animals, optimized and implemented the manufacturing of our drug, and conducted clinical trials, all of which are considered research and development expenditures. Management uses significant judgment in estimating the amount of research and development costs recognized in each reporting period. Management analyzes and estimates the progress of its clinical trials, completion of milestone events per underlying agreements, invoices received and contracted costs when estimating the research and development costs to accrue in each reporting period. Actual results could differ from the Company’s estimates. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Patents </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Costs to secure and defend patents are expensed as incurred and are classified as general and administrative expense in the Company’s consolidated statements of operations. </div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Stock-Based Compensation </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes stock-based compensation expense based on the grant date fair value of stock options and restricted stock units granted to employees, officers, and directors. Awards that vest as the recipient provides service are expensed on a straight-line basis over the requisite service period. The Company uses the Black-Scholes option pricing model to determine the grant date fair value of stock options as management believes it is the most appropriate valuation method for its option grants. The Black-Scholes model requires inputs for risk-free interest rate, dividend yield, volatility and expected lives of the options. The expected lives for options granted represent the period of time that options granted are expected to be outstanding. The Company uses the simplified method for determining the expected lives of options. Expected volatility is based upon an industry estimate or blended rate including the Company’s historical trading activity. The risk-free rate for periods within the expected life of the option is based on the U.S. Treasury yield curve in effect at the time of the grant. The Company estimates the forfeiture rate based on historical data. This analysis is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluated</div> at least annually and the forfeiture rate is adjusted as necessary. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Income Taxes </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company uses the asset and liability method to account for income taxes. Deferred tax assets and liabilities are determined based on the expected future tax consequences of temporary differences between the Company’s financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates expected to be in effect in the years in which the differences are expected to reverse. The Company currently maintains a 100% valuation allowance on its deferred tax assets. </div> 1 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Comprehensive Loss </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-owner</div> sources. Changes in unrealized gains and losses on marketable securities represent the only difference between the Company’s net loss and comprehensive loss. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Basic and Diluted Loss Per Common Share </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic net loss per share is computed using the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed using the weighted average number of common shares outstanding and the weighted average dilutive potential common shares outstanding using the treasury stock method. However, for the six months ended June 30, 2023 and 2022, diluted net loss per share is the same as basic net loss per share because the inclusion of weighted average shares of common stock issuable upon the exercise of stock options and warrants or vesting of restricted stock units, and common stock issuable upon the conversion of preferred stock would be anti-dilutive. The following table summarizes outstanding securities not included in the computation of diluted net loss per common share, as their inclusion would be anti-dilutive: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:76%"></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended June 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Common stock options</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,583,540</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,976,545</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted stock units</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">222,300</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Preferred stock</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,369,797</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,969,797</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Warrants</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,403</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,899</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr></table> The following table summarizes outstanding securities not included in the computation of diluted net loss per common share, as their inclusion would be anti-dilutive: <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:76%"></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended June 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Common stock options</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,583,540</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,976,545</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted stock units</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">222,300</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Preferred stock</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,369,797</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,969,797</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Warrants</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,403</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,899</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr></table> 2583540 2976545 222300 0 2369797 1969797 18403 14899 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Recent Accounting Pronouncements </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">3. Liquidity and Uncertainties </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is subject to risks common to development stage companies in the biopharmaceutical industry including, but not limited to, uncertainty of product development and commercialization, dependence on key personnel, uncertainty of market acceptance of products and product reimbursement, product liability, uncertain protection of proprietary technology, potential inability to raise additional financing necessary for development and commercialization, and compliance with the U.S. Food and Drug Administration (FDA) and other government regulations. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has incurred losses since inception, including approximately $162.7 million for the six months ended June 30, 2023, resulting in an accumulated deficit of approximately $1,125 million as of June 30, 2023. Management expects to incur losses for the foreseeable future. To date, the Company has funded its operations primarily through proceeds from sales of the Company’s capital stock and debt financings. The Company believes that its cash, cash equivalents and marketable securities at June 30, 2023 will be sufficient to fund operations past one year from the issuance of these financial statements. To meet its future capital needs, the Company intends to raise additional capital through debt or equity financings, collaborations, partnerships or other strategic transactions. However, there can be no assurance that the Company will be able to complete any such transactions on acceptable terms or otherwise. The inability of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations and financial condition. The Company has the ability to delay certain research activities and related clinical expenses if necessary due to liquidity concerns until a date when those concerns are <div style="letter-spacing: 0px; top: 0px;;display:inline;">relieved</div>. </div> -162700000 -1125000000 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">4. Cash, Cash Equivalents and Marketable Securities </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A summary of cash, cash equivalents and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> marketable securities held by the Company as of June 30, 2023 and December 31, 2022 is as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:65%"></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30, 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cost</div></div></td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">gains</div></div></td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">losses</div></div></td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">value</div></div></td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents:</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash (Level 1)</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,185</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> —  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,185</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds (Level 1)</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">69,011</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">69,011</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cash and cash equivalents</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">77,196</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">77,196</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Marketable securities:</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate debt securities due within <div style="letter-spacing: 0px; top: 0px;;display:inline;">1<div style="display:inline;"> </div></div>year of date of purchase (Level 2)</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">144,036</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(105</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">143,944</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government and government sponsored entities due within 1 year of date of purchase (Level 2)</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">77,275</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">77,278</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cash, cash equivalents and marketable securities</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">298,507</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(108</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 298,418</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:64%"></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cost</div></div></td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">gains</div></div></td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">losses</div></div></td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">value</div></div></td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents:</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash (Level 1)</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,100</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> —  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> —  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,100</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds (Level 1)</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">316,449</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">316,449</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cash and cash equivalents</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">331,549</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">331,549</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Marketable securities:</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate debt securities due within 1 year of date of purchase (Level 2)</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27,257</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(39</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27,225</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cash, cash equivalents and marketable securities</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 358,806</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(39</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 358,774</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A summary of cash, cash equivalents and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> marketable securities held by the Company as of June 30, 2023 and December 31, 2022 is as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:65%"></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30, 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cost</div></div></td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">gains</div></div></td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">losses</div></div></td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">value</div></div></td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents:</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash (Level 1)</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,185</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> —  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,185</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds (Level 1)</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">69,011</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">69,011</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cash and cash equivalents</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">77,196</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">77,196</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Marketable securities:</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate debt securities due within <div style="letter-spacing: 0px; top: 0px;;display:inline;">1<div style="display:inline;"> </div></div>year of date of purchase (Level 2)</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">144,036</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(105</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">143,944</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government and government sponsored entities due within 1 year of date of purchase (Level 2)</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">77,275</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">77,278</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cash, cash equivalents and marketable securities</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">298,507</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(108</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 298,418</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:64%"></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cost</div></div></td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">gains</div></div></td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">losses</div></div></td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">value</div></div></td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents:</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash (Level 1)</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,100</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> —  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> —  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,100</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds (Level 1)</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">316,449</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">316,449</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cash and cash equivalents</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">331,549</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">331,549</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Marketable securities:</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate debt securities due within 1 year of date of purchase (Level 2)</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27,257</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(39</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27,225</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cash, cash equivalents and marketable securities</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 358,806</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(39</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 358,774</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> 8185000 8185000 69011000 69011000 77196000 77196000 P1Y 144036000 13000 105000 143944000 P1Y 77275000 6000 3000 77278000 298507000 19000 108000 298418000 15100000 15100000 316449000 316449000 331549000 331549000 P1Y 27257000 7000 39000 27225000 358806000 7000 39000 358774000 <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">5. Accrued Liabilities </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accrued liabilities as of June 30, 2023 and December 31, 2022 consisted of the following (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:76%"></td> <td style="vertical-align:bottom;width:5%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30,<br/> 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,<br/> 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Contract research organization costs</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 58,050</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 53,119</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other clinical study related costs</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,605</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,582</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Manufacturing and drug supply</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,556</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,262</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Compensation and benefits</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,453</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,864</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Professional fees</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,494</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,867</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,603</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">767</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total accrued liabilities</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">81,761</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">91,461</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accrued liabilities as of June 30, 2023 and December 31, 2022 consisted of the following (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:76%"></td> <td style="vertical-align:bottom;width:5%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30,<br/> 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,<br/> 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Contract research organization costs</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 58,050</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 53,119</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other clinical study related costs</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,605</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,582</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Manufacturing and drug supply</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,556</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,262</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Compensation and benefits</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,453</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,864</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Professional fees</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,494</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,867</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,603</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">767</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total accrued liabilities</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">81,761</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">91,461</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> 58050000 53119000 3605000 6582000 3556000 11262000 5453000 14864000 9494000 4867000 1603000 767000 81761000 91461000 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">6. Long Term Debt </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2022 the Company and its wholly-owned subsidiary, Canticle Pharmaceuticals, Inc., entered into the $250.0 million Loan Facility with the several banks and other financial institutions or entities party thereto (each, a “Lender” and collectively referred to as the “Lenders”), and Hercules Capital, Inc. (“Hercules”), in its capacity as administrative agent and collateral agent for itself and the Lenders. Under the terms of the Loan Facility, the first $50.0 million tranche was drawn at closing. The Company also could draw up to an additional $125.0 million in two separate tranches upon achievement of certain resmetirom clinical and regulatory milestones. A fourth tranche of $75.0 million could be drawn by the Company, subject to the approval of Hercules. The Loan Facility had a minimum interest rate of 7.45% and adjusts with changes in the prime rate. The Company will pay interest-only monthly payments of accrued interest under the Loan Facility for a period of 30 months, which period may be extended to 36, 48, and 60 months upon the successive achievement of certain clinical and regulatory milestones and if the Company maintains compliance with applicable covenants. The Loan Facility matures in May 2026 and may be extended an additional year upon the achievement of certain clinical and regulatory milestones. The Loan Facility is secured by a security interest in substantially all of the Company’s assets, other than intellectual property. It includes an end of term charge of 5.35% of the aggregate principal amount, which is accounted for in the loan discount. In connection with the first tranche drawn at closing, the Company issued Hercules a warrant to purchase 14,899 shares of Company common stock, which had a Black-Scholes value of $0.6 million. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February 3, 2023, the Company entered into the First Amendment (the “Amendment”) to the Loan Facility (as amended, the “Amended Loan Facility”). Under the Amended Loan Facility, an additional $35.0 million was drawn under a second, expanded, $65.0 million tranche (“Tranche 2”) in February of 2023 following the Company’s achievement of the Phase 3 clinical development milestone. An additional $15.0 million was drawn under Tranche 2 in June of 2023. The Company has the ability to draw the remaining $15.0 million available under Tranche 2 by September 30, 2023<div style="null;text-indent: 0px;;display:inline;"> </div><div style="null;text-indent: 0px;;display:inline;">in accordance with the Amended Loan Facility.</div> The third tranche (“Tranche 3”) of $75.0 million remains unchanged by the Amendment, and such borrowings are available subject to the Company obtaining a certain FDA approval for resmetirom. Coincident with the expansion of Tranche 2 borrowing capacity by $15 million, the Amendment reduced the fourth tranche under the Loan Facility (“Tranche 4”) by $15.0 million to $60.0 million , which amount is available subject to Hercules’ sole discretion. In connection with the $35.0 million drawn under <div style="null;text-indent: 0px;;display:inline;">Tranche 2</div> at the closing of the Amendment and $15.0 million drawn in June of 2023, the Company issued to Hercules and affiliates Tranche 2 Warrants to purchase 3,504 shares of common stock, which had a Black-Scholes value of $0.7 million. The Amendment reduced the interest rate under the Amended Loan Facility to the greater of (i) the prime rate as reported in The Wall Street Journal plus 2.45% and (ii) 8.25%. The Amendment and the Amended Loan Facility summary terms were disclosed in the Company’s Current Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">8-K</div> filed with the Securities and Exchange Commission on February 9, 2023. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Loan Facility includes affirmative and restrictive financial covenants commencing on January 1, 2023, including maintenance of a minimum cash, cash equivalents and liquid funds covenant of $35.0 million, which may decrease in certain circumstances if the Company achieves certain clinical milestones and a revenue milestone, and a revenue-based covenant that could apply commencing at or after the time that financial reporting is due for the quarter ending September 30, 2024. The Loan Facility contains event of default provisions for: the Company’s failure to make required payments or maintain compliance with covenants under the Loan Facility; the Company’s breach of certain representations or default under certain obligations outside the Loan Facility; insolvency, attachment or judgment events affecting the Company; and any circumstance which has occurred or could reasonably be expected to have a material adverse effect on the Company, provided that, any failure to achieve a clinical milestone or approval milestone under the Loan Facility shall not in and of itself constitute a material adverse effect. The Loan Facility also includes customary covenants associated with a secured loan facility, including covenants concerning financial reporting obligations, and certain limitations on indebtedness, liens (including a negative pledge on intellectual property and other assets), investments, distributions (including dividends), collateral, investments, distributions, transfers, mergers or acquisitions, taxes, corporate changes, and deposit accounts. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June 30, 2023, the outstanding principal under the Loan Facility was $100.0 million. The interest rate as of June 30, 2023 was 10.70%. As of June 30, 2023, the Company was in compliance with all loan covenants and provisions. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Future minimum payments, including interest and principal, under the loans payable outstanding as of June 30, 2023 are as follows (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:87%"></td> <td style="vertical-align:bottom;width:5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Period Ending June 30, 2023:</div></div> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em;">2023 (remaining six months)</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,372</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2024</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,878</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2025</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">69,044</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Thereafter</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">46,363</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">131,657</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less amount representing interest</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(26,307</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less unamortized discount</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6,101</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loans payable, net of discount</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">99,249</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> 250000000 50000000 125000000 75000000 0.0745 The Company will pay interest-only monthly payments of accrued interest under the Loan Facility for a period of 30 months, which period may be extended to 36, 48, and 60 months upon the successive achievement of certain clinical and regulatory milestones 0.0535 14899 600000 35000000 65000000 15000000 15000000 75000000 15000000 15000000 60000000 35000000 15000000 3504 700000 0.0245 0.0825 35000000 2024-09-30 100000000 0.107 <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Future minimum payments, including interest and principal, under the loans payable outstanding as of June 30, 2023 are as follows (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:87%"></td> <td style="vertical-align:bottom;width:5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Period Ending June 30, 2023:</div></div> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em;">2023 (remaining six months)</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,372</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2024</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,878</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2025</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">69,044</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Thereafter</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">46,363</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">131,657</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less amount representing interest</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(26,307</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less unamortized discount</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6,101</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loans payable, net of discount</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">99,249</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> 5372000 10878000 69044000 46363000 131657000 26307000 6101000 99249000 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">7. Stockholders’ Equity </div></div> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Common Stock </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each common stockholder is entitled to one vote for each share of common stock held. The common stock will vote together with all other classes and series of stock of the Company as a single class on all actions to be taken by the Company’s stockholders. Each share of common stock is entitled to receive dividends, as and when declared by the Company’s board of directors. The Company has never declared cash dividends on its common stock and does not expect to do so in the foreseeable future. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Preferred Stock </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Series A and B Preferred Stock have a par value of $0.0001 per share and are convertible into shares of the common stock at a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-to-one</div></div> ratio, subject to adjustment as provided in the Certificates of Designation of Preferences, Rights and Limitations of Series A Preferred Stock and Series B Preferred Stock that the Company filed with the Secretary of State of the State of Delaware on June 21, 2017 and December 22, 2022, respectively. The terms of the Series A and B Preferred Stock are set forth in such Certificates of Designation. Each share of the Series A and B Preferred Stock is convertible into shares of Common Stock following notice that may be given at the holder’s option. Upon any liquidation, dissolution or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">winding-up</div> of the Company, whether voluntary or involuntary, after the satisfaction in full of the debts of the Company and the payment of any liquidation preference owed to the holders of shares of capital stock of the Company ranking prior to the Series A and B Preferred Stock upon liquidation, the holders of the Series A and B Preferred Stock shall participate pari passu with the holders of the Common Stock (on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-if-converted-to-Common-Stock</div></div></div></div> basis) in the net assets of the Company. Shares of the Series A and B Preferred Stock will generally have no voting rights, except as required by law. Shares of the Series A and B Preferred Stock will be entitled to receive dividends before shares of any other class or series of capital stock of the Company (other than dividends in the form of the Common Stock) equal to the dividend payable on each share of the Common Stock, on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">December 2022 Registered Direct Offering </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2022, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with a group of institutional accredited investors, who were existing, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> stockholders of the Company, pursuant to which the Company sold securities to the Investors in an offering that was registered under the Company’s existing shelf registration statement (the “2022 Registered Direct Offering”). Under the terms of the Purchase Agreement, the Company sold 44,444 shares of its common stock at a price of $225 per share, and 400,000 shares of its Series B Convertible Preferred Stock at a price of $225 per share. The 2022 Registered Direct Offering resulted in gross proceeds to the Company of approximately $100.0 million, and net proceeds to the Company of approximately $99.5 million. The 2022 Registered Direct Offering closed on December 23, 2022. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <div></div><div> <div style="line-height:normal;background-color:white;display: inline;"> </div> </div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">At-The-Market</div></div> Issuance Sales Agreement </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">In June 2021, the Company entered into an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">at-the-market</div></div> sales agreement (the “2021 Sales Agreement”) with Cowen and Company, LLC (“Cowen”), pursuant to which the Company could, from time to time, issue and sell shares of its common stock. The 2021 Sales Agreement<div style="null;text-indent: 0px;;display:inline;"> initially</div> authorized an aggregate offering of up to $200 million in shares of our common stock, at the Company’s option, through Cowen as its sales agent. Sales of common stock through Cowen could be made by any method that is deemed an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">“at-the-market”</div></div> offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, including by means of ordinary brokers’ transactions at market prices, in block transactions or as otherwise agreed by the Company and Cowen. Subject to the terms and conditions of the 2021 Sales Agreement, Cowen would use commercially reasonable efforts consistent with its normal trading and sales practices to sell the common stock based upon the Company’s instructions (including any price, time or size limits or other customary parameters or conditions the Company imposed). </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">In December 2022, the Company sold 738,900 shares<div style="null;text-indent: 0px;;display:inline;"> of common stock</div> under the 2021 Sales Agreement for an aggregate of $159.1 million in gross proceeds, with net proceeds to the Company of $155.9 million after deducting commissions and other transaction costs. In total, under the 2021 Sales Agreement the Company sold 1,235,943 shares for an aggregate of $199.9 million in gross proceeds, with net proceeds to the Company of approximately $195.8 million after deducting commissions and other transaction costs<div style="null;text-indent: 0px;;display:inline;"> through December 31, 2022.</div> Of those shares sold, 738,900 were sold in 2022, and 497,043 were sold in 2021. All shares were sold pursuant to the Company’s effective shelf registration statement <div style="display:inline;">on Form S-3 (the “Registration Statement”) and</div> the prospectus supplement relating thereto. As of June 30, 2023, no amounts remained reserved and available for sale under the 2021 Sales Agreement and the related prospectus supplement. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">In May 2023, the Company amended the 2021 Agreement (the “Sales Agreement<div style="null;text-indent: 0px;;display:inline;"> Amendment</div>”), with Cowen, pursuant to which the Company may, from time to time, issue and sell<div style="null;text-indent: 0px;;display:inline;"> in additional $200 million in</div> shares of its common stock. The Company is not obligated to make any sales of its common stock under this arrangement. Any shares sold will be sold pursuant to the Company’s effective <div style="null;text-indent: 0px;;display:inline;">Registration Statement</div> on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">S-3</div> (the “Registration Statement”) and prospectus supplement filed pursuant to the Registration Statement. The Sales Agreement Amendment authorizes <div style="null;text-indent: 0px;;display:inline;">sales of</div> shares of our common stock, from time to time, at the Company’s option, through Cowen as its sales agent. Sales of common stock through Cowen may be made by any method that is deemed an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">“at-the-market”</div></div> offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, and as described in the prospectus supplement. In total, under the Sales Agreement<div style="null;text-indent: 0px;;display:inline;"> Amendment,</div> the Company sold 85,901 shares for an aggregate of $22.4 million in gross proceeds, with net proceeds to the Company of approximately $21.8 million after deducting commissions and other transaction costs. All shares were sold pursuant to the Company’s effective <div style="null;text-indent: 0px;;display:inline;">Registration Statement</div> and the prospectus supplement relating thereto. As of June 30, 2023, $177.6 million remained reserved and available for sale under the 2023 Sales Agreement<div style="display:inline;"> </div><div style="display:inline;">Amendment </div>and the Company’s related prospectus supplement. </div> 1 0.0001 1 0 44444 225 400000 225 100000000 99500000 200000000 738900 159100000 155900000 1235943 199900000 195800000 738900 497043 0 200000000 85901 22400000 21800000 177600000 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">8. Stock-based Compensation </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The Company’s 2015 Stock Plan, as amended, is our primary equity incentive compensation plan through which equity based grants are awarded. The 2015 Stock Plan provides for the grant of incentive stock options, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">non-statutory</div> stock options, restricted stock, restricted stock units and other stock-based compensation awards to employees, officers, directors, and consultants of the Company. The administration of the 2015 Stock Plan is under the general supervision of the Compensation Committee of the Board of Directors. The terms of stock options awarded under the 2015 Stock Plan, in general, are determined by the Compensation Committee, provided the exercise price per share generally shall not be set at less than the fair market value of a share of the common stock on the date of grant and the term shall not be greater than ten years from the date the option is granted. As of June 30, 2023, the Company had restricted stock units and options outstanding to purchase<div style="null;text-indent: 0px;;display:inline;"> an aggregate of</div> 2,805,840 shares of its common stock, which includes options outstanding under its prior incentive compensation plan, the 2006 Stock Plan. As of June 30, 2023, 670,634 shares were available for future issuance under the 2015 Stock Plan. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Stock Options </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The following table summarizes stock option activity during the six months ended June 30, 2023: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width:73%"></td> <td style="vertical-align:bottom;width:6%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> average exercise<br/> price</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at January 1, 2023</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,857,054</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">81.78</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options granted</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,205</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">283.08</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options exercised</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(270,609</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">89.26</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options cancelled</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8,110</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">84.12</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at June 30, 2023</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,583,540</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">81.40</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercisable at June 30, 2023</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,719,944</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">76.62</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> </table> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center;text-indent: 0px;"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total cash received by the Company as a result of stock option exercises was $21.8 million and $0 million, respectively, for the six months ended June 30, 2023 and 2022. The total intrinsic value of options exercised was $48.9 million and $0 million, respectively, for the six months ended June 30, 2023 and 2022. The weighted-average grant date fair values, based on the Black-Scholes option model, of options granted during the six months ended June 30, 2023 and 2022 were $219.02 and $55.84, respectively. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Restricted Stock Units </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company’s share-based compensation plan provides for awards of restricted stock units to employees, officers, directors and consultants to the Company. Restricted stock units vest over the service period, and are subject to forfeiture if employment or service terminates before vesting. As of June 30, 2023, the Company had 222,300 restricted stock units outstanding, with a weighted average grant date fair value of $294.19 per unit. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Stock-Based Compensation Expense </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense during the six months ended June 30, 2023 and 2022 was as follows (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:69%"></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended June 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended June 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation expense by type of award:</div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock options</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,431</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,944</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,029</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,421</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted stock units</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,542</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,194</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total stock-based compensation expense</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,973</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,944</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22,223</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,421</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Effect of stock-based compensation expense by line item:</div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,184</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,301</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,570</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,488</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,789</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,643</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,653</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,933</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total stock-based compensation expense included in net loss</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,973</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,944</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22,223</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,421</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unrecognized stock-based compensation expense as of June 30, 2023 was $98.2 million with a weighted average remaining period of 2.90 years. </div> P10Y 2805840 670634 <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The following table summarizes stock option activity during the six months ended June 30, 2023: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width:73%"></td> <td style="vertical-align:bottom;width:6%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> average exercise<br/> price</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at January 1, 2023</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,857,054</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">81.78</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options granted</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,205</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">283.08</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options exercised</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(270,609</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">89.26</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options cancelled</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8,110</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">84.12</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at June 30, 2023</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,583,540</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">81.40</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercisable at June 30, 2023</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,719,944</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">76.62</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> </table> 2857054 81.78 5205 283.08 270609 89.26 8110 84.12 2583540 81.4 1719944 76.62 21800000 0 48900000 0 219.02 55.84 222300 294.19 <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense during the six months ended June 30, 2023 and 2022 was as follows (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:69%"></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended June 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended June 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation expense by type of award:</div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock options</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,431</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,944</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,029</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,421</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted stock units</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,542</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,194</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total stock-based compensation expense</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,973</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,944</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22,223</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,421</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Effect of stock-based compensation expense by line item:</div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,184</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,301</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,570</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,488</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,789</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,643</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,653</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,933</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total stock-based compensation expense included in net loss</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,973</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,944</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22,223</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,421</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> 7431000 7944000 16029000 15421000 3542000 0 6194000 0 10973000 7944000 22223000 15421000 5184000 3301000 10570000 6488000 5789000 4643000 11653000 8933000 10973000 7944000 22223000 15421000 98200000 P2Y10M24D <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">9. Commitments and Contingencies </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has a Research, Development and Commercialization Agreement with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Hoffmann-La</div> Roche (“Roche”) which grants the Company a sole and exclusive license to develop, use, sell, offer for sale and import any Licensed Product as defined by the agreement. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The agreement requires future milestone payments to Roche. Remaining milestones under the agreement total $8 million and are payable upon Madrigal achieving specified objectives related to future regulatory approval in the United States and Europe of resmetirom or a product developed from resmetirom. Furthermore, a tiered single-digit royalty is payable on net sales of resmetirom or a product developed from resmetirom, subject to certain reductions. The Company has not achieved any additional product development or regulatory milestones and had no Licensed Product sales for the six months ended June 30, 2023 and 2022. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has entered into customary contractual arrangements and letters of intent in preparation for and in support of the clinical trials. </div> 8000000 0 0 EXCEL 55 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 56 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 57 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 58 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 145 200 1 false 43 0 false 6 false false R1.htm 1001 - Document - Cover Page Sheet http://www.madrigalpharma.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1002 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 1003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1004 - Statement - Condensed Consolidated Statements Of Operations Sheet http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfOperations Condensed Consolidated Statements Of Operations Statements 4 false false R5.htm 1005 - Statement - Condensed Consolidated Statements Of Comprehensive Loss Sheet http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss Condensed Consolidated Statements Of Comprehensive Loss Statements 5 false false R6.htm 1006 - Statement - Condensed Consolidated Statements Of Stockholders' Equity Sheet http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfStockholdersEquity Condensed Consolidated Statements Of Stockholders' Equity Statements 6 false false R7.htm 1007 - Statement - Condensed Consolidated Statements Of Cash Flows Sheet http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements Of Cash Flows Statements 7 false false R8.htm 1008 - Disclosure - Organization, Business and Basis of Presentation Sheet http://www.madrigalpharma.com/role/OrganizationBusinessAndBasisOfPresentation Organization, Business and Basis of Presentation Notes 8 false false R9.htm 1009 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 1010 - Disclosure - Liquidity and Uncertainties Sheet http://www.madrigalpharma.com/role/LiquidityAndUncertainties Liquidity and Uncertainties Notes 10 false false R11.htm 1011 - Disclosure - Cash, Cash Equivalents and Marketable Securities Sheet http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecurities Cash, Cash Equivalents and Marketable Securities Notes 11 false false R12.htm 1012 - Disclosure - Accrued Liabilities Sheet http://www.madrigalpharma.com/role/AccruedLiabilities Accrued Liabilities Notes 12 false false R13.htm 1013 - Disclosure - Long Term Debt Sheet http://www.madrigalpharma.com/role/LongTermDebt Long Term Debt Notes 13 false false R14.htm 1014 - Disclosure - Stockholders' Equity Sheet http://www.madrigalpharma.com/role/StockholdersEquity Stockholders' Equity Notes 14 false false R15.htm 1015 - Disclosure - Stock-based Compensation Sheet http://www.madrigalpharma.com/role/StockBasedCompensation Stock-based Compensation Notes 15 false false R16.htm 1016 - Disclosure - Commitments and Contingencies Sheet http://www.madrigalpharma.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 16 false false R17.htm 1017 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPolicies 17 false false R18.htm 1018 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPolicies 18 false false R19.htm 1019 - Disclosure - Cash, Cash Equivalents and Marketable Securities (Tables) Sheet http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesTables Cash, Cash Equivalents and Marketable Securities (Tables) Tables http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecurities 19 false false R20.htm 1020 - Disclosure - Accrued Liabilities (Tables) Sheet http://www.madrigalpharma.com/role/AccruedLiabilitiesTables Accrued Liabilities (Tables) Tables http://www.madrigalpharma.com/role/AccruedLiabilities 20 false false R21.htm 1021 - Disclosure - Long Term Debt (Tables) Sheet http://www.madrigalpharma.com/role/LongTermDebtTables Long Term Debt (Tables) Tables http://www.madrigalpharma.com/role/LongTermDebt 21 false false R22.htm 1022 - Disclosure - Stock-based Compensation (Tables) Sheet http://www.madrigalpharma.com/role/StockBasedCompensationTables Stock-based Compensation (Tables) Tables http://www.madrigalpharma.com/role/StockBasedCompensation 22 false false R23.htm 1023 - Disclosure - Summary of Significant Accounting Policies - Income Taxes (Details) Sheet http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails Summary of Significant Accounting Policies - Income Taxes (Details) Details 23 false false R24.htm 1024 - Disclosure - Summary of Significant Accounting Policies - Basic and Diluted Loss Per Common Share (Details) Sheet http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedLossPerCommonShareDetails Summary of Significant Accounting Policies - Basic and Diluted Loss Per Common Share (Details) Details 24 false false R25.htm 1025 - Disclosure - Liquidity and Uncertainties (Details) Sheet http://www.madrigalpharma.com/role/LiquidityAndUncertaintiesDetails Liquidity and Uncertainties (Details) Details http://www.madrigalpharma.com/role/LiquidityAndUncertainties 25 false false R26.htm 1026 - Disclosure - Cash, Cash Equivalents and Marketable Securities (Details) Sheet http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails Cash, Cash Equivalents and Marketable Securities (Details) Details http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesTables 26 false false R27.htm 1027 - Disclosure - Accrued Liabilities (Details) Sheet http://www.madrigalpharma.com/role/AccruedLiabilitiesDetails Accrued Liabilities (Details) Details http://www.madrigalpharma.com/role/AccruedLiabilitiesTables 27 false false R28.htm 1028 - Disclosure - Long Term Debt - Schedule of Maturities of Long-Term Debt (Details) Sheet http://www.madrigalpharma.com/role/LongTermDebtScheduleOfMaturitiesOfLongTermDebtDetails Long Term Debt - Schedule of Maturities of Long-Term Debt (Details) Details 28 false false R29.htm 1029 - Disclosure - Long Term Debt (Details) Sheet http://www.madrigalpharma.com/role/LongTermDebtDetails Long Term Debt (Details) Details http://www.madrigalpharma.com/role/LongTermDebtTables 29 false false R30.htm 1030 - Disclosure - Stockholders' Equity (Deficit) - Common Stock (Details) Sheet http://www.madrigalpharma.com/role/StockholdersEquityDeficitCommonStockDetails Stockholders' Equity (Deficit) - Common Stock (Details) Details http://www.madrigalpharma.com/role/StockholdersEquity 30 false false R31.htm 1031 - Disclosure - Stockholders' Equity (Deficit) - Preferred Stock (Details) Sheet http://www.madrigalpharma.com/role/StockholdersEquityDeficitPreferredStockDetails Stockholders' Equity (Deficit) - Preferred Stock (Details) Details http://www.madrigalpharma.com/role/StockholdersEquity 31 false false R32.htm 1032 - Disclosure - Stockholders' Equity (Deficit) - Registered Offering (Details) Sheet http://www.madrigalpharma.com/role/StockholdersEquityDeficitRegisteredOfferingDetails Stockholders' Equity (Deficit) - Registered Offering (Details) Details http://www.madrigalpharma.com/role/StockholdersEquity 32 false false R33.htm 1033 - Disclosure - Stockholders' Equity (Deficit) - At The Market Issuances (Details) Sheet http://www.madrigalpharma.com/role/StockholdersEquityDeficitAtTheMarketIssuancesDetails Stockholders' Equity (Deficit) - At The Market Issuances (Details) Details http://www.madrigalpharma.com/role/StockholdersEquity 33 false false R34.htm 1034 - Disclosure - Stock-based Compensation - Stock Option (Details) Sheet http://www.madrigalpharma.com/role/StockBasedCompensationStockOptionDetails Stock-based Compensation - Stock Option (Details) Details 34 false false R35.htm 1035 - Disclosure - Stock-based Compensation - Expense (Details) Sheet http://www.madrigalpharma.com/role/StockBasedCompensationExpenseDetails Stock-based Compensation - Expense (Details) Details 35 false false R36.htm 1036 - Disclosure - Stock-based Compensation - Unrecognized Expense (Details) Sheet http://www.madrigalpharma.com/role/StockBasedCompensationUnrecognizedExpenseDetails Stock-based Compensation - Unrecognized Expense (Details) Details 36 false false R37.htm 1037 - Disclosure - Stock-based Compensation - Restricted Stock Units (Details) Sheet http://www.madrigalpharma.com/role/StockBasedCompensationRestrictedStockUnitsDetails Stock-based Compensation - Restricted Stock Units (Details) Details 37 false false R38.htm 1038 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.madrigalpharma.com/role/CommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://www.madrigalpharma.com/role/CommitmentsAndContingencies 38 false false All Reports Book All Reports d530762d10q.htm d530762dex102.htm d530762dex103.htm d530762dex104.htm d530762dex105.htm d530762dex311.htm d530762dex312.htm d530762dex321.htm d530762dex51.htm mdgl-20230630.xsd mdgl-20230630_cal.xml mdgl-20230630_def.xml mdgl-20230630_lab.xml mdgl-20230630_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 60 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d530762d10q.htm": { "axisCustom": 3, "axisStandard": 17, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 392, "http://xbrl.sec.gov/dei/2023": 30 }, "contextCount": 145, "dts": { "calculationLink": { "local": [ "mdgl-20230630_cal.xml" ] }, "definitionLink": { "local": [ "mdgl-20230630_def.xml" ] }, "inline": { "local": [ "d530762d10q.htm" ] }, "labelLink": { "local": [ "mdgl-20230630_lab.xml" ] }, "presentationLink": { "local": [ "mdgl-20230630_pre.xml" ] }, "schema": { "local": [ "mdgl-20230630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] } }, "elementCount": 329, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 4, "total": 4 }, "keyCustom": 29, "keyStandard": 171, "memberCustom": 17, "memberStandard": 22, "nsprefix": "mdgl", "nsuri": "http://www.madrigalpharma.com/20230630", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "1001 - Document - Cover Page", "menuCat": "Cover", "order": "1", "role": "http://www.madrigalpharma.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1010 - Disclosure - Liquidity and Uncertainties", "menuCat": "Notes", "order": "10", "role": "http://www.madrigalpharma.com/role/LiquidityAndUncertainties", "shortName": "Liquidity and Uncertainties", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1011 - Disclosure - Cash, Cash Equivalents and Marketable Securities", "menuCat": "Notes", "order": "11", "role": "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecurities", "shortName": "Cash, Cash Equivalents and Marketable Securities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "mdgl:AccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1012 - Disclosure - Accrued Liabilities", "menuCat": "Notes", "order": "12", "role": "http://www.madrigalpharma.com/role/AccruedLiabilities", "shortName": "Accrued Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "mdgl:AccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1013 - Disclosure - Long Term Debt", "menuCat": "Notes", "order": "13", "role": "http://www.madrigalpharma.com/role/LongTermDebt", "shortName": "Long Term Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1014 - Disclosure - Stockholders' Equity", "menuCat": "Notes", "order": "14", "role": "http://www.madrigalpharma.com/role/StockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1015 - Disclosure - Stock-based Compensation", "menuCat": "Notes", "order": "15", "role": "http://www.madrigalpharma.com/role/StockBasedCompensation", "shortName": "Stock-based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1016 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "16", "role": "http://www.madrigalpharma.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1017 - Disclosure - Summary of Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "17", "role": "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1018 - Disclosure - Summary of Significant Accounting Policies (Tables)", "menuCat": "Tables", "order": "18", "role": "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1019 - Disclosure - Cash, Cash Equivalents and Marketable Securities (Tables)", "menuCat": "Tables", "order": "19", "role": "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesTables", "shortName": "Cash, Cash Equivalents and Marketable Securities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "PAsOn06_30_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002 - Statement - Condensed Consolidated Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "PAsOn06_30_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "mdgl:AccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1020 - Disclosure - Accrued Liabilities (Tables)", "menuCat": "Tables", "order": "20", "role": "http://www.madrigalpharma.com/role/AccruedLiabilitiesTables", "shortName": "Accrued Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "mdgl:AccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1021 - Disclosure - Long Term Debt (Tables)", "menuCat": "Tables", "order": "21", "role": "http://www.madrigalpharma.com/role/LongTermDebtTables", "shortName": "Long Term Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1022 - Disclosure - Stock-based Compensation (Tables)", "menuCat": "Tables", "order": "22", "role": "http://www.madrigalpharma.com/role/StockBasedCompensationTables", "shortName": "Stock-based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "us-gaap:IncomeTaxPolicyTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": "2", "first": true, "lang": null, "name": "mdgl:DeferredTaxAssetsPercentageOfValuationAllowance", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1023 - Disclosure - Summary of Significant Accounting Policies - Income Taxes (Details)", "menuCat": "Details", "order": "23", "role": "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails", "shortName": "Summary of Significant Accounting Policies - Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:IncomeTaxPolicyTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": "2", "first": true, "lang": null, "name": "mdgl:DeferredTaxAssetsPercentageOfValuationAllowance", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P01_01_2023To06_30_2023_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1024 - Disclosure - Summary of Significant Accounting Policies - Basic and Diluted Loss Per Common Share (Details)", "menuCat": "Details", "order": "24", "role": "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedLossPerCommonShareDetails", "shortName": "Summary of Significant Accounting Policies - Basic and Diluted Loss Per Common Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P01_01_2023To06_30_2023_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P04_01_2023To06_30_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1025 - Disclosure - Liquidity and Uncertainties (Details)", "menuCat": "Details", "order": "25", "role": "http://www.madrigalpharma.com/role/LiquidityAndUncertaintiesDetails", "shortName": "Liquidity and Uncertainties (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R26": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "PAsOn06_30_2023", "decimals": "-3", "first": true, "lang": null, "name": "mdgl:CashAndCashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGains", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1026 - Disclosure - Cash, Cash Equivalents and Marketable Securities (Details)", "menuCat": "Details", "order": "26", "role": "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails", "shortName": "Cash, Cash Equivalents and Marketable Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "PAsOn06_30_2023", "decimals": "-3", "first": true, "lang": null, "name": "mdgl:CashAndCashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGains", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "mdgl:AccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "PAsOn06_30_2023", "decimals": "-3", "first": true, "lang": null, "name": "mdgl:AccruedContractResearchCostsCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1027 - Disclosure - Accrued Liabilities (Details)", "menuCat": "Details", "order": "27", "role": "http://www.madrigalpharma.com/role/AccruedLiabilitiesDetails", "shortName": "Accrued Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "mdgl:AccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "PAsOn06_30_2023", "decimals": "-3", "first": true, "lang": null, "name": "mdgl:AccruedContractResearchCostsCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "PAsOn06_30_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1028 - Disclosure - Long Term Debt - Schedule of Maturities of Long-Term Debt (Details)", "menuCat": "Details", "order": "28", "role": "http://www.madrigalpharma.com/role/LongTermDebtScheduleOfMaturitiesOfLongTermDebtDetails", "shortName": "Long Term Debt - Schedule of Maturities of Long-Term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "PAsOn06_30_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "PAsOn06_30_2023", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1029 - Disclosure - Long Term Debt (Details)", "menuCat": "Details", "order": "29", "role": "http://www.madrigalpharma.com/role/LongTermDebtDetails", "shortName": "Long Term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "PAsOn06_30_2023", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "div", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "PAsOn06_30_2023", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:PreferredStockSharesAuthorized", "div", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "PAsOn06_30_2023", "decimals": "INF", "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": "0", "first": true, "lang": null, "name": "mdgl:CommonStockVotingRightsNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Vote", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1030 - Disclosure - Stockholders' Equity (Deficit) - Common Stock (Details)", "menuCat": "Details", "order": "30", "role": "http://www.madrigalpharma.com/role/StockholdersEquityDeficitCommonStockDetails", "shortName": "Stockholders' Equity (Deficit) - Common Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": "0", "first": true, "lang": null, "name": "mdgl:CommonStockVotingRightsNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Vote", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "div", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "PAsOn06_30_2023", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1031 - Disclosure - Stockholders' Equity (Deficit) - Preferred Stock (Details)", "menuCat": "Details", "order": "31", "role": "http://www.madrigalpharma.com/role/StockholdersEquityDeficitPreferredStockDetails", "shortName": "Stockholders' Equity (Deficit) - Preferred Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "PAsOn06_30_2017_ConvertibleSeriesAAndBPreferredStockMemberusgaapStatementClassOfStockAxis", "decimals": "4", "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P12_01_2022To12_23_2022_PurchaseAgreementMemberMDGLAgreementAxis_TwoThousandAndTwentyTwoRegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis", "decimals": "-5", "first": true, "lang": null, "name": "mdgl:ProceedsFromIssuanceorSaleofEquityGross", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1032 - Disclosure - Stockholders' Equity (Deficit) - Registered Offering (Details)", "menuCat": "Details", "order": "32", "role": "http://www.madrigalpharma.com/role/StockholdersEquityDeficitRegisteredOfferingDetails", "shortName": "Stockholders' Equity (Deficit) - Registered Offering (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P12_01_2022To12_23_2022_PurchaseAgreementMemberMDGLAgreementAxis_TwoThousandAndTwentyTwoRegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis", "decimals": "-5", "first": true, "lang": null, "name": "mdgl:ProceedsFromIssuanceorSaleofEquityGross", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P01_01_2022To12_31_2022_AtTheMarketIssuanceSalesAgreementMemberusgaapTypeOfArrangementAxis_TwoThousandAndTwentyOneSalesAgreementMemberMDGLAgreementAxis", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1033 - Disclosure - Stockholders' Equity (Deficit) - At The Market Issuances (Details)", "menuCat": "Details", "order": "33", "role": "http://www.madrigalpharma.com/role/StockholdersEquityDeficitAtTheMarketIssuancesDetails", "shortName": "Stockholders' Equity (Deficit) - At The Market Issuances (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P01_01_2022To12_31_2022_AtTheMarketIssuanceSalesAgreementMemberusgaapTypeOfArrangementAxis_TwoThousandAndTwentyOneSalesAgreementMemberMDGLAgreementAxis", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "PAsOn06_30_2023", "decimals": "INF", "first": true, "lang": null, "name": "mdgl:ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsAndOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1034 - Disclosure - Stock-based Compensation - Stock Option (Details)", "menuCat": "Details", "order": "34", "role": "http://www.madrigalpharma.com/role/StockBasedCompensationStockOptionDetails", "shortName": "Stock-based Compensation - Stock Option (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "PAsOn06_30_2023", "decimals": "INF", "first": true, "lang": null, "name": "mdgl:ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsAndOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "mdgl:ScheduleOfShareBasedCompensationExpenseAllocationOfCompensationCostsAndRecognizedPeriodCostsTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P04_01_2023To06_30_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1035 - Disclosure - Stock-based Compensation - Expense (Details)", "menuCat": "Details", "order": "35", "role": "http://www.madrigalpharma.com/role/StockBasedCompensationExpenseDetails", "shortName": "Stock-based Compensation - Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "mdgl:ScheduleOfShareBasedCompensationExpenseAllocationOfCompensationCostsAndRecognizedPeriodCostsTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P04_01_2023To06_30_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "PAsOn06_30_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1036 - Disclosure - Stock-based Compensation - Unrecognized Expense (Details)", "menuCat": "Details", "order": "36", "role": "http://www.madrigalpharma.com/role/StockBasedCompensationUnrecognizedExpenseDetails", "shortName": "Stock-based Compensation - Unrecognized Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "PAsOn06_30_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "PAsOn06_30_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1037 - Disclosure - Stock-based Compensation - Restricted Stock Units (Details)", "menuCat": "Details", "order": "37", "role": "http://www.madrigalpharma.com/role/StockBasedCompensationRestrictedStockUnitsDetails", "shortName": "Stock-based Compensation - Restricted Stock Units (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "PAsOn06_30_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1038 - Disclosure - Commitments and Contingencies (Details)", "menuCat": "Details", "order": "38", "role": "http://www.madrigalpharma.com/role/CommitmentsAndContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P04_01_2023To06_30_2023", "decimals": null, "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "true" }, "groupType": "statement", "isDefault": "false", "longName": "1004 - Statement - Condensed Consolidated Statements Of Operations", "menuCat": "Statements", "order": "4", "role": "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfOperations", "shortName": "Condensed Consolidated Statements Of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P04_01_2023To06_30_2023", "decimals": null, "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "true" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P04_01_2023To06_30_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005 - Statement - Condensed Consolidated Statements Of Comprehensive Loss", "menuCat": "Statements", "order": "5", "role": "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss", "shortName": "Condensed Consolidated Statements Of Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P04_01_2023To06_30_2023", "decimals": "-3", "lang": null, "name": "us-gaap:ComprehensiveIncomeNetOfTax", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "PAsOn12_31_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006 - Statement - Condensed Consolidated Statements Of Stockholders' Equity", "menuCat": "Statements", "order": "6", "role": "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfStockholdersEquity", "shortName": "Condensed Consolidated Statements Of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": "-3", "lang": null, "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1007 - Statement - Condensed Consolidated Statements Of Cash Flows", "menuCat": "Statements", "order": "7", "role": "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows", "shortName": "Condensed Consolidated Statements Of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1008 - Disclosure - Organization, Business and Basis of Presentation", "menuCat": "Notes", "order": "8", "role": "http://www.madrigalpharma.com/role/OrganizationBusinessAndBasisOfPresentation", "shortName": "Organization, Business and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1009 - Disclosure - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "9", "role": "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530762d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 43, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r640" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r641" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r638" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r638" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r638" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r642" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r638" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r638" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r638" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r638" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r637" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r639" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "mdgl_AccruedCompensationAndBenefitsCurrent": { "auth_ref": [], "calculation": { "http://www.madrigalpharma.com/role/AccruedLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Compensation And Benefits, Current.", "label": "Accrued Compensation And Benefits Current", "verboseLabel": "Compensation and benefits" } } }, "localname": "AccruedCompensationAndBenefitsCurrent", "nsuri": "http://www.madrigalpharma.com/20230630", "presentation": [ "http://www.madrigalpharma.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "mdgl_AccruedContractResearchCostsCurrent": { "auth_ref": [], "calculation": { "http://www.madrigalpharma.com/role/AccruedLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Contract Research Costs, Current.", "label": "Accrued Contract Research Costs Current", "verboseLabel": "Contract research organization costs" } } }, "localname": "AccruedContractResearchCostsCurrent", "nsuri": "http://www.madrigalpharma.com/20230630", "presentation": [ "http://www.madrigalpharma.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "mdgl_AccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accrued Liabilities Disclosure.", "label": "Accrued Liabilities Disclosure [Text Block]", "verboseLabel": "Accrued Liabilities" } } }, "localname": "AccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://www.madrigalpharma.com/20230630", "presentation": [ "http://www.madrigalpharma.com/role/AccruedLiabilities" ], "xbrltype": "textBlockItemType" }, "mdgl_AccruedManufacturingAndDrugSupplyCurrent": { "auth_ref": [], "calculation": { "http://www.madrigalpharma.com/role/AccruedLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued manufacturing and drug supply Current.", "label": "Accrued Manufacturing and Drug Supply Current", "terseLabel": "Manufacturing and drug supply" } } }, "localname": "AccruedManufacturingAndDrugSupplyCurrent", "nsuri": "http://www.madrigalpharma.com/20230630", "presentation": [ "http://www.madrigalpharma.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "mdgl_AccruedOtherClinicalStudyRelatedCostsCurrent": { "auth_ref": [], "calculation": { "http://www.madrigalpharma.com/role/AccruedLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued other clinical study related costs current.", "label": "Accrued Other Clinical Study Related Costs Current", "terseLabel": "Other clinical study related costs" } } }, "localname": "AccruedOtherClinicalStudyRelatedCostsCurrent", "nsuri": "http://www.madrigalpharma.com/20230630", "presentation": [ "http://www.madrigalpharma.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "mdgl_AgreementAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement.", "label": "Agreement [Axis]" } } }, "localname": "AgreementAxis", "nsuri": "http://www.madrigalpharma.com/20230630", "presentation": [ "http://www.madrigalpharma.com/role/StockholdersEquityDeficitAtTheMarketIssuancesDetails", "http://www.madrigalpharma.com/role/StockholdersEquityDeficitRegisteredOfferingDetails" ], "xbrltype": "stringItemType" }, "mdgl_AgreementDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement.", "label": "Agreement [Domain]" } } }, "localname": "AgreementDomain", "nsuri": "http://www.madrigalpharma.com/20230630", "presentation": [ "http://www.madrigalpharma.com/role/StockholdersEquityDeficitAtTheMarketIssuancesDetails", "http://www.madrigalpharma.com/role/StockholdersEquityDeficitRegisteredOfferingDetails" ], "xbrltype": "domainItemType" }, "mdgl_AtTheMarketIssuanceSalesAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to at-the-market issuance sales agreement for the sale of the entity's common shares.", "label": "At The Market Issuance Sales Agreement [Member]", "verboseLabel": "At-The-Market Issuance Sales Agreement" } } }, "localname": "AtTheMarketIssuanceSalesAgreementMember", "nsuri": "http://www.madrigalpharma.com/20230630", "presentation": [ "http://www.madrigalpharma.com/role/StockholdersEquityDeficitAtTheMarketIssuancesDetails" ], "xbrltype": "domainItemType" }, "mdgl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGains": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the gross unrealized gains for cash and cash equivalents securities, at a point in time, which are categorized neither as held-to-maturity nor trading securities.", "label": "Cash and Cash Equivalents and Available for Sale Securities, Gross Unrealized Gains", "terseLabel": "Total cash, cash equivalents and marketable securities, Unrealized gains" } } }, "localname": "CashAndCashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGains", "nsuri": "http://www.madrigalpharma.com/20230630", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "mdgl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLosses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This item represents the gross unrealized losses for cash and cash equivalents securities, at a point in time, which are categorized neither as held-to-maturity nor trading securities.", "label": "Cash and Cash Equivalents and Available for Sale Securities, Gross Unrealized Losses", "negatedLabel": "Total cash, cash equivalents and marketable securities, Unrealized losses" } } }, "localname": "CashAndCashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLosses", "nsuri": "http://www.madrigalpharma.com/20230630", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "mdgl_CashCashEquivalentsAndShortTermInvestmentsAtCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings, and cash and cash equivalents.", "label": "Cash, Cash Equivalents, and Short-term Investments, At Cost", "verboseLabel": "Total cash, cash equivalents and marketable securities, Cost" } } }, "localname": "CashCashEquivalentsAndShortTermInvestmentsAtCost", "nsuri": "http://www.madrigalpharma.com/20230630", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "mdgl_CommonStockAggregateOfferingPrice": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the maximum aggregate offering price the entity may issue and sell shares of its common stock from time to time, at the entity's option, according to at-the-market issuance sales agreement with third party.", "label": "Common Stock Aggregate Offering Price", "terseLabel": "Maximum aggregate offering price" } } }, "localname": "CommonStockAggregateOfferingPrice", "nsuri": "http://www.madrigalpharma.com/20230630", "presentation": [ "http://www.madrigalpharma.com/role/StockholdersEquityDeficitAtTheMarketIssuancesDetails" ], "xbrltype": "monetaryItemType" }, "mdgl_CommonStockVotingRightsNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of votes per share that common stockholders are entitled to receive.", "label": "Common Stock Voting Rights Number", "terseLabel": "Number of votes per share that common stockholders are entitled to receive" } } }, "localname": "CommonStockVotingRightsNumber", "nsuri": "http://www.madrigalpharma.com/20230630", "presentation": [ "http://www.madrigalpharma.com/role/StockholdersEquityDeficitCommonStockDetails" ], "xbrltype": "integerItemType" }, "mdgl_ConvertibleSeriesAAndBPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Series A and B Preferred Stock [Member]", "verboseLabel": "Convertible Series A and B Preferred Stock" } } }, "localname": "ConvertibleSeriesAAndBPreferredStockMember", "nsuri": "http://www.madrigalpharma.com/20230630", "presentation": [ "http://www.madrigalpharma.com/role/StockholdersEquityDeficitPreferredStockDetails" ], "xbrltype": "domainItemType" }, "mdgl_CowenCo.LlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represent of Cowen & Co. LLC Member.", "label": "Cowen Co. Llc [Member]", "terseLabel": "Cowen & Co. LLC" } } }, "localname": "CowenCo.LlcMember", "nsuri": "http://www.madrigalpharma.com/20230630", "presentation": [ "http://www.madrigalpharma.com/role/StockholdersEquityDeficitAtTheMarketIssuancesDetails" ], "xbrltype": "domainItemType" }, "mdgl_DebtDescriptionAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt description axis.", "label": "Debt Description [Axis]" } } }, "localname": "DebtDescriptionAxis", "nsuri": "http://www.madrigalpharma.com/20230630", "presentation": [ "http://www.madrigalpharma.com/role/LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "mdgl_DebtDescriptionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt description domain.", "label": "Debt Description [Domain]" } } }, "localname": "DebtDescriptionDomain", "nsuri": "http://www.madrigalpharma.com/20230630", "presentation": [ "http://www.madrigalpharma.com/role/LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "mdgl_DebtInstrumentInterestPaymentsTerms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument, interest payments terms.", "label": "Debt Instrument Interest Payments Terms", "terseLabel": "Debt Instrument Interest Payments Terms" } } }, "localname": "DebtInstrumentInterestPaymentsTerms", "nsuri": "http://www.madrigalpharma.com/20230630", "presentation": [ "http://www.madrigalpharma.com/role/LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "mdgl_DeferredTaxAssetsPercentageOfValuationAllowance": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of valuation allowance on the deferred tax assets.", "label": "Deferred Tax Assets, Percentage Of Valuation Allowance", "terseLabel": "Valuation allowance on deferred tax assets (as a percent)" } } }, "localname": "DeferredTaxAssetsPercentageOfValuationAllowance", "nsuri": "http://www.madrigalpharma.com/20230630", "presentation": [ "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "mdgl_DrawnInTwoSeparateTranchesUponAchievementOfResmetiromClinicalAndRegulatoryMilestoneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Drawn in two separate tranches upon achievement of resmetirom clinical and regulatory milestone.", "label": "Drawn In Two Separate Tranches Upon Achievement of Resmetirom Clinical And Regulatory Milestone [Member]", "terseLabel": "Drawn In Two Separate Tranches Upon Achievement of Resmetirom Clinical And Regulatory Milestone" } } }, "localname": "DrawnInTwoSeparateTranchesUponAchievementOfResmetiromClinicalAndRegulatoryMilestoneMember", "nsuri": "http://www.madrigalpharma.com/20230630", "presentation": [ "http://www.madrigalpharma.com/role/LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "mdgl_HoffmanLaRocheMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Hoffman-La Roche.", "label": "Hoffman La Roche [Member]", "terseLabel": "Hoffmann-La Roche (\"Roche\")" } } }, "localname": "HoffmanLaRocheMember", "nsuri": "http://www.madrigalpharma.com/20230630", "presentation": [ "http://www.madrigalpharma.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "mdgl_IncreaseDecreaseInAccruedInterestNetOfInterestReceived": { "auth_ref": [], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of accrued interest expense incurred but not yet paid, net of interest received on maturity of investments.", "label": "Increase (Decrease) In Accrued Interest, Net Of Interest Received", "terseLabel": "Accrued interest, net of interest received on maturity of investments" } } }, "localname": "IncreaseDecreaseInAccruedInterestNetOfInterestReceived", "nsuri": "http://www.madrigalpharma.com/20230630", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mdgl_LiquidityAndUncertaintiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Liquidity And Uncertainties Disclosure Abstract", "label": "Liquidity and Uncertainties" } } }, "localname": "LiquidityAndUncertaintiesDisclosureAbstract", "nsuri": "http://www.madrigalpharma.com/20230630", "xbrltype": "stringItemType" }, "mdgl_LoanFacilityAndAmendedLoanFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loan facility and amended loan facility.", "label": "Loan Facility And Amended Loan Facility [Member]" } } }, "localname": "LoanFacilityAndAmendedLoanFacilityMember", "nsuri": "http://www.madrigalpharma.com/20230630", "presentation": [ "http://www.madrigalpharma.com/role/LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "mdgl_LoanFacilityAndAmendedLoanFacilityOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loan Facility And Amended Loan Facility [Member].", "label": "Loan Facility And Amended Loan Facility One [Member]" } } }, "localname": "LoanFacilityAndAmendedLoanFacilityOneMember", "nsuri": "http://www.madrigalpharma.com/20230630", "presentation": [ "http://www.madrigalpharma.com/role/LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "mdgl_LoanFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loan facility member.", "label": "Loan Facility [Member]" } } }, "localname": "LoanFacilityMember", "nsuri": "http://www.madrigalpharma.com/20230630", "presentation": [ "http://www.madrigalpharma.com/role/LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "mdgl_LongTermDebtFloorInterestRatePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long term debt floor interest rate percentage.", "label": "Long Term Debt Floor Interest Rate Percentage", "terseLabel": "Long term debt floor interest rate percentage" } } }, "localname": "LongTermDebtFloorInterestRatePercentage", "nsuri": "http://www.madrigalpharma.com/20230630", "presentation": [ "http://www.madrigalpharma.com/role/LongTermDebtDetails" ], "xbrltype": "percentItemType" }, "mdgl_MaturityPeriodFromDateOfPurchaseToClassifyInvestmentAsMarketableSecurities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the maturity period from date of purchase to classify an investment as marketable securities.", "label": "Maturity Period from Date of Purchase to Classify Investment as Marketable Securities", "verboseLabel": "Maturity period from date of purchase to classify an investment as marketable securities" } } }, "localname": "MaturityPeriodFromDateOfPurchaseToClassifyInvestmentAsMarketableSecurities", "nsuri": "http://www.madrigalpharma.com/20230630", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "durationItemType" }, "mdgl_PatentsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for patents.", "label": "Patents [Policy Text Block]", "terseLabel": "Patents" } } }, "localname": "PatentsPolicyTextBlock", "nsuri": "http://www.madrigalpharma.com/20230630", "presentation": [ "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "mdgl_PercenatgeOfTermChargesOnAggregatePrincipalAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percenatge of term charges on aggregate principal amount.", "label": "Percenatge of Term charges on aggregate principal amount", "terseLabel": "Percenatge of Term charges on aggregate principal amount" } } }, "localname": "PercenatgeOfTermChargesOnAggregatePrincipalAmount", "nsuri": "http://www.madrigalpharma.com/20230630", "presentation": [ "http://www.madrigalpharma.com/role/LongTermDebtDetails" ], "xbrltype": "percentItemType" }, "mdgl_PreferredStockNumberOfVotingRights": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of voting rights of preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Preferred Stock, Number Of Voting Rights", "terseLabel": "Preferred shares number voting rights" } } }, "localname": "PreferredStockNumberOfVotingRights", "nsuri": "http://www.madrigalpharma.com/20230630", "presentation": [ "http://www.madrigalpharma.com/role/StockholdersEquityDeficitPreferredStockDetails" ], "xbrltype": "integerItemType" }, "mdgl_ProceedsFromIssuanceOrSaleOfEquityNet": { "auth_ref": [], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, and other types of equity, net of transaction costs.", "label": "Proceeds From Issuance Or Sale Of Equity, Net", "terseLabel": "Proceeds from issuances of stock, excluding related parties, net of transaction costs" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquityNet", "nsuri": "http://www.madrigalpharma.com/20230630", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mdgl_ProceedsFromIssuanceorSaleofEquityGross": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance or sale of equity gross.", "label": "Proceeds From Issuance or Sale of Equity Gross", "terseLabel": "Proceeds from issuance or sale of equity, Gross" } } }, "localname": "ProceedsFromIssuanceorSaleofEquityGross", "nsuri": "http://www.madrigalpharma.com/20230630", "presentation": [ "http://www.madrigalpharma.com/role/StockholdersEquityDeficitRegisteredOfferingDetails" ], "xbrltype": "monetaryItemType" }, "mdgl_ProceedsFromTheSaleOfRelatedPartyStockAndExerciseOfCommonStockOptionsNetOfTransactionCosts": { "auth_ref": [], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from the sale of related party stock and exercise of common stock options, net of transaction costs.", "label": "Proceeds From The Sale Of Related Party Stock And Exercise Of Common Stock Options Net Of Transaction Costs", "terseLabel": "Proceeds from the sale of related party stock and exercise of common stock options, net of transaction costs" } } }, "localname": "ProceedsFromTheSaleOfRelatedPartyStockAndExerciseOfCommonStockOptionsNetOfTransactionCosts", "nsuri": "http://www.madrigalpharma.com/20230630", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mdgl_PurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Purchase Agreement [Member]", "terseLabel": "Purchase Agreement" } } }, "localname": "PurchaseAgreementMember", "nsuri": "http://www.madrigalpharma.com/20230630", "presentation": [ "http://www.madrigalpharma.com/role/StockholdersEquityDeficitRegisteredOfferingDetails" ], "xbrltype": "domainItemType" }, "mdgl_RemainingMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of future milestone payments remaining to be paid under the agreement.", "label": "Remaining Milestone Payments", "verboseLabel": "Remainder of future milestone payments" } } }, "localname": "RemainingMilestonePayments", "nsuri": "http://www.madrigalpharma.com/20230630", "presentation": [ "http://www.madrigalpharma.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "mdgl_RemainingSecuritiesUnderShelfRegistrationValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of common stock that remains reserved for future issuances under shelf registration with the Securities and Exchange Commission of the United States.", "label": "Remaining Securities Under Shelf Registration, Value", "terseLabel": "Remaining reserved amount under shelf registration" } } }, "localname": "RemainingSecuritiesUnderShelfRegistrationValue", "nsuri": "http://www.madrigalpharma.com/20230630", "presentation": [ "http://www.madrigalpharma.com/role/StockholdersEquityDeficitAtTheMarketIssuancesDetails" ], "xbrltype": "monetaryItemType" }, "mdgl_ResearchDevelopmentAndCommercializationAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Research, Development and Commercialization Agreement with Hoffmann-La Roche (\"Roche\") which grants a sole and exclusive license to develop, use, sell, offer for sale and import any Licensed Product as defined by the agreement.", "label": "Research Development And Commercialization Agreement [Member]", "terseLabel": "Research, Development and Commercialization Agreement" } } }, "localname": "ResearchDevelopmentAndCommercializationAgreementMember", "nsuri": "http://www.madrigalpharma.com/20230630", "presentation": [ "http://www.madrigalpharma.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "mdgl_ScheduleOfShareBasedCompensationExpenseAllocationOfCompensationCostsAndRecognizedPeriodCostsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the income statement for the period. This may include the amount of total share-based compensation cost, including the amounts attributable to each share-based compensation plan and any related tax benefits. It includes the reporting line for the costs expensed.", "label": "Schedule of Share Based Compensation Expense Allocation of Compensation Costs and Recognized Period Costs [Table Text Block]", "terseLabel": "Schedule of stock-based compensation expense" } } }, "localname": "ScheduleOfShareBasedCompensationExpenseAllocationOfCompensationCostsAndRecognizedPeriodCostsTableTextBlock", "nsuri": "http://www.madrigalpharma.com/20230630", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "mdgl_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsAndOptionsOutstandingNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award, restricted stock units and options, outstanding, number.", "label": "Share Based Compensation Arrangement By Share Based Payment Award, Restricted Stock Units and Options, Outstanding, Number", "terseLabel": "Options outstanding to purchase of common stock" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsAndOptionsOutstandingNumber", "nsuri": "http://www.madrigalpharma.com/20230630", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationStockOptionDetails" ], "xbrltype": "sharesItemType" }, "mdgl_StockIssuedDuringPeriodSharesNewIssuesExcludingSalesToRelatedParties": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period, excluding stock issued to related parties.", "label": "Stock Issued During Period Shares New Issues Excluding Sales To Related Parties", "terseLabel": "Issuance of common and preferred shares in equity offerings, excluding to related parties, net of transaction costs (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssuesExcludingSalesToRelatedParties", "nsuri": "http://www.madrigalpharma.com/20230630", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "mdgl_StockIssuedDuringPeriodSharesRelatedPartiesAndExerciseOfCommonStockOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of new shares issued to related parties and exercise of common stock options, net of transaction costs.", "label": "Stock Issued During Period Shares Related Parties and Exercise of Common Stock Options", "terseLabel": "Sale of common shares to related parties and exercise of common stock options, net of transaction cost ( in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRelatedPartiesAndExerciseOfCommonStockOptions", "nsuri": "http://www.madrigalpharma.com/20230630", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "mdgl_StockIssuedDuringPeriodValueNewIssuesExcludingSalesToRelatedParties": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period, excluding stock issued to related parties.", "label": "Stock Issued During Period Value New Issues Excluding Sales to Related Parties", "terseLabel": "Issuance of common and preferred shares in equity offerings, excluding to related parties, net of transaction costs" } } }, "localname": "StockIssuedDuringPeriodValueNewIssuesExcludingSalesToRelatedParties", "nsuri": "http://www.madrigalpharma.com/20230630", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "mdgl_StockIssuedDuringPeriodValueRelatedPartiesAndExerciseOfCommonStockOptions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Number of new shares issued to related parties and exercise of common stock options, net of transaction costs.", "label": "Stock Issued During Period Value Related Parties and Exercise of Common Stock Options", "terseLabel": "Sale of common shares to related parties and exercise of common stock options, net of transaction cost" } } }, "localname": "StockIssuedDuringPeriodValueRelatedPartiesAndExerciseOfCommonStockOptions", "nsuri": "http://www.madrigalpharma.com/20230630", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "mdgl_TermLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term loan member.", "label": "Term Loan [Member]", "terseLabel": "Term Loan [Member]" } } }, "localname": "TermLoanMember", "nsuri": "http://www.madrigalpharma.com/20230630", "presentation": [ "http://www.madrigalpharma.com/role/LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "mdgl_TrancheAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tranche axis.", "label": "Tranche [Axis]" } } }, "localname": "TrancheAxis", "nsuri": "http://www.madrigalpharma.com/20230630", "presentation": [ "http://www.madrigalpharma.com/role/LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "mdgl_TrancheDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tranche.", "label": "Tranche [Domain]" } } }, "localname": "TrancheDomain", "nsuri": "http://www.madrigalpharma.com/20230630", "presentation": [ "http://www.madrigalpharma.com/role/LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "mdgl_TrancheFouthMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tranche fouth.", "label": "Tranche fouth [Member]" } } }, "localname": "TrancheFouthMember", "nsuri": "http://www.madrigalpharma.com/20230630", "presentation": [ "http://www.madrigalpharma.com/role/LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "mdgl_TrancheThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tranche three.", "label": "Tranche three [Member]" } } }, "localname": "TrancheThreeMember", "nsuri": "http://www.madrigalpharma.com/20230630", "presentation": [ "http://www.madrigalpharma.com/role/LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "mdgl_TrancheTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tranche two.", "label": "Tranche Two [Member]" } } }, "localname": "TrancheTwoMember", "nsuri": "http://www.madrigalpharma.com/20230630", "presentation": [ "http://www.madrigalpharma.com/role/LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "mdgl_TwoThousandAndTwentyOneSalesAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand and twenty one sales agreement.", "label": "Two Thousand and Twenty One Sales Agreement [Member]", "terseLabel": "2021 Sales Agreement" } } }, "localname": "TwoThousandAndTwentyOneSalesAgreementMember", "nsuri": "http://www.madrigalpharma.com/20230630", "presentation": [ "http://www.madrigalpharma.com/role/StockholdersEquityDeficitAtTheMarketIssuancesDetails" ], "xbrltype": "domainItemType" }, "mdgl_TwoThousandAndTwentyThreeSalesAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Two Thousand And Twenty Three Sales Agreement [Member]", "terseLabel": "2023 Sales Agreement" } } }, "localname": "TwoThousandAndTwentyThreeSalesAgreementMember", "nsuri": "http://www.madrigalpharma.com/20230630", "presentation": [ "http://www.madrigalpharma.com/role/StockholdersEquityDeficitAtTheMarketIssuancesDetails" ], "xbrltype": "domainItemType" }, "mdgl_TwoThousandAndTwentyTwoRegisteredDirectOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Two Thousand and Twenty Two Registered Direct Offering [Member]", "verboseLabel": "2022 Registered Direct Offering" } } }, "localname": "TwoThousandAndTwentyTwoRegisteredDirectOfferingMember", "nsuri": "http://www.madrigalpharma.com/20230630", "presentation": [ "http://www.madrigalpharma.com/role/StockholdersEquityDeficitRegisteredOfferingDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r137", "r138", "r246", "r273", "r389", "r600", "r602" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.madrigalpharma.com/role/CommitmentsAndContingenciesDetails", "http://www.madrigalpharma.com/role/StockholdersEquityDeficitAtTheMarketIssuancesDetails", "http://www.madrigalpharma.com/role/StockholdersEquityDeficitRegisteredOfferingDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r229", "r230", "r231", "r232", "r296", "r421", "r441", "r470", "r471", "r527", "r546", "r550", "r551", "r580", "r597", "r598", "r607", "r614", "r618", "r625", "r681", "r690", "r691", "r692", "r693", "r694", "r695" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationStockOptionDetails", "http://www.madrigalpharma.com/role/StockholdersEquityDeficitAtTheMarketIssuancesDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r229", "r230", "r231", "r232", "r289", "r296", "r326", "r327", "r328", "r397", "r421", "r441", "r470", "r471", "r527", "r546", "r550", "r551", "r580", "r597", "r598", "r607", "r614", "r618", "r625", "r628", "r677", "r681", "r691", "r692", "r693", "r694", "r695" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationStockOptionDetails", "http://www.madrigalpharma.com/role/StockholdersEquityDeficitAtTheMarketIssuancesDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r229", "r230", "r231", "r232", "r289", "r296", "r326", "r327", "r328", "r397", "r421", "r441", "r470", "r471", "r527", "r546", "r550", "r551", "r580", "r597", "r598", "r607", "r614", "r618", "r625", "r628", "r677", "r681", "r691", "r692", "r693", "r694", "r695" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationStockOptionDetails", "http://www.madrigalpharma.com/role/StockholdersEquityDeficitAtTheMarketIssuancesDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r137", "r138", "r246", "r273", "r389", "r601", "r602" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.madrigalpharma.com/role/CommitmentsAndContingenciesDetails", "http://www.madrigalpharma.com/role/StockholdersEquityDeficitAtTheMarketIssuancesDetails", "http://www.madrigalpharma.com/role/StockholdersEquityDeficitRegisteredOfferingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r18", "r624" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r22" ], "calculation": { "http://www.madrigalpharma.com/role/AccruedLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 10.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "totalLabel": "Total accrued liabilities", "verboseLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/AccruedLiabilitiesDetails", "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current [Abstract]" } } }, "localname": "AccruedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r22" ], "calculation": { "http://www.madrigalpharma.com/role/AccruedLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r28", "r29", "r73", "r115", "r432", "r446", "r447" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 17.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r1", "r10", "r29", "r361", "r364", "r388", "r442", "r443", "r654", "r655", "r656", "r663", "r664", "r665" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated other comprehensive income (loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r68" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 16.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in-capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r335", "r336", "r337", "r458", "r663", "r664", "r665", "r686", "r700" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition", "terseLabel": "Compensation expense related to stock options for services" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r11", "r43", "r91" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "terseLabel": "Hercules warrant" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AgencySecuritiesMember": { "auth_ref": [ "r670", "r671" ], "lang": { "en-us": { "role": { "documentation": "Securities issued by government sponsored entities.", "label": "Agency Securities [Member]", "terseLabel": "U.S. government and government sponsored entities due within 1 year of date of purchase" } } }, "localname": "AgencySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r330", "r342" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r264", "r383", "r612", "r613", "r658" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Amortization of debt issuance costs and discount" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r161" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Outstanding securities not included in the computation of diluted net loss per common share as their inclusion would be anti-dilutive (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r38" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Anti-dilutive securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r38" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedLossPerCommonShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [ "r352" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CommitmentsAndContingenciesDetails", "http://www.madrigalpharma.com/role/StockholdersEquityDeficitAtTheMarketIssuancesDetails", "http://www.madrigalpharma.com/role/StockholdersEquityDeficitRegisteredOfferingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r94", "r110", "r136", "r166", "r173", "r177", "r213", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r354", "r358", "r374", "r429", "r491", "r624", "r636", "r679", "r680", "r688" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r107", "r116", "r136", "r213", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r354", "r358", "r374", "r624", "r679", "r680", "r688" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r187" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Marketable securities, unrealized gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r188" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Marketable securities, unrealized losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r184", "r221", "r428" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "verboseLabel": "Marketable securities, cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r185", "r221", "r423", "r668" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Marketable securities, fair value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r182", "r221" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Debt Securities, Available-for-sale, Current", "terseLabel": "Marketable securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r301", "r302", "r303", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r325", "r326", "r327", "r328", "r329" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationExpenseDetails", "http://www.madrigalpharma.com/role/StockBasedCompensationRestrictedStockUnitsDetails", "http://www.madrigalpharma.com/role/StockBasedCompensationStockOptionDetails", "http://www.madrigalpharma.com/role/StockBasedCompensationUnrecognizedExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r50", "r51" ], "lang": { "en-us": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]", "terseLabel": "Carrying value" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r33", "r109", "r599" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [ "r109" ], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": { "auth_ref": [ "r667" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).", "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]", "terseLabel": "Cash, Cash Equivalents and Marketable Securities" } } }, "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecurities" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "auth_ref": [ "r653" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.", "label": "Cash, Cash Equivalents, and Short-term Investments", "verboseLabel": "Total cash, cash equivalents and marketable securities, Fair value" } } }, "localname": "CashCashEquivalentsAndShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r33", "r79", "r133" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r0", "r79" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental disclosure of cash flow information:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_CashMember": { "auth_ref": [ "r109" ], "lang": { "en-us": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.", "label": "Cash [Member]", "terseLabel": "Cash" } } }, "localname": "CashMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r104", "r112", "r113", "r114", "r136", "r155", "r156", "r158", "r160", "r164", "r165", "r213", "r233", "r235", "r236", "r237", "r240", "r241", "r271", "r272", "r275", "r278", "r285", "r374", "r452", "r453", "r454", "r455", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r479", "r500", "r519", "r590", "r591", "r592", "r593", "r594", "r643", "r659", "r666" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/StockholdersEquityDeficitPreferredStockDetails", "http://www.madrigalpharma.com/role/StockholdersEquityDeficitRegisteredOfferingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [ "r352" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "verboseLabel": "Stockholders' Equity (Deficit)" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/StockholdersEquityDeficitAtTheMarketIssuancesDetails", "http://www.madrigalpharma.com/role/StockholdersEquityDeficitPreferredStockDetails", "http://www.madrigalpharma.com/role/StockholdersEquityDeficitRegisteredOfferingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r86", "r227", "r228", "r596", "r678" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r626", "r627", "r628", "r630", "r631", "r632", "r633", "r663", "r664", "r686", "r698", "r700" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfStockholdersEquity", "http://www.madrigalpharma.com/role/StockholdersEquityDeficitRegisteredOfferingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r67" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r67", "r479" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r67" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r11", "r67", "r479", "r497", "r700", "r701" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r67", "r431", "r624" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 15.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, par value $0.0001 per share authorized: 200,000,000 at June 30, 2023 and December 31, 2022; 18,459,033 and 18,102,523 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r30", "r118", "r120", "r127", "r424", "r439" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Loss" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r48", "r603" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principle of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConversionOfStockSharesConverted1": { "auth_ref": [ "r35", "r36", "r37" ], "lang": { "en-us": { "role": { "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Shares Converted", "terseLabel": "Preferred stock conversion ratio" } } }, "localname": "ConversionOfStockSharesConverted1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/StockholdersEquityDeficitPreferredStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r615", "r617", "r697" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate debt securities due within 1 year of date of purchase" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "auth_ref": [ "r35", "r37" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Converted Instrument, Amount", "terseLabel": "Debt conversion, converted instrument, amount" } } }, "localname": "DebtConversionConvertedInstrumentAmount1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1": { "auth_ref": [ "r35", "r37" ], "lang": { "en-us": { "role": { "documentation": "The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Converted Instrument, Warrants or Options Issued", "terseLabel": "Debt conversion, converted instrument, warrants or options issued" } } }, "localname": "DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/LongTermDebtDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r87", "r134", "r242", "r248", "r249", "r250", "r251", "r252", "r253", "r258", "r265", "r266", "r268" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Long Term Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/LongTermDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r17", "r63", "r64", "r95", "r96", "r139", "r243", "r244", "r245", "r246", "r247", "r249", "r254", "r255", "r256", "r257", "r259", "r260", "r261", "r262", "r263", "r264", "r384", "r609", "r610", "r611", "r612", "r613", "r660" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r53", "r55", "r243", "r384", "r610", "r611" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Debt instrument, Face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r24", "r244" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/LongTermDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [ "r139", "r243", "r244", "r245", "r246", "r247", "r249", "r254", "r255", "r256", "r257", "r259", "r260", "r261", "r262", "r263", "r264", "r267", "r384", "r609", "r610", "r611", "r612", "r613", "r660" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "verboseLabel": "Commitments and Contingencies" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r26", "r139", "r243", "r244", "r245", "r246", "r247", "r249", "r254", "r255", "r256", "r257", "r259", "r260", "r261", "r262", "r263", "r264", "r384", "r609", "r610", "r611", "r612", "r613", "r660" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r26", "r44", "r45", "r52", "r53", "r55", "r57", "r89", "r90", "r139", "r243", "r244", "r245", "r246", "r247", "r249", "r254", "r255", "r256", "r257", "r259", "r260", "r261", "r262", "r263", "r264", "r267", "r384", "r609", "r610", "r611", "r612", "r613", "r660" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r52", "r55", "r682" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "negatedLabel": "Less unamortized discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/LongTermDebtScheduleOfMaturitiesOfLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount": { "auth_ref": [ "r25" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date.", "label": "Debt Instrument, Unused Borrowing Capacity, Amount", "terseLabel": "Unused borrowing capacity that can be drawn" } } }, "localname": "DebtInstrumentUnusedBorrowingCapacityAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r5", "r170" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization expense" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r297", "r300", "r331", "r332", "r334", "r619" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Stock-based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "verboseLabel": "Stock-based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net loss per common share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r128", "r145", "r146", "r147", "r148", "r149", "r153", "r155", "r158", "r159", "r160", "r162", "r369", "r370", "r425", "r440", "r604" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic net loss per common share" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r128", "r145", "r146", "r147", "r148", "r149", "r155", "r158", "r159", "r160", "r162", "r369", "r370", "r425", "r440", "r604" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted net loss per common share" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r38", "r39" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Basic and Diluted Loss Per Common Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r333" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total", "terseLabel": "Unrecognized stock compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationUnrecognizedExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r333" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted average remaining period (in years)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationUnrecognizedExpenseDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationExpenseDetails", "http://www.madrigalpharma.com/role/StockBasedCompensationStockOptionDetails", "http://www.madrigalpharma.com/role/StockBasedCompensationUnrecognizedExpenseDetails", "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedLossPerCommonShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r11", "r105", "r122", "r123", "r124", "r140", "r141", "r142", "r144", "r150", "r152", "r163", "r214", "r215", "r286", "r335", "r336", "r337", "r350", "r351", "r360", "r361", "r362", "r363", "r364", "r365", "r368", "r375", "r376", "r377", "r378", "r379", "r380", "r388", "r442", "r443", "r444", "r458", "r519" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r256", "r373", "r610", "r611" ], "lang": { "en-us": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "Fair value" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r256", "r290", "r291", "r292", "r293", "r294", "r295", "r371", "r394", "r395", "r396", "r610", "r611", "r615", "r616", "r617" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r15", "r49", "r256", "r610", "r611" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r256", "r290", "r295", "r371", "r394", "r615", "r616", "r617" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r256", "r290", "r295", "r371", "r395", "r610", "r611", "r615", "r616", "r617" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r256", "r290", "r291", "r292", "r293", "r294", "r295", "r394", "r395", "r396", "r610", "r611", "r615", "r616", "r617" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r8", "r16" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r216", "r217", "r218", "r219", "r220", "r222", "r223", "r224", "r267", "r283", "r366", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r438", "r608", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r672", "r673", "r674", "r675" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r76", "r502" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 6.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r75" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements Of Operations" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r225", "r226", "r503" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r226", "r503" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r121", "r344", "r345", "r346", "r347", "r348", "r349", "r451" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "auth_ref": [ "r4" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.", "label": "Increase (Decrease) in Accounts Payable, Trade", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayableTrade", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r4" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "verboseLabel": "Accrued expense" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r4" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r54", "r99", "r125", "r169", "r382", "r504", "r634", "r699" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebtExcludingAmortization": { "auth_ref": [ "r77", "r263", "r612", "r613" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.", "label": "Interest Expense, Debt, Excluding Amortization", "negatedLabel": "Less amount representing interest" } } }, "localname": "InterestExpenseDebtExcludingAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/LongTermDebtScheduleOfMaturitiesOfLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeOther": { "auth_ref": [], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest income earned from interest bearing assets classified as other.", "label": "Interest Income, Other", "verboseLabel": "Interest income" } } }, "localname": "InterestIncomeOther", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r21", "r136", "r213", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r355", "r358", "r359", "r374", "r478", "r605", "r636", "r679", "r688", "r689" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r72", "r97", "r434", "r624", "r661", "r676", "r687" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders' Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r23", "r108", "r136", "r213", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r355", "r358", "r359", "r374", "r624", "r679", "r688", "r689" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r17", "r60", "r61", "r62", "r65", "r136", "r213", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r355", "r358", "r359", "r374", "r679", "r688", "r689" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 12.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "Total long term liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Long term liabilities:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": { "auth_ref": [ "r19" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Current Borrowing Capacity", "terseLabel": "Line of Credit Facility, Current Borrowing Capacity" } } }, "localname": "LineOfCreditFacilityCurrentBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityExpirationDate1": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Date the credit facility terminates, in YYYY-MM-DD format.", "label": "Line of Credit Facility, Expiration Date", "terseLabel": "Line of credit facility, expiration date" } } }, "localname": "LineOfCreditFacilityExpirationDate1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/LongTermDebtDetails" ], "xbrltype": "dateItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r19" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "verboseLabel": "Line of credit facility, maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "auth_ref": [ "r19" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "terseLabel": "Line of Credit Facility, Remaining Borrowing Capacity" } } }, "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LoansPayableCurrent": { "auth_ref": [ "r22" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.", "label": "Loans Payable, Current", "terseLabel": "Loans payable, net of discount" } } }, "localname": "LoansPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/LongTermDebtScheduleOfMaturitiesOfLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r17", "r96", "r255", "r269", "r610", "r611", "r696" ], "calculation": { "http://www.madrigalpharma.com/role/LongTermDebtScheduleOfMaturitiesOfLongTermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-Term Debt", "totalLabel": "Long-Term Debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/LongTermDebtScheduleOfMaturitiesOfLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtByMaturityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Fiscal Year Maturity [Abstract]" } } }, "localname": "LongTermDebtByMaturityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r7", "r139", "r260" ], "calculation": { "http://www.madrigalpharma.com/role/LongTermDebtScheduleOfMaturitiesOfLongTermDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/LongTermDebtScheduleOfMaturitiesOfLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r7", "r139", "r260" ], "calculation": { "http://www.madrigalpharma.com/role/LongTermDebtScheduleOfMaturitiesOfLongTermDebtDetails": { "order": 4.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "Thereafter" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/LongTermDebtScheduleOfMaturitiesOfLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r7", "r139", "r260" ], "calculation": { "http://www.madrigalpharma.com/role/LongTermDebtScheduleOfMaturitiesOfLongTermDebtDetails": { "order": 3.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/LongTermDebtScheduleOfMaturitiesOfLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "auth_ref": [ "r662" ], "calculation": { "http://www.madrigalpharma.com/role/LongTermDebtScheduleOfMaturitiesOfLongTermDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "terseLabel": "2023 (remaining six months)" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/LongTermDebtScheduleOfMaturitiesOfLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r111" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 13.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.", "label": "Long-Term Debt, Excluding Current Maturities", "verboseLabel": "Loan payable, net of discount" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r56" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Marketable Securities, Policy [Policy Text Block]", "terseLabel": "Marketable Securities" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r684" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r132" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r132" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r79", "r80", "r81" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r74", "r81", "r98", "r106", "r117", "r119", "r124", "r136", "r143", "r145", "r146", "r147", "r148", "r151", "r152", "r157", "r166", "r172", "r176", "r178", "r213", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r370", "r374", "r437", "r499", "r517", "r518", "r606", "r634", "r679" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net Loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss", "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfStockholdersEquity", "http://www.madrigalpharma.com/role/LiquidityAndUncertaintiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r166", "r172", "r176", "r178", "r606" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r386" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 11.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "verboseLabel": "Lease liability" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r385" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r58", "r92", "r448", "r449" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization, Business and Basis of Presentation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/OrganizationBusinessAndBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r82", "r83", "r84", "r92" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r22" ], "calculation": { "http://www.madrigalpharma.com/role/AccruedLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "verboseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r3", "r9", "r93" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Unrealized loss on available-for-sale securities", "verboseLabel": "Unrealized loss on marketable securities" } } }, "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss", "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive income (loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r32" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedLabel": "Payment of debt issuance costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r669" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchases of marketable securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r78" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment, net of disposals" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at Fair Value Measurement [Member]" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [ "r626", "r627", "r630", "r631", "r632", "r633", "r698", "r700" ], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred Stock" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfStockholdersEquity", "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedLossPerCommonShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r66", "r271" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.madrigalpharma.com/role/StockholdersEquityDeficitPreferredStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r66", "r479" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r66", "r271" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r66", "r479", "r497", "r700", "r701" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r66", "r430", "r624" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 19.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred stock, par value $0.0001 per share authorized: 5,000,000 shares at June 30, 2023 and December 31, 2022; 2,369,797 and 2,369,797 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r653" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrimeRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.", "label": "Prime Rate [Member]" } } }, "localname": "PrimeRateMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromBankDebt": { "auth_ref": [ "r31" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from bank borrowing during the year.", "label": "Proceeds from Bank Debt", "terseLabel": "Proceeds from issuance of loan payable" } } }, "localname": "ProceedsFromBankDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r2" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "verboseLabel": "Net proceeds after deducting commissions and other transactions costs" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/StockholdersEquityDeficitAtTheMarketIssuancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfDebt": { "auth_ref": [ "r657" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Proceeds from Issuance of Debt", "terseLabel": "Proceeds from issuance of debt" } } }, "localname": "ProceedsFromIssuanceOfDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r2", "r452" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Proceeds from Issuance or Sale of Equity", "terseLabel": "Proceeds from issuance or sale of equity" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/StockholdersEquityDeficitRegisteredOfferingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "auth_ref": [ "r129", "r130", "r669" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale", "terseLabel": "Sales and maturities of marketable securities" } } }, "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r2", "r14" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds resulting from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationStockOptionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r106", "r117", "r119", "r131", "r136", "r143", "r151", "r152", "r166", "r172", "r176", "r178", "r213", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r353", "r356", "r357", "r370", "r374", "r426", "r436", "r457", "r499", "r517", "r518", "r606", "r621", "r622", "r635", "r656", "r679" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r6", "r427", "r435", "r624" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "auth_ref": [ "r685" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.", "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r343" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Costs" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [ "r109" ], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted stock units", "verboseLabel": "Restricted Stock Units (RSUs)" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationExpenseDetails", "http://www.madrigalpharma.com/role/StockBasedCompensationRestrictedStockUnitsDetails", "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedLossPerCommonShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r69", "r91", "r433", "r445", "r447", "r456", "r480", "r624" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 18.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets", "http://www.madrigalpharma.com/role/LiquidityAndUncertaintiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r105", "r140", "r141", "r142", "r144", "r150", "r152", "r214", "r215", "r335", "r336", "r337", "r350", "r351", "r360", "r362", "r363", "r365", "r368", "r442", "r444", "r458", "r700" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r167", "r168", "r171", "r174", "r175", "r179", "r180", "r181", "r287", "r288", "r422" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Revenue from Contract with Customer, Including Assessed Tax", "terseLabel": "Licensed product sales" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r126", "r136", "r167", "r168", "r171", "r174", "r175", "r179", "r180", "r181", "r213", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r374", "r426", "r679" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 7.0, "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Total revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "verboseLabel": "Revenues:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r387", "r623" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Obtaining a right-of-use asset in exchange for a lease liability" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/StockholdersEquityDeficitRegisteredOfferingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "verboseLabel": "Schedule of Accrued Liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/AccruedLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r38" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r38" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Summary of the outstanding securities not included in the computation of diluted net loss per common share as their inclusion would be anti-dilutive" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.", "label": "Cash, Cash Equivalents and Investments [Table Text Block]", "terseLabel": "Summary of cash, cash equivalents and available-for-sale marketable securities" } } }, "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r352" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/StockholdersEquityDeficitAtTheMarketIssuancesDetails", "http://www.madrigalpharma.com/role/StockholdersEquityDeficitPreferredStockDetails", "http://www.madrigalpharma.com/role/StockholdersEquityDeficitRegisteredOfferingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfInvestmentsLineItems": { "auth_ref": [ "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Investments [Line Items]", "terseLabel": "Cash, Cash Equivalents and Marketable Securities" } } }, "localname": "ScheduleOfInvestmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfInvestmentsTable": { "auth_ref": [ "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investments owned by investment company.", "label": "Schedule of Investments [Table]" } } }, "localname": "ScheduleOfInvestmentsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "terseLabel": "Schedule of Maturities of Long-Term Debt [Table Text Block]" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/LongTermDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r298", "r299", "r301", "r302", "r303", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r325", "r326", "r327", "r328", "r329" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationExpenseDetails", "http://www.madrigalpharma.com/role/StockBasedCompensationRestrictedStockUnitsDetails", "http://www.madrigalpharma.com/role/StockBasedCompensationStockOptionDetails", "http://www.madrigalpharma.com/role/StockBasedCompensationUnrecognizedExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r12", "r13", "r47" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of stock option activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-Term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [ "r651", "r652", "r683" ], "lang": { "en-us": { "role": { "documentation": "Series B preferred stock.", "label": "Series B Preferred Stock [Member]", "verboseLabel": "Series B Preferred Stock" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/StockholdersEquityDeficitRegisteredOfferingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r4" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense, Total", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r313", "r314" ], "lang": { "en-us": { "role": { "definitionGuidance": "Outstanding restricted units", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r313", "r314" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "verboseLabel": "Weighted average grant date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [ "r298", "r299", "r301", "r302", "r303", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r325", "r326", "r327", "r328", "r329" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Unrecognized stock-based compensation expense", "verboseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationExpenseDetails", "http://www.madrigalpharma.com/role/StockBasedCompensationRestrictedStockUnitsDetails", "http://www.madrigalpharma.com/role/StockBasedCompensationStockOptionDetails", "http://www.madrigalpharma.com/role/StockBasedCompensationUnrecognizedExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Shares available for future issuance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationStockOptionDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Additional disclosures" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationStockOptionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable at the end of the year (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationStockOptionDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable at the end of the year (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationStockOptionDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r320" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Total intrinsic value of options exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationStockOptionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r311" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Options cancelled (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationStockOptionDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Options granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationStockOptionDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average grant date fair value of options (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationStockOptionDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r305", "r306" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding at the end of the year (in shares)", "periodStartLabel": "Outstanding at the beginning of the year (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationStockOptionDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationStockOptionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r305", "r306" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding at the end of the year (in dollars per share)", "periodStartLabel": "Outstanding at the beginning of the year (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationStockOptionDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted average exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationStockOptionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r301", "r302", "r303", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r325", "r326", "r327", "r328", "r329" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationExpenseDetails", "http://www.madrigalpharma.com/role/StockBasedCompensationRestrictedStockUnitsDetails", "http://www.madrigalpharma.com/role/StockBasedCompensationStockOptionDetails", "http://www.madrigalpharma.com/role/StockBasedCompensationUnrecognizedExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r310" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Options exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationStockOptionDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r311" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Options cancelled (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationStockOptionDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Options granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationStockOptionDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r297", "r304", "r323", "r324", "r325", "r326", "r329", "r338", "r339", "r340", "r341" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r620" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Expiration period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationStockOptionDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "verboseLabel": "Shares issued, Price per share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/StockholdersEquityDeficitRegisteredOfferingDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r104", "r112", "r113", "r114", "r136", "r155", "r156", "r158", "r160", "r164", "r165", "r213", "r233", "r235", "r236", "r237", "r240", "r241", "r271", "r272", "r275", "r278", "r285", "r374", "r452", "r453", "r454", "r455", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r479", "r500", "r519", "r590", "r591", "r592", "r593", "r594", "r643", "r659", "r666" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/StockholdersEquityDeficitPreferredStockDetails", "http://www.madrigalpharma.com/role/StockholdersEquityDeficitRegisteredOfferingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r11", "r27", "r105", "r122", "r123", "r124", "r140", "r141", "r142", "r144", "r150", "r152", "r163", "r214", "r215", "r286", "r335", "r336", "r337", "r350", "r351", "r360", "r361", "r362", "r363", "r364", "r365", "r368", "r375", "r376", "r377", "r378", "r379", "r380", "r388", "r442", "r443", "r444", "r458", "r519" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r140", "r141", "r142", "r163", "r422", "r450", "r469", "r472", "r473", "r474", "r475", "r476", "r477", "r479", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r492", "r493", "r494", "r495", "r496", "r498", "r501", "r502", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r519", "r629" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfStockholdersEquity", "http://www.madrigalpharma.com/role/LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements Of Stockholders' Equity" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r140", "r141", "r142", "r163", "r422", "r450", "r469", "r472", "r473", "r474", "r475", "r476", "r477", "r479", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r492", "r493", "r494", "r495", "r496", "r498", "r501", "r502", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r519", "r629" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r11", "r66", "r67", "r91", "r452", "r519", "r591" ], "lang": { "en-us": { "role": { "definitionGuidance": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Number of shares sold by the entity" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/StockholdersEquityDeficitAtTheMarketIssuancesDetails", "http://www.madrigalpharma.com/role/StockholdersEquityDeficitRegisteredOfferingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r11", "r66", "r67", "r91", "r310" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Options exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationStockOptionDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r11", "r66", "r67", "r91", "r458", "r519", "r591", "r635" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Value of shares sold by the entity" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/StockholdersEquityDeficitAtTheMarketIssuancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r67", "r70", "r71", "r85", "r481", "r497", "r520", "r521", "r624", "r636", "r661", "r676", "r687", "r700" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 14.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets", "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "definitionGuidance": "Stockholders' Equity", "label": "Stockholders' Equity Note [Abstract]", "terseLabel": "Stockholders' Equity (Deficit)", "verboseLabel": "Stockholders' Equity (Deficit)" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r88", "r135", "r270", "r272", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r284", "r286", "r367", "r522", "r523", "r595" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r381", "r390" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r381", "r390" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r381", "r390" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/StockholdersEquityDeficitRegisteredOfferingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r59" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "Substantial Doubt about Going Concern [Text Block]", "terseLabel": "Liquidity and Uncertainties" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/LiquidityAndUncertainties" ], "xbrltype": "textBlockItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r267", "r283", "r366", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r438", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r672", "r673", "r674", "r675" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Major Types of Debt and Equity Securities [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r352" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CommitmentsAndContingenciesDetails", "http://www.madrigalpharma.com/role/StockholdersEquityDeficitAtTheMarketIssuancesDetails", "http://www.madrigalpharma.com/role/StockholdersEquityDeficitRegisteredOfferingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r40", "r41", "r42", "r100", "r101", "r102", "r103" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [ "r626", "r627", "r630", "r631", "r632", "r633" ], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrants" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedLossPerCommonShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r154", "r160" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted weighted average number of common shares outstanding" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r153", "r160" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic weighted average number of common shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(3)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(4)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org//718/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.C.Q3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "808", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(21))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(16))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(2)(a))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(h)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(g)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(h)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(14))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column B)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column B))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 10))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(3)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 10))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 12))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 13))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org//205/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column B))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "https://asc.fasb.org//205-40/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r637": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r638": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r639": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r641": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r642": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r644": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r645": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r646": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r647": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r648": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r649": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r667": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org//320/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r678": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org//450/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(i)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "8", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org//235/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "https://asc.fasb.org//250/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org//275/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org//440/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org//470/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org//505/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org//810/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 61 0001193125-23-205535-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-205535-xbrl.zip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�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end

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�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